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List of Abbreviations 
a  C-terminal amide 
AA  amino acid residue1
Abu  Ǆ-aminobutyric acid 
Ac  acetyl 
ACPC trans-2-aminocyclopentane
carboxylic acid 
Ada  1-adamantaneacetyl 
ADP  adenosine 5’-diphosphate 
Ala (A) alanine 
AM  aminomethyl 
anh.  anhydrous 
aq.  aqueous 
Ar  aromatic 
Arg (R) arginine 
Asn (N) asparagine 
Asp (D) aspartic acid 
AP alkaline phosphatase 
ATCC American type culture 
collection 
Ava  ǅ-aminovaleric acid2
ǃAla  ǃ-alanine
BF2  buforin II 
BHI  brain/heart infusion 
bm  broad multiplet 
Bn  benzyl 
Boc  tert.-butoxycarbonyl
BOP (benzotriazol-1-yloxy)tris- 
(dimethylamino)phosphonium
hexafluorophosphate 
Bu butyl 
c (prefix) cyclo 
Cx n-alkyl chain containing x
carbon atoms 
CAP  cationic antimicrobial peptide 
Capro (S)-3-amino-1-carboxymethyl 
caprolactame
CD  circular dichroism 
CFU  colony-forming units 
Clt  (2-chlorotriphenyl)methyl 
CMP  cytidine 5’-monophosphate 
Cmpi  N-carboxymethylpiperazine 
COSY  correlated spectroscopy 
CPC cetylpyridinium chloride 
                                                          
1 Where applicable, amino acid residues are of the L-
configuration unless otherwise stated. 
2 Due to shortage of unique one-letter codes, Ava is 
denoted with X in Chapter 4 and Tmd(Phe) with Z in 
Chapter 7.
CPMBN Cys-polymyxin B nonapeptide 
CTAB cetyltrimethylammonium 
bromide
Cys (C) cysteine 
Dab  (X) ǂ,Ǆ-diaminobutyric acid2
dansyl 5-dimethylamino-1-
naphthalenesulfonyl
DAST  diethylaminosulfurtrifluoride 
DCC N,N’-dicyclohexylcarbodiimide 
DCE  1,2-dichloroethane 
Dde 1-(4,4-dimethyl-2,6-dioxo- 
cyclohex-1-ylidene)ethyl 
Dhb (U) ǂ-aminodehydrobutyric acid 
DIAD diisoproyl azodicarboxylate 
DiBAl-H  diisobutylaluminum hydride 
DIC N,N’-diisopropylcarbodiimide 
DiPEA N,N-diisopropylethylamine 
DMAP  4-dimethylaminopyridine 
DMF N,N-dimethylformamide 
DMSO  dimethylsulfoxide 
DNA  deoxyribonucleic acid 
DOSPER 1,3-dioleyloxy-2-(6-carboxy-
spermidyl)propylamide 
DPPA  diphenylphosphoryl azide 
DPX  dansylated polymyxin B 
DRC  (S7T)-drosocin 
DTT  dithiothreitol 
EDC N-(3-dimethylaminopropyl)-
NĻ-ethylcarbodiimide 
EDTA  ethylenediaminetetraacetate 
ESI  electrospray interface 
Et  ethyl 
eq.  equivalent(s) 
E-gel gel containing ethylene glycol  
F (prefix)  fluorous 
FA or fa  fatty acyl 
FDA (United States) Federal Drug 
Administration 
FITC  fluoresceinyl isothiocyanate 
Fmoc  9-fluorenylmethoxycarbonyl 
Gal  galactose 
G_ Gram-negative
G+  Gram-positive 
Glc  glucose 
Gln (Q) glutamine 
Glu (E) glutamic acid 
Gly (G) glycine 
GRAVY grand average of hydropathy 
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G-gel gel containing glycerol 
HATU O-(7-azabenzotriazol-1-yl)-
N,N,NĻ,NĻ-tetramethyluronium 
hexafluorophosphate 
hBD human ǃ-defensin
HCTU O-(6-chlorobenzotriazol-1-yl)-
N,N,NĻ,NĻ-tetramethyluronium 
hexafluorophosphate 
Hep L-glycero-D-manno-heptose
HEPES N-(2-hydroxyethyl)piperazine-
N'-(2-ethanesulfonic acid) 
His (H) histidine 
HMDS  hexamethyldisilazane 
HOAt  1-hydroxy-7-azabenzotriazole 
HOBt  1-hydroxybenzotriazole 
HPLC high-performance liquid 
chromatography 
HRMS high-resolution mass 
spectrometry
HSer (ǃS) ǃ3-homoserine
HTyr (ǃY) ǃ3-homotyrosine
IBX  triacetoxyiodobenzoic acid 
IL  interleukin 
Ile (I) isoleucine 
IM  inner (cytoplasmic) membrane 
IR infrared 
ISB iso-sensitest broth 
ISO International Organization for 
Standardization 
ivDde 1-(4,4-dimethyl-2,6-dioxocyclo- 
hex-1-ylidene)-3-methylbutyl 
Kdo 3-deoxy-D-manno-oct-2-
ulosonic acid 
KFF  KFF peptide (KFF)3K
LB  Luria-Bertani (broth) 
LBP  LPS-binding protein 
LC  liquid chromatography 
LCMS liquid chromatography/mass 
spectrometry
Leu  (L) leucine 
LPS  lipopolysaccharide 
Lys (K) lysine 
OM  outer membrane 
Orn (O) ornithine 
Mamb  m-(aminomethyl)benzoic acid 
MALDI matrix-assisted laser 
desorption/ionisation 
Me  methyl 
MeArg (MeR) Nǂ-methylarginine 
MeSer (MeS) N-methylserine
Met (M) methionine 
MHC minimal hemolytic 
concentration
MIC minimal inhibitory 
concentration, i.e. the lowest 
concentration at which no 
bacterial growth can be 
detected by spectroscopic 
analysis after incubation for a 
specified time, compared with 
a positive control (Triton X-
100).
MIM N-methyl-N’-alkyl 
imidazolium 
MMT  (4-methoxytriphenyl)methyl 
MOA (S)-6-methyloctanoyl, -oic acid 
Mpa 3-maleimidopropionyl 
MPD N-methyl-N-alkyl-
pyrrolidinium 
MS  mass spectrometry 
MS/MS  tandem mass spectrometry 
Msc  methylsulfonylethoxycarbonyl 
Mtt  (4-methyltriphenyl)methyl 
MW  microwave (oven) 
n (prefix)  natural 
n-  normal (linear) 
n/a  not applicable 
n/d  not determined 
NBE  nutrient broth E 
NCL  native chemical ligation 
nG  not glycosylated 
NMP  N-methylpyrrolidone 
NMR  nuclear magnetic resonance 
NOE  nuclear Overhauser effect 
NOESY nuclear Overhauser effect 
spectroscopy 
Orn (O) ornithine 
Pamb  p-(aminomethyl)benzoic acid 
PAMP pathogen-associated molecular 
pattern
PBS  phosphate-buffered saline 
PE  petroleum ether 40/60 
PEG  polyethyleneglycol 
Ph  phenyl 
Phe (F) phenylalanine 
PhPip 4-phenyl-4-carboxymethyl- 
piperidine
PMB  polymyxin B 
PMBN  polymyxin B nonapeptide 
PNT  pentamidine (derivative) 
Pro (P) proline 
PyBOP (benzotriazol-1-yloxy)- 
tripyrrolidinophosphonium 
hexafluorophosphate 
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PyBroP bromotripyrrolidino- 
phosphonium
hexafluorophosphate
QAC quaternary ammonium 
compound 
RBC  red blood cell  
Ref.  reference 
Rf  retardation factor 
RNA  ribonucleic acid 
ROESY  rotating frame NOESY 
RP  reversed phase 
Rt  retention time 
RT  room temperature 
RTD  rhesus ǉ-defensin 
s (prefix)  synthetic
SAA  sugar amino acid 
Sar  sarcosine 
sat.  saturated 
SCL  3-carboxypropanesulfonamide 
Ser (S) serine 
SIC streptococcal inhibitor of 
complement 
SPE  solid-phase extraction 
SPPS  solid-phase peptide synthesis 
SPy  2-pyridylsulfenyl 
SS  disulfide linkage 
StBu  tert.butylsulfenyl 
Su  succinimidyl 
tBu tert.butyl 
TCA  trichloroacetic acid 
TCEP  tris(carboxyethyl)phoshine 
TES  triethylsilane 
TFA  trifluoroacetic acid 
TFE  2,2,2-trifluoroethanol 
THF  tetrahydrofuran 
THP  tetrahydropyran 
Thr (T) threonine 
TIC  total ion count 
TIS  triisopropylsilane 
Tmd 3-(trifluoromethyl)-3H-
diazirin-3-yl
TMS trimethylsilyl 
TNBS 2,4,6-trinitrobenzenesulfonic 
acid
TNF  tumor necrosis factor 
TLC  thin-layer chromatography 
TLR  Toll-like receptor 
TOCSY  total correlation spectroscopy 
TOF  time-of-flight 
Tr  triphenylmethyl 
Tran  tranexamic acid 
Trp (W) tryptophane 
TTC  tritrpticin 
Tyr (Y) tyrosine 
UDP  uridine 5’-diphosphate 
UV  ultraviolet 
Val (V) valine 
W-gel gel containing water 
Z  benzyloxycarbonyl2
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1 | Gram-negative Bacterial Sepsis 
With the discovery in the 1930s of natural and synthetic compounds that were able to kill 
pathogenic bacteria, man appeared to leave their natural ancient enemies behind. Thanks to these 
antibiotics, mortality rates resulting from common diseases indeed steeply declined. However, 
bacterial resistance grew against the early classes of antibiotics through a combination of careless 
application and high rates of mutation.1 Nowadays, with increasing bacterial resistance to 
conventional antibiotics being an accepted problem, the on-going search for new antibiotics is an 
important subject worldwide2 as witnessed by the countless reports on modification of existing 
antibiotics3 and the search for antibiotics with new modes of action.4,5
Bacterial infections can in principle be cured by removal of the causative agent. In most 
cases, treatment with the correct antibiotic or a balanced cocktail of drugs will result in 
countering of the pathogen. In some cases however, e.g. if bacterial infection has turned into 
bacterial infestation (sepsis, or blood poisoning), or if the patient is already immuno-
compromised, antibiotics can no longer be of effective assistance to the immune systems in their 
protective task. Moreover, treatment of Gram-negative (G_) bacterial infections with established 
antibiotics might cause aggravation of a patient’s condition rather than improving it by release of 
immunogenic membrane components.6 If septic patients are not treated carefully, their condition 
can result in septic shock, an inflammatory syndrome resulting from loss of the homeostasis 
maintained by the body. Although there is no general definition of this syndrome, microvascular 
occlusion and vascular instability lead via effects of fever, coagulopathy, vasodilatation and 
capillary leak to multiple organ failure and, eventually, death.7 The recent estimation of 750,000 
annual cases of septic shock in IC (intensive care) units in the USA accompanied by mortality 
rates of ~30-50%8 shows that bacterial sepsis and septic shock remain conditions that are difficult 
to treat. 
This introduction presents a global overview of the present day status of established antibiotics 
and research approaches towards new classes of antibacterial compounds. Focusing on 
approaches to treat G_ bacterial infections, a biological background of G_ bacterial infections is 
given, and the potential of the class of cationic antimicrobial peptides (CAPs) will be discussed in 
greater detail. 
General Introduction 
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2 | Endotoxin and Sepsis 
The toxicity of the group of molecules referred to as ‘toxins’ arises from disruption of cellular 
processes e.g. by binding nucleic acids, inhibiting enzymes or by having modulating effects on 
the immune response. Exotoxins are substances that are secreted by bacteria including anthrax 
toxic complex, diphtheria toxin, tetanus toxin, botulinum toxin, cholera toxin and heat-labile 
enterotoxin.9,10,11 In contrast, endotoxins are not secreted but are antigens of a specific bacterium, 
mostly as integrated part of the membrane.12
2.1 | Lipopolysaccharide (LPS) 
In G_ bacteria, the term endotoxin refers to a unique membrane-associated molecular structure, 
which is collectively called lipopolysaccharide (LPS). LPS alone can induce all of the characteristic 
features of septic shock in humans.13
Differing from Gram-positive (G+) bacteria, in which the cell’s contents are protected by a 
single cytoplasmic membrane and a peptidoglycan layer, G_ species contain an extra membrane 
outside of their peptidoglycan. This characteristic outer membrane consists of phospholipid 
bilayer, of which the outside possesses an overall anionic character (see Figure 1). The abundant, 
negatively charged LPS is equally distributed over the outer membrane, with Mg2+ ions
coordinating to the phosphate groups that connect the LPS moieties near their hydrophobic 
anchors.14 LPS contains a few typical segments (Figure 1). The O-antigen substructure of LPS, 
pointing outwards into the extracellular space, is a repeating branched polysaccharide mostly 
composed of glucose (Glc) and galactose (Gal) units. In this region, the largest structural variation 
among G_ species is found. Approaching the membrane, the core oligosaccharide structure of LPS 
is divided into two parts. The outer cores consists mainly of Gal, Glc and occasionally, heptose 
residues. The inner core typically contains residues of unusual 3-deoxy-D-manno-oct-2-
ulopyranosonic acid (Kdo) and L-glycero-D-manno-heptose (Hep). Carbohydrate variations in the 
core contribute to the general complex heterogeneity of LPS from a single species and presence or 
absence of modifications is profoundly dependent on the growh conditions of the bacterium.  
The base structure of the inner core is decorated with additional carbohydrate residues in 
non-stoichometric fashion, and with phosphate, pyrophosphorylethanolamine (PPEtN) or 
phosphorylcholine to a varying degree. 
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FIGURE 1 | Schematic representation of the structure of Escherichia coli K12 LPS, consisting of the O-
antigen, outer and inner cores, and Lipid A. The oval transmembrane structure represents an 
outer membrane protein. The overall negative charge is caused by phosphate groups in the 
inner core and Lipid A. 
2.2 | Lipid A 
Lipid A (Figure 2) is the most conserved substructure of LPS in G_ bacteria and anchors the core 
structure of LPS to the membrane. Lipid A, the actual part of LPS responsible for its toxic effects, 
consists of a glucosamine dimer that is O-phosphorylated at the 1 (α) and 4’ positions; the inner 
core extends from the 6’ primary hydroxyl function connecting to the first Kdo moiety. Lipid A is 
polyacylated with ǃ-hydroxyalkanoyl chains, providing hydrophobic anchors. Variations in the 
Lipid A structure from Figure 2 (e.g. acyl chain composition, lack of phosphates, different 
saccharides) can be found in Rhizobium, Aquiflex, Rhodobacter, Campylobacter, Helicobacter and 
Yersinia species.15,19b  Different acyl substitution patterns yield overall different shapes, which are 
at the basis of different signalling pathways (see § 3.1) and toxic effects of LPSs.16 Synthetic Lipid 
A analogues lacking a disaccharide motif display potent Lipid A-like activity, assuming a major 
role for the phosphate and lipid parts in activity;17 however, 1-O-dephosphoryl Lipid A has been 
reported to be devoid of toxicity.18 The structure, biosynthesis and diversification of Lipid A/LPS 
and their separate components have been the subject of a number of reviews.19
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FIGURE 2 | Structure of Lipid A from E. coli K12. Numbers denote the number of carbon atoms in each   
chain.
2.3 | Biological effects of LPS 
At the onset of G_ bacterial infection, LPS is bound by LPS-binding protein (LBP), facilitating 
complex formation with the CD14 receptor. This way, the endotoxin is recognized as pathogen-
associated molecular pattern (PAMP)20 by Toll-like receptor (TLR) 421 present on macrophages, 
neutrophils, monocytes, dendritic cells and endothelial cells in mammals.22 Atypical (modified) 
LPSs were found to interact with TLR2 rather than TLR4.23 TLRs 2 and 4 are two of the 11 human 
TLRs known to date that are capable of identifying highly conserved PAMPs and mediate the 
correct immune response upon activation.24 Originally thought to involve one single TLR per 
PAMP, it is becoming evident that TLRs might collaborate with each other and with other innate 
immune receptors for recognition of a specific pathogen, leading to cumulative effects for a 
response towards this pathogen.25
Interaction of LPS with TLR4 triggers the biosynthesis of various immune inflammatory 
mediators, most notably tumor necrosis factor α (TNF-α),26 interleukin 1ǃ (IL-1ǃ),27 IL-6,28 and IL-
8.29 Besides this, the production of co-stimulatory compounds that are required for the adaptive 
immune response, is activated.30 Furthermore, LPS causes upregulation of adhesion molecules 
such as ICAM-1, VCAM-1 and E-selectin31 that are involved in recruitment of leukocytes towards 
inflamed endothelium.32 The human body normally carefully controls the systemic 
concentrations of the mediators that regulate the immune response. However, if systemic 
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concentrations reach too high levels, the homeostasis maintained by the body is disturbed, 
resulting in septic shock.  
3 | Countering Infections and Sepsis 
3.1 | Classical antibiotic treatment 
Classical treatment of infections involves the administration of an appropriate antibiotic. A 
number of classes of antibiotics are currently in clinical use, including tetracyclines,33
quinolones,34 ǃ-lactams,35 macrolides,36 aminoglycosides,37 azoles,38 oxazolidinones,39 peptide 
antibiotics,40 glycopeptides,3c nitroimidazoles,41 sulfonamides,42 and ansamycins (Figure 3).43
Figure 3 also displays fosfomycin,44 D-cycloserine,45 trimethoprim42 and mupirocin,46 compounds 
that are the only member in their classes.  
Unfortunately, bacteria have adapted to evade antibacterial action by target site residue 
modification, active efflux, overexpression of degrading proteins or decreased uptake.49 Serious 
resistance is encountered in the infamous methicillin-resistant Staphylococcus aureus (MRSA).47 As
even the glycopeptide antibiotic vancomycin, an antibiotic of last resort, succumbs to resistance 
(Enterococci),48 new antibiotics that act through alternative mechanisms are needed. Resistance of 
potentially pathogenic G_ bacterial serotypes of Escherichia coli (commonly involved in urinary 
and gastrointestinal tract infections) or Pseudomonas aeruginosa (infections involving burns and 
hospital-acquired pneumonia) is a serious matter,49 especially when considering that these 
pathogens are less susceptible to conventional antibiotics due to their extra outer membrane.  
In the past decades, mostly variations within classes (i.e. modification of an established scaffold) 
of antibiotics have been reported,50 and only a small number of members of completely new
classes have been approved by the FDA in the past decades. Two of the few are the oxazolidinone 
linezolid (ZyvoxTM) and the lipopeptide daptomycin (CubicinTM, Figure 3),51 and these are 
indicated against G+ bacteria only.52
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FIGURE 3 | Structures of representative examples of commonly used classes of antibiotics. 
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3.2 | Approaches towards new antibiotics
Research towards new antibiotics acting through other mechanisms than the established arsenal 
for the treatment of G_ infections has yielded some examples with potential for further 
investigation. The following examples are illustrative.53
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The fact that LPS is essential for bacterial growth prompted investigation towards inhibitors of 
enzymes involved in the biosynthesis of LPS. An inhibitor of the unique enzyme CMP-Kdo 
synthetase in the Kdo synthesis pathway, 2,8-dideoxy-8-amino-Kdo, showed bacterial growth 
inhibition in the low Ǎg/mL range. The Ala-Ala conjugate of this compound (Figure 4) was 
prepared to enhance cellular uptake,54 but this compound was not therapeutically useful as the 
dipeptide was hydrolyzed too rapidly.55 Inhibitors of the enzyme Kdo8P synthetase that catalyzes 
the condensation of phosphoenolpyruvate with D-arabinose-5-phosphate en route to Kdo have 
been reported (Figure 4).56 The conserved L-glycero-D-manno-heptose (Hep) is attached to Kdo, 
and is not found in mammalian cells. The recent elucidation of the structure of ADP-6-
epimerase,57 an enzyme in the biosynthetic pathway of Hep may inspire the design and synthesis 
of new antibacterial compounds. 
FIGURE 4 | Kdo analogues as inhibitors of the LPS biosynthesis pathway. 
Another approach in targeting the biosynthesis of LPS is inhibition of the enzyme LpxC.58 This 
enzyme catalyzes the deacetylation of UDP-3-O-acyl-GlcNAc, a key step in the synthesis of Lipid 
A. Indeed, inhibitors are reported based on a hydroxamic acid functionality (e.g. L-161,240 and 
BB-78484, Figure 5).59
Removal of the 1-O-phosphate from Lipid A is an interesting objective to neutralize G_
bacteria in situ as monophosphoryl Lipid A is non-toxic (§ 2). Alkaline phosphatase (AP) from 
human placenta60 or calf intestine61 has proven to be effective in this respect as it improved 
survival in challenged mice. A possible drawback to this approach is the problem of antigenicity: 
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treatment with recombinant AP might provoke undesired immunological responses upon 
application of AP at the next occasion of infection. 
FIGURE 5 | Inhibitors of LpxC, a deacetylase in the LPS biosynthesis pathway. 
During bacterial infection, lymphocytes suffer from faster inactivation through apoptosis than in 
a normal health situation. As this impairs host defenses, preventing the death of these cells might 
increase the survival of challenged mice. Indeed, mice were successfully treated with the known 
caspase inhibitor Z-VAD (Figure 6) that inhibits caspase-regulated apoptosis.62
FIGURE 6 | Structure of the caspase inhibitor Z-VAD and E5564, a compound displaying LPS antagonism. 
Although a number of the above mentioned research objectives might seem promising, no actual 
drug has yet arisen from any of these approaches. More progress has been made in the structural 
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derivatization of Lipid A. This approach has led to the development of the in vivo active LPS 
antagonists E5531 and E5564 (eritoran, Figure 6),63 the latter showing good results in phase I 
clinical trials. The structure of eritoran is based on the unusual Lipid A structure of the non-toxic 
bacterium Rhodobacter capsulatus and blocks interaction of LPS with TLR4.64
4 | Cationic Antimicrobial Peptides (CAPs) 
4.1 | Natural CAPs 
Bacteria are an important source of peptide-based antibiotics. In 1947, one of the first peptides 
that were isolated was polymyxin B, a cyclic, cationic lipopeptide from Bacillus polymyxa.65 From 
this point on, more bacterial cationic antimicrobial peptides (CAPs) were discovered, all based on 
peptide structures containing uncommon amino acids. In the 1980s, cecropins66 and magainins67
were among the first to be identified in multicellular organisms. Isolated from pig and frog 
respectively, these CAPs were found to be linear and constructed from proteogenic amino acid 
residues unlike the bacterial CAPs previously identified. Both cecropins and magainins are 
specificially active against bacterial cells, in contrast to melittin, the main lytic cationic peptide in 
bee venom.68 To date, hundreds of peptides with antibacterial, antifungal, antiviral and/or 
antiprotozoal activity have been extracted from various organisms, including other mammals69,70
and amphibians,71 insects,72 birds,73 fish,74 and shellfish75 (see Table 2, page 24). The wide-spread 
presence of CAPs indicates that these peptides may constitute an ancient antibiotic approach. 
Indeed, one group of antibacterial peptides was determined to stem from a common ancestral 
precursor around 150 million years old,76 surviving evolutionary selection. 
The human innate immune system also deploys antimicrobial peptides,77,78,79,80 most 
notably the CAP subgroup of defensins,81 divided in two major classes – the α- and ǃ-defensins 
(see Table 1).  
TABLE 1 | Defensins of the innate immune system. 
 kDa Residues Cys Pairings Source 
α-defensins 3.5-4.5 29-35 1-6, 2-4, 3-5 Human, rabbit, rat, 
guinea pig, mouse 
ß-defensins 4-6 36-42 1-5, 2-4, 3-6 Human, cow, turkey, 
chicken, pig, penguin 
ǉ-defensins 2 18 1-4, 2-5, 3-6 rhesus monkey 
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The 6 known human α-defensins (human neutrophil peptides HNP 1-4 and human defensins HD 
5 and 6), are found primarily in neutrophils (HNPs) and intestines (HDs). The human β-defensins 
(hBD 1-6) are larger and characterized by a different pattern of disulfide bridges (see Table 2 and 
Figure 7A); they are mainly isolated from epithelia. Members of the α- and β-defensin classes are 
also encountered in other species. The rhesus monkey θ-defensins are the only cyclic defensins 
isolated to date. 
Besides discrete peptides, naturally occurring (cationic) proteolytic fragments of several 
proteins were found to exhibit antibacterial activity; e.g. from lysozyme,82 from histone 2A 
(yielding buforins I and II),83 and from the N-terminal domain of the Helicobacter pylori L1 
protein.84 An α-helical domain in lactoferrin yields lactoferricin,85 and cathelicidins stem from 
cathelins.86 New CAPs are furthermore discovered through screening of protein or DNA 
sequences for putative amphiphilic stretches, as in the cases of tritrpticin87 and lactoferrampin.88 
 
CAPs come in numerous variations in length, charge, and primary/secondary structures (see 
Figure 7), but all are amphiphilic.89 Parameters as hydrophobicity, amphiphilicity, polar angle, 
charge and conformation govern the activity of a CAP but no general rule exists for predicting 
activity.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 7 | 3D structures based on NMR models showing the diversity of CAPs, in solution (A) or in 
membrane mimetic conditions (B-D).
202b
 A. human ß-defensin 2 (hBD-2), a triple-stranded ß-
sheet with 3 Cys-Cys bridges; B. magainin 2, α-helix; C. ß-turn/loop structure of bovine 
bactenecin; D. Extended structure of indolicidin. Only backbones and SS bridges are shown. 
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4.2 | Classification of CAPs 
Natural CAPs are peptides ranging from ~10 to ~100 amino acids, have an overall net positive 
charge and are amphiphilic. Some CAPs are classified according to their origin (e.g. bacteriocins 
from bacteria, cathelicidins from cathelins). Reference, however, to their primary/secondary 
structure, which is fixed or adopted upon interaction with membranes, is more common.90,91 The 
following paragraphs discuss the different classes of CAPs.
4.2.1 α-Helical CAPs 
Representative members of this class are magainin 267 and melittin,68 both of which adopt an α-
helical structure with facial amphiphilicity (see Table 2, Figures 7B and 8) upon interaction with 
negatively charged membranes. Compared to melittin however, magainin 2 displays far less 
hemolysis. Although no fundamental rule is available on how residues in the amphiphilic helix 
influence activity and selectivity, substitution of amino acids on one side of the helix can greatly 
influence the biological properties.  
FIGURE 8 | Helical wheel representations of the amphiphilic structures of magainin 2 and melittin. View 
is along the helical axis. Ŷ - hydrophobic residue; Ƒ - cationic residue 
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A number of research groups have applied amino acid substitution92 to find residues crucial for 
the selectivity of α-helical CAPs, but the results do not apply for α-helical CAPs other than the 
one used in the concerning study. Besides this derivatization of natural CAPs, artificial helical 
peptides have been synthesized displaying antibacterial activity, such as the α-helical KFF 
peptide (KFF)3K.93
4.2.2 β-sheet and looped CAPs 
The ǃ-sheet CAPs form the second major class, and can be subdivided into several distinctive 
subclasses, most notably those with and without intramolecular Cys-Cys disulfide bonds. The 
cyclic loloatins A-D94 and tyrocidine A127 are examples of the group without disulfide bonds. The 
group of ǃ-sheet/looped CAPs with Cys-Cys bonds comprises peptides ranging from a single S-S 
bond (bovine 12-peptide) to 3 or more (α- and ǃ-defensins). As for the α-helical CAPs, the spatial 
distribution of the amino acid side chains in the ǃ-sheet CAPs is crucial for the antibacterial 
activity, as it governs the amphiphilicity of the CAP (see Table 2, Figures 7C and 9). 
FIGURE 9 | Amphiphilic ß-sheet structures showing hydrophobic (Ŷ) and cationic (Ƒ) regions for protegrin 
I, polyphemusin II and tachyplesin I. Note that there is no obvious separation between sides in 
rhesus ǉ-defensin RTD-1. 
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4.2.3 CAPs with extended structures 
The last major group (Table 2, Figure 7D) comprises the linear CAPs with no propensity to form 
specific α-helical or β-sheet structures upon interaction with a G_ membrane. A number of 
members of this subgroup act through lysis of the bacterial membrane, while for others the 
antibiotic action appears to arise from specific interaction with intracellular bacterial components 
(vide infra, § 4.3.2). The lack of a clear secondary structure appears to be linked to prevalence of 
certain amino acid residues as found in indolicidin (Trp),95 tritrpticin (Trp),96 drosocin (Pro),97
pyrrhocoricin (Pro),98 bactenecins (Pro),99 and histatins (His).100
4.2.4 CAPs containing structural modifications 
Non-ribosomal synthesis or post-translational modification of CAPs results in compounds with 
distinct features. Through these processes, CAPs may display incorporation non-proteogenic 
amino acids, as can be seen in polymyxins,101 ramoplanins,102 nisin Z103 and other bacteriocins, 104
and can contain modifications including glycosylation (e.g. drosocin,97 pyrrhocoricin,98
mannopeptimycins),105 fatty acid conjugation (e.g. polymyxins,101 syringomycins,106 friulimicin),107
and cyclization to macrolactams (e.g. tyrocidins,127 gramicidin S)108 or macrolactones (e.g. 
kahalalide F).109
TABLE 2 | Examples of natural CAPs sorted by secondary structures. 
CAP Sequence Origin 
α-helical
Buforin II TRSSR AGLQF PVGRV HRLLR K frog 
Cecropin A KWKLF KKIEK VGQNI RDGII KAGPA VAWGQ ATQIA Ka      silk moth 
Cecropin P1 SWLSK TAKKL ENSAK KRISE GIAIA IQGGP R pig
Clavanin A VFQFL GKIIH HVGNF VHGFS HVFa tunicate
Crabrolin  FLPLI LRKIV TALa hornet venom 
Dermaseptin 1     ALWKT MLKKL GTMAL HAGKA ALGAA ADTIS QGTQ frog 
Gaegurin 5  FLGAL FKVAS KVLPS VKCAI TKKC frog 
Lactoferrampin WKLLS KAQEK FGKNK SR milk protein 
Lactoferricin B  FKCRR WQWRM KKLG milk protein 
LL-37 LLGDF FRKSK EKIGK EFKRI VQRIK DFLRN LVPRT ES human
Magainin 2 GIGKF LHSAK KFGKA FVGEI MNS frog 
Mastoparan B LKLKS IVSWA KKVLa hornet venom 
Melittin GIGAV LKVLT TGLPA LISWI KRKRQ Qa  bee venom 
Misgurin  RQRVE ELSKF SKKGA AARRR K fish
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Nigrocin 2  GLLSK VLGVG KKVLC GVSGL C frog 
PGLa GMASK AGAIA GKIAK VALKA La frog 
Piscidin 3  FIHHI HRGIV HAGRS IGRFL TG fish
Pleurocidin  GWGSF FKKAA HVGKH VGKAA LTHYL   fish
Temporin A FLPLI GRVLS GILa frog 
Temporin L                FVQWF SKFLG RIL frog 
β-sheet/loop with Cys-Cys bonds
α-Defensin HNP-1 ACYCR IPACI AGERR YGTCI YQGRL WAFCC human
β-Defensin hBD-1 DHYNC VSSGG QCLYS ACPIF TKIQG TCYRG KAKCC K              human
ǉ-Defensin RTD-1 c(GFCRL CRRGV CRCIC TR) monkey 
Androctonin RSVCR QIKIC RRRGG CYYKC TNRPY scorpion 
Bovine 12-peptide RLCRI VVIRV CR cow
Gomesin  ZCRRL CYKQR CVTYC RGR spider 
Protegrin 1  RGGRL CYCRR RFCVC VGGRa pig
Polyphemusin I RRWCF RVCYR GFCYR KCRa crab
Polyphemusin II  RRWCF RVCYK GFCYR KCRa crab
Tachyplesin I KWCFR VCYRG ICYRR CRa crab
β-sheet no Cys-Cys
Gramicidin S c(VOLfP VOLfP) bacterium 
Loloatin D c(VOLyP WfNDW) bacterium 
Tyrocidine A  c(VOLfP FfNQY) bacterium 
Extended structure/rich in certain residues
Apidaecin 1A GNNRP VYIPQ PRPPH PRIa bee
Drosocin  GKPRP YSPRP T*SHPR PIRV fruit fly 
Formaecin I GRPNP VNNKP T*PHPR L ant
Histatin 5  DSHAK RHHGY KRKFH EKHSH RGY human
Indolicidin ILPWK WPWWP WRRa cow
PR-39 RRRPR PPYLP RPRPP PFFPP RLPPR IPPGF PPRFP PRFPa pig
Pyrrhocoricin VDKGS YLPRP T*PPRP IYNRN bug
Tritrpticin VRRFP WWWPF LRR synthetic
Miscellaneous
Polymyxin B fa XTX c(XfLXXT) bacterium 
Polymyxin E fa XTX c(XlLXXT) bacterium 
Syringomycin E fa c(SSXXRFUBJ) bacterium 
Amino acids in lowercase are of the D-configuration. c=cyclo; fa=fatty acyl; U=Dhb; B=Asp(OH) J=Thr(Cl), * 
- glycosylation site, X=Dab, a=carboxamide
4.3 | Targets of CAPs 
Due to their cationic nature, CAPs generally prefer interactions with anionic membranes and 
hence display higher activity against G_ bacteria than G+ species, but exceptions (e.g. nisin Z) that 
preferentially target G+ bacteria are known. Although the majority of CAPs kill bacteria by 
destabilizing the cytoplasmic membrane, some peptides rather bind to essential structures inside 
the bacterial cell. 
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4.3.1 Targeting the cytoplasmic membrane
Many studies have been devoted to elucidate the interaction of CAPs with bacterial membranes 
in order to define a general mode-of-action for CAPs that kill through lysis of the bacterial 
cell.110,111 By virtue of their positive charges, CAPs substitute the divalent metal ions that 
neutralize and cluster LPS. This creates local disturbances of the outer membrane’s integrity, and 
enables more CAPs to translocate over the outer membrane, a process called ‘self-promoted 
uptake’.112 Having bridged the outer membrane, CAPs target the inner membrane by any of the 
postulated general mechanisms (Figure 10).113 Although described here for ǂ-helical CAPs, these 
mechanisms are thought to apply for other subgroups as well.114
One mechanism, referred to as the Carpet mechanism, is based on the covering of the membrane 
by CAPs in a carpet-like fashion. Upon reaching a peptide concentration threshold, the 
membrane becomes unstable and eventually collapses, resulting in permeation and pore 
formation. Ultimately, the membrane disintegrates in a detergent-like manner (Figure 10A).  
1
CAP
2
A B C D
FIGURE 10 | After initial binding of the CAPs to the membrane by virtue of electrostatic interactions (1), 
four possible models (2) have been suggested leading to death of the bacterium; Carpet 
model  (A), Barrel/Stave model (B), Wormhole model (C) and In-Plane Diffusion model (D).
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CAPs exerting activity through this mode of action are considered to be non-cell selective, as 
carpet-like covering may also occur in the cases of non- or less-anionic membranes. Indeed, these 
CAPs (e.g. melittin) display mostly minimal hemolytic concentration (MHC) values close to their 
MIC (minimal inhibitory concentration) values. 
A second mechanism, the so-called Barrel-Stave mechanism is used to explain the 
mechanism of most CAPs that display high cell-selectivity. In this model, CAPs do not cover the 
bacterial membrane, but, after binding to the membrane, assemble to form supramolecular 
structures in the membrane (hydrophilic pores, Figure 10B). Recruitment of additional peptides 
increases the pore size, causes efflux of cell components and eventually leads to cell death. As the 
complexation process is dependent on the composition of the membrane, the CAPs following this 
concept (e.g. magainin 2) are generally non-toxic to erythrocytes.  In the Barrel-Stave model, the 
cationic charges are located in energetically unfavorable close proximity. Therefore, this model 
has been slightly adjusted to give the Wormhole model,113 in which these charges are neutralized 
by negatively charged phospholipid head groups from the membrane (Figure 10C).  
Another model, the In-Plane Diffusion model, explains the activity of CAPs that were 
found to have their ǂ-helical axes aligned (in-plane) with the membrane rather than a 
transmembrane fashion as predicted by the Barrel/Stave mechanism.115 According to this model, 
overlap of long-range disturbances in the membrane induced upon in-plane binding of CAPs 
causes local, transient openings in the inner membrane (Figure 10D).
4.3.2 Targeting internal structures 
A small number of peptides within the CAP class do not act by destruction of bacterial 
membranes, but meet their ultimate targets inside. Bac7(1-35) is able to interfere with bacterial 
components other than the membrane,116 and the bactericidal effects of apidaecin involve 
interactions with molecular targets inside E. coli.117 Well-documented are the cases of the Pro-rich 
insect CAPs drosocin and pyrrhocoricin. These peptide antibiotics were found to bind specifically 
to the E. coli heat-shock protein DnaK, inhibiting its cellular functions.118 Most interestingly, the 
human homologue of this bacterial protein (Hsp60) is not affected by either one. The absence of 
cytotoxicity for these peptides makes them interesting candidates for drug development. Internal 
targets are by no means limited to extended-structured CAPs as is demonstrated by the α-helical 
CAPs buforin II and lactoferricin B, that were found to respectively bind to nucleic acids and to 
inhibit the synthesis of macromolecules in both Escherichia coli and Bacillus subtilis.119,120
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5 | Beyond Natural CAPs
Besides amino acid substitution in natural CAPs for structure/activity studies,121 many reports 
deal with the design of new CAPs and derivatives that are inspired by their amphiphilic nature, a 
number of which is highlighted in the following paragraphs.
5.1 | Peptides & Peptidomimetics
5.1.1 Synthetic cationic antimicrobial α-peptides 
Compounds inspired by CAP helices122 such as the KFF peptide,93 stabilized ǃ-sheet structures 
based on protegrins123,124 and the LPS binding region in LALF (Limulus anti-lipopolysaccharide 
factor) have been designed, displaying natural CAP-like biological activities.125 Even small, de
novo designed extended-structured CAPs composed of 6 amino acids can exert antimicrobial 
activity.126 Furthermore, a combinatorial approach towards cyclic decapeptides yielded 
derivatives that were more potent than the natural CAP tyrocidine A.127
5.1.2 Hybrids 
Several CAPs contain areas with different functionalities. Pyrrhocoricin contains a putative 
pharmacophore and an intracellular delivery domain,128 as does drosocin. Mixing these putative 
domains resulted in peptides with strongly reduced activities.129 However, hybrids of membrane 
active CAPs, cecropin/melittin130 and cecropin/magainin,131 were found to have the 
characteristics of both CAPs. Dimers of a magainin analogue132 and magainin 2 cross-linked to 
PGLa133 showed distinct biological profiles with respect to the monomers. A conjugate of a 
dermaseptin derivative with an RNA III-inhibiting peptide (for the prevention of biofilm 
formation) was able to interfere in Staphylococcus-associated infections.134
5.1.3 Conjugates with lipophilic groups 
Inspired by the architecture of natural antibacterial lipopeptaibols135 and polymyxins, the effects 
of fatty acid conjugation to CAPs have been reported. In polymyxin B, the acyl moiety is 
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considered to be important for activity as deacylated polymyxin B shows significant loss in 
antimicrobial potency.136 Indeed, acylated derivatives of a synthetic D,L-peptide,137 SC4,138
cathepsin G(117-136),139 lactoferrin-derived peptides,140 a cecropin/melittin hybrid141 and
magainin142 displayed improved activity and/or altered selectivity. 
5.1.4 D-Amino acid incorporation
Incorporation of enantiomeric amino acids influences 3D structure and stability, activity, toxicity 
or selectivity. Substitution of L-amino acid residues in melittin,143 pardaxin144 and synthetic 
peptides145 with their D-counterparts leads to analogues of these CAPs with improved selectivity 
and slightly influenced antibacterial activity. A synthetic α-helical peptide containing only DLys
and DLeu residues (an all-D peptide) was significantly more stable against trypsin treatment than 
the corresponding all-L analogue.146 Furthermore, only the all-D peptide could cure mice from 
infection with Pseudomonas aeruginosa and gentamicin-resistant Acinetobacter baumanii,
underlining the importance of CAP stability in serum, which is greatly improved upon 
introduction of enantiomeric amino acid residues. However, the all-D strategy is limited to 
membrane-active CAPs; enantiomeric analogues of pyrrhocoricin and drosocin showed no 
antibacterial activity because of their stereospecific interaction with target proteins inside 
bacterial cells.119
5.1.5 β-Peptides 
Peptides completely composed of ǃ-amino acids (ǃ-peptides) were found to be able to form 
helices.147 Following the concept of amphiphilic helices present in α-peptidic CAPs, the groups of 
Seebach148 and DeGrado149 reported antibacterial activity of their amphiphilic ǃ3-peptides. Using 
constrained trans-2-aminocyclopentane carboxylic acid (ACPC)-based monomers for optimal 
induction of a helical structure,150 ǃ-peptide ǃ-17 (Figure 11)151 was constructed. This peptide 
possessed antibacterial activity comparable to that of magainin 2 amide and melittin, but its 
hemolytic activity was considerably lower. β-Peptides have been shown to be stable towards a 
number of proteases.152
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FIGURE 11 | ACPC constrained residue, helical wheel representation indicating ~5 residues per turn in 
amphiphilic antimicrobial ß-peptide ß-17. View along the helical axis. Ŷ - hydrophobic 
residue; Ƒ - cationic residue.
5.1.6  Peptoids 
Attachment of the side chains of amino acids to the nitrogen atom rather than the Cǂ atom yields 
a class of peptide derivatives known as peptoids (Figure 12). Chiral peptoids have been 
constructed that form amphiphilic helices and show antibacterial activity.153 Through 
combinatorial chemistry, tripeptoids have been constructed that display antimicrobial activity.154
FIGURE 12 | Antimicrobial peptoid and helical wheel representation indicating ~3 residues per turn. View 
along the helical axis. Ŷ - hydrophobic residue; Ƒ - cationic residue.
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5.2 | Amphiphilic scaffolds 
Amphiphilic scaffolds mimicking the separation of cationic and hydrophobic sides in CAPs have 
been synthesized and evaluated for biological activity. For example, the cholic acid scaffold was 
applied (Figure 13) in the preparation of amphiphiles.155 The synthesized cationic steroid-derived 
compounds displayed activity comparable to some natural CAPs.  
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FIGURE 13 | Amphiphilic compounds displaying antibacterial activity.
It should be noted that natural steroid compounds such as squalamine156 (Figure 13) and 
derivatives157 display antibacterial activity as well. Amphiphilic compounds based on the ter-
cyclopentane scaffold158 and indane-based compounds159 also exerted antibiotic activity. The 
group of DeGrado synthesized biologically active, facially amphiphilic arylamide oligomers 
(Figure 13).160 Amphiphilicity also inspired the work on cyclic D,L-α-peptides that were able to 
form tubular structures by self-assembly to permeate membranes and kill both G_ and G+
bacteria.161
5.3 | Structural minimization 
Based on the two activity-determining parameters of CAPs (cationicity and hydrophobicity), 
biologically active structures far less complicated than those of CAPs can be synthesized. 
Amphiphilic molecules composed of no more than a few non-proteogenic, bulky amino acid 
residues already display antibacterial activity against both G_ and G+ bacteria as well as 
hemolysis.162 Extending this simplification further, the bioactive ammonium compounds are 
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among the smallest possible structures displaying both cationicity and hydrophobicity (Figure 
14). For instance, amphiphilic coatings based on alkylated poly(vinylpyridine) applied to surfaces 
kill airborne bacteria upon contact.163,164 However, the trade-off for structural simplification is a 
loss in selectivity: whereas CAPs can be highly selective in their actions, most quaternary 
ammonium compounds lyse bacterial cells and mammalian erythrocytes alike.165   
FIGURE 14 | Quaternary ammonium amphiphilic antibacterial compounds (left); known cetyltrimethyl-
ammonium bromide (CTAB), cetylpyridinium chloride (CPC), and N-methyl-N’-decyl 
imidazolium bromide (MIM). Right: polymerized alkylated vinylpyridine.
6 | Neutralization of LPS 
A number of natural CAPs are capable of strong binding to and neutralizing LPS.166
Unfortunately, the usage of the CAPs tested (e.g. melittin and polymyxin B) is limited to topical 
systems as they display undesired characteristics (hemolysis or nephrotoxicity, respectively). 
Based on these results, structural studies towards LPS-binding optimization of synthetic peptides 
have been reported.167 A recombinant N-terminal sequence of BPI (rBPI23), an LPS binding 
protein,168 fused to the human immunoglobulin IgG abolished the physiological response to LPS 
challenge in human volunteers.169 Other CAPs were also reported to interfere with the LPS/LBP 
complexation process.170 A successful approach that preserves the favorable LPS-neutralizing 
properties of polymyxin B, but circumvents toxicity issues, is the application of hemoperfusion. 
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In this approach, blood from septic patients is cleared from LPS extracorporally by using a 
cartridge containing immobilized polymyxin B.171
FIGURE 15 | Structures of pentamidine, chlorhexidine, spermine and DOSPER.
Research towards existing natural or synthetic structures that are able to scavenge LPS has 
attracted interest in recent years.172 The geometry of the five cationic Dab residues in polymyxin B 
inspired research towards small molecules in which appropriately spaced cationic groups are 
present. Established antibiotics as pentamidine,173 pentamidine congeners,174 and chlorhexidine175
(Figure 15) were found to exhibit Lipid A affinity. The affinity of pentamidine was found to be 3-
fold higher than that of polymyxin B. The appropriate intercation distance for simultaneous 
recognition of both phosphate groups in Lipid A was also observed in the polyamine spermine.174
Lipophilic spermine derivatives176 were shown to have a neutralizing effect on endotoxin as did 
lipopolyamines such as DOSPER (used in nucleic acid transfection studies, Figure 15).177
Although DOSPER alone could not prevent mortality in challenged mice, survival increased 
upon its co-administration with the β-lactam antibiotic ceftazidime compared to ceftazidime 
alone.178
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7 | Clinical & Commercial Application of CAPs 
Colimycin (the methosulfate derivative of polymyxin E) appears to be well-tolerated and is 
successfully used in an aerosol formulation.179 The mixture of polymyxin B, gramicidin S and 
bacitracin is a highly active topical preparation.180 Polymyxin B is also present as topical agent in 
ophthalmologic formulations,181 along with bacitracin, which can be found in cosmetics.182 Nisin 
Z, active against G+ bacteria, is currently used as a food additive and is referred to as E 234.183
The magainin derivative MSI-78 (pexiganan) was rejected by an FDA panel in phase III 
clinical trials against both polymicrobic diabetic foot ulcers and impetigo.5 Nisin has succesfully 
undergone phase I trials against Helicobacter pylori stomach ulcers.180 Iseganan (IB-367, a protegrin 
derivative) is currently in phase III trials for treatment of oral mucositis.184  BPI185 and its 
recombinant fragment (rBPI23) linked to IgG, were reported to be in clinical trials.186 A topical 1% 
gel preparation of omiganan (MBI-226, a 12-residue indolicidin analogue) is currently in phase III 
clinical trials for the prevention of catheter-related bloodstream infections.187
8 | Evolution of Resistance? 
Some bacteria are able to withstand the antibiotic activity of CAPs, and resistance of G_ bacteria 
against CAP family members has been documented.188 For instance, the two-component 
regulatory protein systems PmrA/PmrB (polymyxin resistance) and PhoP/PhoQ govern 
resistance towards CAPs in Pseudomonas aeruginosa.189,190 In P. aeruginosa and Salmonella species, 
the latter system induces modification of Lipid A moieties in the LPS by covalent addition of 4-
amino-4-deoxy-L-arabinose or phosphoethanolamine, decreasing the overall negative charge of 
the bacterial outer membrane (Figure 16).19a,191 Likewise, resistance towards defensins and 
protegrins is enhanced by modification of phosphatidylglycerol with Lys in the cytoplasmic 
membrane of Staphylococcus aureus (G+), changing net charge.192 Efflux pumps belong to the 
arsenal of resistance mechanisms of bacteria,193 along with PgtE endoprotease/peptidase, whose 
presence was demonstrated in the outer membrane of Salmonella species.194 This enzyme, its 
homologue OmpT (Escherichia coli)195 and the porin OmpU (Vibrio cholerae),196 were found to 
decrease susceptibility towards CAPs.
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diminished sensitivity towards CAPs. In unmodified Lipid A, R1 = R2 = R3 = H.
Some reports suggest that association of the antimicrobial peptide with the bacterial membrane’s 
phospholipids is only a partial process in the overall interaction between the two. Nisin Z197 and 
mesentericin Y,198 both active against G+ bacteria, were found to lose target cell specificity upon 
removal of a receptor-binding element in their structures. The corresponding membrane-bound 
receptors are thought to be produced by bacteria as multidrug-resistant (MDR) proteins.199 An
illustration of this concept is the SIC protein secreted by pathogenic Streptococcus pyogenes, which 
was found to be able to render human α-defensins and LL-37 inactive. The high prevalence of S. 
pyogenes M1 serotype infections is most likely caused by the high level of SIC protein secreted by 
this particularly serotype.200
Finally, it has been stated that introduction of CAPs into clinical use may induce the 
evolution of bacterial resistance to our own cationic antimicrobial defense proteins and thus 
severely compromise our natural defenses against infection.201 However, reports have appeared 
that claimed zero to marginal evolving bacterial resistance against certain CAPs,51,202 leaving the 
possibility for these particular CAPs to become clinically useful  antibiotics. 
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9 | Conclusion 
The research towards, and development of, antibiotics with new modes of action are important 
objectives in attempting to counter the growing bacterial resistance against commonly used 
antibacterial drugs. Despite all efforts, only a small number of new compounds have been 
approved for clinical use in the last decade, of which only two have a novel mechanism of action. 
In particular, (potential) resistance of pathogenic G_ bacteria poses a threat to public health. 
However, among the newest antibacterials approved there are no compounds indicated against 
G_ infections.  Besides the fact that treatment of G_ pathogens is intrinsically hampered by the 
presence of an extra membrane, countering a G_ pathogen leads to release of immunogenic 
endotoxins that may very well aggravate the patient’s condition. Members of the class of cationic 
antimicrobial peptides (CAPs), appear to represent a solution to these issues. The favorable 
properties of CAPs are summarized in Table 4, together with issues that will need to be 
addressed in the development of CAPs. 
TABLE 4 | Properties of CAPs. 
Resistance + The minute time scale antibacterial action of membrane-active CAPs does not 
allow for spontaneous bacterial adaptations.  
+ Mutations in targets of CAPs targeting internal structures are unlikely to yield 
viable resistant species as these internal structures are mostly essential for bacterial 
growth.
+ Resistance against the secondary structure types of CAPs is unlikely as this would 
yield unviable ‘self-resistant’ species. 
Selectivity + Most CAPs (both membrane-active CAPs and CAPs with internal targets) target 
prokaryotes selectively (in particular G
_
 bacteria), allowing for directed treatment in 
mammals. 
- Many CAPs show hemolytic activity (although at higher concentrations than needed 
for antibacterial activity). 
LPS Neutralization + A number of CAPs are able to neutralize LPS and might be able to prevent sepsis 
during/after treatment of the bacterial infection. 
Stability + Mammalian CAPs composed of proteogenic amino acids can be metabolized and 
excreted by the body. 
- CAPs composed of proteogenic acids are inherently susceptible towards proteolytic 
cleavage, requiring studies towards stabilization.  
- Oral availability of most CAPs is low or zero.  
- CAPs that are proteolytically too stable might exert toxicity. 
Toxicity - Non-ribosomally synthesized bacterial CAPs might exert (organ-specific) toxicity 
due to the fact that they are rather resistant towards proteolytic breakdown. 
- CAPs that are less-selective display hemolysis. 
Optimization - As there is no general rule by which the activities of natural or synthetic CAPs can 
be predicted, optimization of lead structures might be a time-consuming process. 
General Introduction 
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Based on their specific characteristics, a number of CAPs was considered promising for clinical 
development (see § 7). In order to become lead structures for clinical antibiotic development, 
CAPs should possess the favorable properties from Table 4 regarding cell-selectivity, activity and 
stability, ideally combined with the ability to take care of LPS after eradication of the G_
bacterium.5,203,204
10 | Outline
Chapter 1 of this thesis deals with the biological evaluation of analogues of the CAP drosocin 
from the fruit fly Drosophila melanogaster. This CAP is fully selective towards G_ bacteria, but is 
rather unstable in serum. Amino acid substitutions yielded a series of lead analogues that display 
a far higher stability than the natural CAP while maintaining or slightly increasing the 
antibacterial activity. 
Polymyxin B1 (from Bacillus polymyxa) is the subject of Chapter 2. This bactericide is 
among the most potent CAPs known and is used as standard control in various biological assays. 
Nature appears to have optimized the structure of polymyxins, as no analogues more active than 
polymyxin B1 have been reported to date. A new synthetic route towards polymyxin B1 is 
presented and applied in the synthesis of several polymyxin analogues.  
During the polymyxin syntheses, a by-product was detected having identical molecular 
weight but a different retention time on LC. Chapter 3 deals with the identification of this by-
product as a regioisomer of the polymyxins, resulting from an NαÆNγ acyl migration. 
In an approach to circumvent the negative nephrotoxic aspects of polymyxin B1 while 
preserving its Lipid A affinity, conjugates of non-toxic, deacylated polymyxin B1 (polymyxin B 
nonapeptide) and other CAPs were designed. The preparation of these conjugates and their 
biological evaluation are described in Chapter 4.
Chapter 5 describes the synthesis of amphiphilic compounds inspired by the cationic and 
hydrophobic properties of CAPs. Quaternary ammonium compounds (QACs) are among the 
most easily synthesized compounds displaying antimicrobial activity in solution. Stable gel 
formulations containing biologically active quaternized N-methylimidazolium and N-
methylpyrrolidinium bromides and water, ethylene glycol or glycerol were prepared and 
assayed for antimicrobial activity against G_ and G+ bacteria. 
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Chapter 6 discloses a peptide-related topic. As the chemical synthesis of peptides is not always 
straightforward and purification procedures can be tedious, a new approach for synthetic peptide 
purification is presented. Exploiting specific fluorine-fluorine interactions, purifications using 
fluorous HPLC or fluorous SPE were performed to solely yield the desired compounds. To enable 
this, a novel base-labile fluorous amine protecting group was designed and synthesized. 
Finally, Chapter 7 discusses some future prospects regarding the research described in 
this thesis. Notably, the approach of conjugating a Lipid A-affinity moiety to a CAP is further 
extended, and the anti-malarial drug pentamidine, displaying a higher affinity for Lipid A than 
polymyxin B, was derivatized to provide it with a handle for conjugation to CAPs.  
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1.1 | Introduction
Cationic antimicrobial peptides (CAPs) have found attraction as lead structures in combating 
bacterial infections,1 and much research effort has been directed in recent years towards the 
elucidation of their mode of action.2,3 From the amassed data it becomes apparent that a majority 
of CAPs exert their activity through adoption of a defined secondary structure upon contact with 
anionic bacterial cell membrane components. As a result, either bacterial cell lysis or disturbance 
of membrane transport events occurs, with bacterial cell death as a result. The fact that a large 
number of CAPs appear to be indiscriminate to cell type and are often equally effective in killing 
mammalian cells normally limits their use to topical applications.  
Drosocin, a CAP isolated from Drosophila melanogaster, is a 19-mer peptide containing 
three Pro-Arg-Pro repeats and an O-glycosylation site at Thr11 (Table 1).4 The antibacterial 
activity of drosocin, like other members of the proline-rich CAPs (Table 1), appears not to be 
based on cell lysis. Rather, drosocin’s activity towards bacteria is based on inhibition of a specific 
intracellular heat-shock protein named DnaK resulting in cell death.5 This finding explains the 
observation that all-D drosocin, composed of D-amino acids,6 does not possess any antibacterial 
activity, in contrast to most all-D CAPs.7 Drosocin, and related proline-rich CAPs, are further 
distinguished from other CAPs by the lack of toxicity towards human erythrocytes and their 
apparent bias in activity towards Gram-negative bacteria.4 These properties combined make 
drosocin a very attractive lead structure in the search for new and effective antibacterial agents. 
TABLE 1 | Sequences of drosocin and selected related Pro-rich CAP family members. 
CAP Sequence
Drosocin G - K P R P Y S P R P T* S H P R P I R V 
Pyrrhocoricin V D K G S – Y L P R P T* – P P R P I Y N R N 
Formaecin I G – R P N P V N N K P T* P H P R - L 
* Glycosylation site 
A major hurdle in the development of drosocin-based antibacterial agents is the inherent 
instability of drosocin towards proteolytic activities present in mammalian sera. In fact, drosocin 
and its congeners are degraded in sera at such a rate that effective treatment of bacterial 
infections would require relatively large doses of the peptide.8 Any strategy that leads to drosocin 
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analogues with enhanced proteolytic stability without impairing antibacterial activity should 
therefore be an important step forwards in the development of new antibacterial agents.  
1.2 | First Generation Drosocin Analogues
1.2.1 | Design & Synthesis  
The reported finding that the first step in the proteolytic degradation of drosocin in human serum 
comprises cleavage of the peptide bond8 between Tyr6 and Ser7 was an incentive to design a 
series of drosocin (DRC) analogues (2-12, Table 2) in which either of the two or both positions at 
the cleavage site were substituted. This included replacement of Ser7 with Leu (3), Thr (4, 10), D-
Ser (5, 11), N-Me-Ser (2) or β3-HSer (6, 12; see Figure 1) and replacement of Tyr6 with Phe (8, 10), 
D-Tyr (7, 11) or β3-HTyr (9, 12). As a negative control, unrelated peptide 17 was included in the 
array.9
FIGURE 1 | Structures of β3-HSer and β3-HTyr used in this study; in this nomenclature, H indicates a 
homoamino acid with the amine function at the ş-carbon and the sidechain connected to the 
3rd backbone carbon atom. Fmoc derivatives of both amino acids are commercially available. 
Although non-glycosylated DRC (nG-DRC 1, Table 2) is about 7 times less active than native 
drosocin,4  it was decided to omit the O-glycosyl modification at Thr11 to simplify the synthetic 
procedure. The preparation of the non-glycosylated linear peptides in Table 2 was accomplished 
using standard Fmoc-based SPPS techniques using the appropriate Fmoc-amino acid building 
blocks and PyBOP/DiPEA as the activator system. Automated peptide synthesis was employed 
in all instances except for the Tyr6-N-Me-Ser7 stretch in 2 that was introduced manually. In this 
particular case, the Nǂ-methyl amino acid was introduced on the growing peptide chain using 
PyBOP and successive elongation with tyrosine was achieved using the stronger activator 
H2N OH
O
HO
β3-HSer
H2N OH
O
β3-HTyr
HO
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PyBroP.10 All peptides were purified to homogeneity by reverse phase HPLC prior to biological 
assessment. 
TABLE 2 | Synthetic peptides used in this study. 
HRMS [M+H]+# SequenceA              
Calculated Found 
1 GKPRP DYDDSPRP TSHPR PIRV 2197.234 2197.220 
2 GKPRP DYMeSPRP TSHPR PIRV 2211.250 2211.237 
3 GKPRP DYDDLPRP TSHPR PIRV 2223.294 2223.280 
4 GKPRP DYDDTPRP TSHPR PIRV 2211.250 2211.241 
5 GKPRP DYDDSPRP TSHPR PIRV 2195.255 2195.236 
6 GKPRP DYDßSPRP TSHPR PIRV 2211.250 2211.241 
7 GKPRP DFDDSPRP TSHPR PIRV 2181.240 2181.251 
8 GKPRP DYDDSPRP TSHPR PIRV 2197.234 2197.201 
9 GKPRP ßYDDSPRP TSHPR PIRV 2211.250 2211.241 
10 GKPRP DFDDTPRP TSHPR PIRV 2195.255 2195.236 
11 GKPRP DYDDSPRP TSHPR PIRV 2197.234 2197.218 
12 GKPRP ßYDßSPRP TSHPR PIRV 2225.266 2225.197 
17 NTDGS DTDDDYGI LQINS R 1753.8B 1753.7B
  A Modifications are highlighted in bold face, Me = N-methylated amino acid D = D-amino acid, ş = ş3-homo-            
   amino acid; B not HRMS. 
1.2.2 | Antibacterial Activity 
The results of the analysis of the antibacterial activity of DRC analogues 1-12 against E. coli ATCC 
11775 are summarized in Table 3.11 None of the prepared peptides possess any hemolytic activity 
at concentrations up to 300ǍM. N-Methylation of the endopeptidase-sensitive peptide bond 
(peptide 2) results in a considerably lower antibacterial activity as compared to the 
unglycosylated native form (1).  
In contrast, the DRC analogues containing a single amino acid substitution of Tyr6 or 
Ser7 (compounds 4-9) display equal or better antibacterial activity. Analogue 3 however, which 
contains a Ser7ÆLeu replacement to resemble the stable Tyr-Leu-Pro-Arg-Pro (YLPRP) pentamer 
present in the related CAP pyrrhocoricin9 (Table 1), displayed a loss in activity. The double 
mutant DRC analogues 11 and 12 were four times less active than reference compound 1. The 
positive exception is represented by peptide 10 with a 3.1μM minimal inhibitory concentration. 
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TABLE 3 | MIC (minimal inhibitory concentration) values of drosocin analogues and serum stability assay. 
Compound MIC (M)A Intact (%)B
1 (nG-DRC) 6.3 3 
2 25 11 
3 12.5 n/d
4 1.6 15 
5 3.1 1 
6 3.1 31 
7 3.1 19 
8 6.3 16 
9 3.1 2 
10 3.1 26 
11 25 17 
12 12.5 <1 
17 >100 n/d
A Against E. coli ATCC 11775; B Percentage of intact peptide after 8h of digestion in 25% human serum as 
determined by MALDI-MS peak height of the corresponding peptide; n/d - not determined. 
1.2.3 | Serum Stability 
The next research objective was to evaluate the proteolytic stability of non-glycosylated drosocin 
(1) and analogues 2 and 4-12. The experiments were performed in 25% pooled human serum to 
increase peptide recovery and to allow monitoring of the degradation over an 8h period. The 
relative abundance of the intact peptide was determined by comparison of the MALDI mass 
spectral peak heights with those at t=0.8,12
Based on the results, non-glycosylated drosocin and analogues 1, 2 and 4-12 can be 
roughly divided into two categories. The first is represented by the peptides that are almost 
completely degraded after a digestion period of eight hours (that is, less than 5% intact peptide 
remains). In this group, analogues 5, 9, and 12 accompany reference compound 1. Peptides 2, 4, 6-
8, 10 and 11 form the second category and display improved serum stability. Interestingly, all 
analogues comprising single proteogenic amino acid replacements (4, 7, and 10) appear to be 
more stable than parent peptide 1. On average, 20% of intact peptide was detected after eight 
hours of digestion in serum, compared to only 3% for 1. The improved serum stability and 
antimicrobial activity found for these peptides (4, 7 and 10) illustrate that substitution of one or 
two amino acids by closely related ones can already be beneficial. 
The analogues having substitutions with ǃ3- or D-amino acids feature distinct differences 
in serum stability. For instance, the serum stability was improved ten times by the introduction of 
ǃ3-serine moiety at position 7 (6), while the other two ǃ3-amino acid containing analogues (9, 12)
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demonstrated a proteolytic stability similar to 1. The opposite result was observed for the D-
amino acid containing analogues 5, 8 and 11. Here, 16 and 17% of the peptide remained intact 
after 8h of proteolytic digestion in the case of analogues 8 and 11, respectively, whereas a single 
L- to D-serine replacement in 5 did not improve the serum stability at all.  
In addition to the percentage of intact peptide after 8h of proteolytic digestion, early degradation 
products provide useful information about the serum stability of the peptides tested. For this 
purpose, the degradation fragments formed after two hours of digestion were identified (Table 
4), together with their respective intensities.12
The most abundant degradation product of non-glycosylated DRC (1) after 2h is lacking 
6 N-terminal residues (i.e. cleavage between Tyr6 and Ser7), which is consistent with literature 
data.8 This particular cleavage product is considerably less abundant from drosocin analogues 2-
12 or even fully absent.13 N-methylation (in 2) yields the lowest increase in stability of the 
susceptible amide bond. As mentioned previously, the proteolytic stabilities of peptides 5, 9 and
12 are similar to 1, but the low serum stability of these analogues is reflected by the high 
abundances of proteolytic fragments –N1, –N3 and –N5, rather than fragment –N6 which is the 
most abundant cleavage product in 1.
TABLE 4 | Abundances of major degradation products. 
Degradation productsA
Compound –N1 –N3 –N5 –N6 –N8
1 2 1 0 5 3
2 1 1 1 3 0
4 1 1 1 1 1
5 5 3 2 1 0
6 1 1 1 1 1
7 2 1 1 2 2
8 1 1 1 0 0
9 3 2 3 0 0
10 1 1 1 2 2
11 2 1 1 1 0
12 4 3 5 0 1
A Major degradation products are displayed as missing N-terminal residues after 2h digestion in 25% human 
serum, e.g. –N3 indicates loss of the first three N-terminal residues. The relative MALDI-MS spectral peak 
heights were measured and divided into 6 classes (not detected (0), 1-25mm (1), 26-50mm (2), 51-75mm 
(3), 76-100mm (4) and >100mm (5)). Numbers are averages of three experiments. 
Stabilized Drosocin Analogues 
51
1.3 | Second Generation Drosocin Analogues 
Based on the results of the 1st generation DRC analogues, attention was focussed on further 
stabilization of DRC analogues against proteolytic inactivation. Fragments missing some of the 
N-terminal residues were encountered in the 1st generation analogues (see Table 4) as a result of 
aminopeptidase activities. Due to its favorable outcome in the stability/antimicrobial tests and its 
completely proteogenic composition, compound 4 (Ser7ÆThr) was selected as lead structure for 
further elaboration. On the premise that N-terminal capping of natural peptides may result in 
enhanced stability towards aminopeptidase activities, the N-terminal Gly residue in 4 was 
replaced subsequently by sarcosine (Sar, N-methylglycine) and the lengthened Gly derivatives ǃ-
alanine  (ǃAla), γ-aminobutyric acid (Abu) and δ-aminovaleric acid (Ava).  
TABLE 5 | 2nd Generation DRC analogues containing N-terminal modifications. 
HRMS
Compound SequenceA Calculated Found 
13 Sar KPRP YTPRP TSHPR PIRV 2225.266 2225.263 
14 ßAlaKPRP YTPRP TSHPR PIRV 2225.266 2225.260 
15 Abu KPRP YTPRP TSHPR PIRV 2239.281 2239.282 
16 Ava KPRP YTPRP TSHPR PIRV 2253.671 2253.308 
A Modifications are highlighted in bold face. 
The resulting set of doubly modified DRC analogues 13-16 (Table 5) was subjected to identical 
stability and antimicrobial assays as the 1st generation analogues. Obtained MIC values are 
summarized in Table 6. Compared to parent peptide 4 (MIC 1.6ǍM), its derivatives 13-16 have on 
average slightly reduced MIC values, although comparison with DRC (1, MIC 6.3ǍM) shows that 
these 2nd generation analogues are as potent as the natural non-glycosylated CAP. None of the 2nd
generation DRC analogues displayed hemolytic activity up to concentrations of 300ǍM. N-
terminal stability is increased within these N-terminally modified analogues as no –N1, –N3 or –
N5 fragments were detected (Table 6). The overall stability is increased dramatically as ~80% of 
these peptides remains intact after 8h incubation in serum – for analogue 14 an increase of ~5.5-
fold compared with peptide 4 and ~30-fold regarding peptide 1 (see also Figure 2 for selected 
degradation curves). 
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TABLE 6 | MIC values of 2nd generation DRC analogues and serum stability assay. For comparison, data of 
lead structure 4 is added.
Degradation Products after 2h
Compound MIC (M)A Intact (%)B -N1 -N3 -N5 -N6 -N8
4 1.6 15 1 1 1 1 1
13 6.3 77 0 0 0 1 1
14 3.1 87 0 0 0 2 0
15 6.3 76 0 0 0 2 1
16 6.3 84 0 0 0 1 1
A Minimal inhibitory concentration against E. coli ATCC 11775; B Percentage of intact peptide after 8h of 
digestion in 25% human serum as determined by MALDI-MS peak height of the corresponding peptide. 
FIGURE 2 | Selected degradation curves (averages of three experiments) of nG-DRC 1 and analogues 4,12
and 15.
1.4 | Conclusion 
Substitution of selected amino acid residues at sites that are susceptible to proteolytic cleavage 
results in DRC analogues with enhanced stability, while leaving the antibacterial properties 
intact. In the 1st generation DRC analogues, both antimicrobial activity and stability were 
increased with respect to native nG-DRC 1. Analogue 4 was selected as lead for the design of a 
2nd generation of analogues containing a modified N-terminus to overcome unwanted 
aminopeptidase inactivation. N-terminal modifications on 4 led to the synthesis of a 2nd
generation of DRC analogues (13-16) with almost 30-fold increase in stability compared to nG-
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DRC 1, while being equally potent. For future studies towards the design of DRC-based drugs, 
analogues 13-16 can serve as a new lead structures. 
1.5 | Experimental Section 
1.5.1 | General 
LCMS analyses were performed using a Jasco 900 LC system with detection at 214 and 254nm connected to 
a Perkin Elmer Q-TOF monoquad mass spectrometer in positive ion mode. Crude peptides were purified on 
a ÄKTA Explorer HPLC system. In all cases, Alltech Alltima C18 analytical (150x4.6mm or 250x4.6mm) and 
semi-preparative (250x10.0mm) were used. Applied buffer systems – Jasco: A. H2O; B. MeCN; C. 0.1% aq. 
TFA (always 10% C present in the gradients); ÄKTA: A. 0.1% TFA in 5% MeCN/H2O; B. 0.1% TFA in 80% 
MeCN/H2O. Eluents were degassed before use and kept under Ar flow. MALDI-MS analyses were 
performed on a Bruker Biflex III mass spectrometer. Electrospray tandem mass analyses were performed on 
a Q-TOF mass spectrometer (Micromass) at a cone voltage of 20V.
1.5.2 | SPPS 
Peptides were synthesized using either an ABI-433A (50Ǎmol scale, Applied Biosystems) synthesizer or Syro 
2000 (10Ǎmol scale, MultiSyntech) using customized Fmoc-based protocols. Amino acid residues were used 
in 5-fold excess, using PyBOP (5eq.)/DiPEA (10eq., ABI-433A) or BOP (5eq.)/DiPEA (10eq., Syro 2000) as 
activating systems and 20% piperidine/NMP as Fmoc-deprotecting mixture. The first amino acid, Fmoc-
Val-OH (5eq.) was manually coupled to TentaGel PHB resin (0.24mmol/g) with DIC (5eq.) and DMAP 
(0.1eq.) in DMF for 2h. Loading was established by UV determination of the amount of Fmoc-chromophore 
released after treatment of a sample with 20% piperidine/DMF for 10min. Loading was 0.20mmol/g (85%). 
N-Methyl amino acids (4eq.) were coupled manually with BOP (4eq.)/HOBt (4eq.)/DiPEA(8eq.) in DMF. 
Amino acids to be reacted with N-methyl amino acids were also coupled manually, using the amino acid 
(5eq.) and preactivation with PyBroP (5eq.) and DiPEA (10eq.) in DMF. The potent activating reagent HATU 
worked equally efficient in acylations of N-methyl amino acids. In case the chloranil test was positive, 
coupling was repeated. After removal of the N-terminal Fmoc group, crude peptides were treated with 
TFA/TIS/H2O (95/2.5/2.5, v/v/v) for cleavage from the resin and removal of protecting groups, and 
subsequently precipitated in Et2O. Centrifugation and decantation of solvents yielded the crude products. 
After HPLC purification, the target peptides were obtained: 1 (nG-DRC), yield 42%, purity 96%, HPLC Rt 
9.34min; 2 (S7MeS), yield 5%, purity 95%, HPLC Rt 9.29min; 3 (S7L), yield 65%, purity 99%, HPLC Rt 
9.36min; 4 (S7T), yield 11%, purity 98%, HPLC Rt 9.20min; 5 (S7DS), yield 11%, purity 99%, HPLC Rt 
9.20min; 6 (S7βS), yield 5%, purity >99%, HPLC Rt 9.18min; 7 (Y6F), yield 12%, purity 99%, HPLC Rt 
9.49min; 8 (Y6DY), yield 7%, purity 90%, HPLC Rt 9.32min; 9 (Y6βY), yield 12%, purity 99%, HPLC Rt 
9.14min; 10 (Y6F/S7T), yield 11%, purity 99%, HPLC 9.50min; 11 (Y6DY/S7DS), yield 13%, purity 99%, 
HPLC Rt 9.24min; 12 (Y6βY/S7βS), yield 6%, purity 91%, HPLC Rt 9.18min; 13 (G1Sar/S7T), yield 3.1mg 
(1,41Ǎmol, 14%), purity >99%, HPLC Rt 9.59min; 14 (G1βAla/S7T), yield 2.5mg (1.41Ǎmol, 11%), purity 98%, 
HPLC Rt 9.56min; 15 (G1Abu/S7T), yield 2.3mg (1.02Ǎmol, 10%), purity 97%, HPLC Rt 9.55min; 16
(G1Ava/S7T), yield 1.6mg (0.72Ǎmol, 7%), purity 98%, HPLC Rt 9.56min. 
1.5.3 | Antibacterial Assay 
Antibacterial assays were performed in sterilized round-bottom 96-well plates with a final volume of 110ǍL
as follows. The bacteria (E. coli ATCC 11775) were grown in nutrient broth E (NBE; beef extract 1g/L, yeast 
extract 2g/L, peptone 5g/L and NaCl 5g/L) and kept at 40C. Lyophilized peptides were dissolved in NBE to 
give a concentration of 400ǍM and filtered using 0.22Ǎm filter discs. A 16h culture in NBE was adjusted to 
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5×106 CFU/mL and transferred to the micro titer plate wells (10ǍL) containing each 100ǍL of a serial 2-fold 
dilution (200-0.4ǍM) of the tested peptide in NBE. Plates were incubated while gently shaking at 370C for 
24h. Next, 80ǍL suspension of each well was transported into a flat-bottom 96-well plate. The absorbance 
was measured at 600nm using a μQuant micro plate spectrophotometer (Bio-Tek Instruments). All peptides 
were measured in quadruplo. The peptide with sequence NTDGSTDYGILQINSR was used as negative 
control.
1.5.4 | Hemolysis Assay 
The hemolytic activity of the peptides was determined in quadruplo. Human blood was collected in EDTA-
tubes and centrifuged to remove the buffy coat. The residual erythrocytes were washed three times in 0.85% 
saline. Serial dilutions of the peptides in saline were prepared in sterilized round-bottom 96-well plates 
using 100ǍL volumes (100-0.2ǍM). Red blood cells were diluted with saline to 1/25 packed volume of cells 
and 50ǍL of the resulting cell suspension was added to each well. Plates were incubated while gently 
shaking at 370C for 4h. Next, the micro titer plate was quickly centrifuged and 50ǍL supernatant of each well 
was transported into a flat-bottom 96-well plate. The absorbance was measured at 405nm using a μQuant
micro plate spectrophotometer (Bio-Tek Instruments). The Ablank was measured in the absence of additives 
and 100% hemolysis (Atot) in the presence of 1% Triton X-100 in saline. The percentage of hemolysis is 
determined as (Apep-Ablank)/(Atot-Ablank)×100. 
1.5.5 | Serum Stability Assay 
The serum stability studies were carried out in triplicate. Briefly, 10ǍL of an aqueous peptide solution 
(0.8mg/mL) was added to 1mL freshly pooled 25% human serum in PBS. The mixtures were thermostated 
at 370C under gentle stirring. At t=0, 1, 2, 4, 6 and 8h, 100ǍL of each mixture was taken out and precipitated 
in 230ǍL 15% aq. TCA. Samples were stored at 00C for 20min and centrifuged for 5min at 00C. The 
supernatants (250ǍL of each) were immediately stored at -80ºC until analyzed by MALDI mass 
spectrometry. The spectra were recorded in the linear mode, using ǂ-cyanohydroxycinnamic acid in 50% 
MeCN in 0.1% aqueous TFA. Serum control samples consisted of 100ǍL of pooled 25% human serum 
solution in PBS precipitated in 230ǍL 15% aq. TCA. Peptide reference samples consisted of 10ǍL of the 
peptide stock solution diluted in 1mL H2O, of which 100ǍL was added to 230ǍL 15% aq. TCA. MALDI peak 
heights were measured from prints that were generated using standard procedures.12
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2.1 | Introduction
The family of polymyxins is a group of highly potent cationic antimicrobial peptides (CAPs) 
isolated from Bacillus polymyxa.1 The general structure comprises (see Figure 1) of a cyclic 
heptapeptide bound to a linear tripeptide, both of which contain a high percentage of the rare 
amino acid L-α,γ-diaminobutyric acid (Dab).  Furthermore, the γ-amino group of Dab4 is linked 
via an amide bond to the C-terminus of residue 10, while its α-amino group is connected to Dab3 
of the linear tripeptide. The α-amino group of the N-terminal Dab residue is acylated with a 
distinctive hydrophobic chain.2 Of the substantial amount of unique polymyxins known, only 
polymyxin B is widely used and studied. Within the polymyxin B mixture, polymyxin B1 (PMB1, 
1) is the most abundant component. 
                                  
A. Natural polymyxin families (R = acyl chain)
PolymyxinA AA3 DAA6 AA7 AA10 Ref.
A / M LDab Leu Thr Thr 1d,3 
B LDab Phe Leu Thr 1 
C / P LDab Phe Thr Thr 4 
D DSer Leu Thr Thr 5 
E LDab Leu Leu Thr 6 
S DSer Phe Leu Thr 7 
T LDab Phe Leu Leu 8 
B. Components of polymyxin B 
Polymyxin R 
B1 (1) (S)-6-methyloctanoyl 
Ile7-B1 (S)-6-methyloctanoyl 
B2 (2) 6-methylheptanoyl 
B3 (3) C8
B4 (4) C7
B5 (5) C9
B6 (6) 3-hydroxy-6-methyloctanoylB
FIGURE 1 | General structures of polymyxins and subdivision of polymyxin B. A Additionally, polymyxin F 
has been reported (ref. 9); B Chiralities at C3 and C6 were not established. 
The presence of positively charged residues (i.e. the five Dab units), as well as the amphiphilic 
nature are crucial for PMB1’s activity against Gram-negative bacteria. Although the exact mode 
of action is still a matter of debate, various stages can be distinguished in the membrane 
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permeabilization process.10 Initially, binding of 1 to the anionic Lipid A domain11 leads to 
disruption of the lipopolysaccharide (LPS) lamellar phase.12 Next, the hydrophobic tail is inserted 
into the outer membrane (OM), followed by self-promoted uptake of the remainder of the 
molecule. After the internalization process, the antibiotic causes disruption of the inner 
(cytoplasmic) membrane (IM) which eventually leads to cell death.13
It is also well established that PMB1 decreases the effects of sepsis by binding and 
neutralizing LPS that is released in the course of Gram-negative infections.14 These properties 
make PMB1 a good candidate as antibiotic for therapeutic purposes. However, its nephrotoxicity 
to humans has thus far limited the clinical use of this antibiotic to topical treatment of infections.15
2.2 | Design & Synthesis 
The first synthesis of PMB1 (1) was reported by Vogler and co-workers16 who constructed the 
linear peptide by fragment condensation in solution, which was successively cyclized using DCC. 
Later on, Sharma et al.17 showed for the synthesis of 1 that the linear peptide, obtained via SPPS 
could be cyclized with diphenylphosphoryl azide (DPPA)18 and DiPEA. Unfortunately, in our 
hands incomplete DPPA-mediated cyclization led to an inseparable mixture of target compound 
1 and its undesired linear counterpart. It was expected that the release of linear fragments could 
be prevented by executing the cyclization19 with concomitant cleavage from the solid support.20
An essential element in this approach is the use of the safety-catch sulfonamide linker, originally 
developed by Kenner21 and modified by Backes et al.22 Attractive features of this type of linker are 
the stability under acidic and nucleophilic conditions and the cleavage by nucleophilic 
displacement after N-alkylation of the sulfonamide moiety. It was reasoned that use of low-
substituted resin was desirable in order to prevent any cross coupling during on-resin 
cyclization.
Thus, the safety-catch linker 3-carboxypropanesulfonamide (SCL) was quantitatively 
coupled to low-loaded polystyrene aminomethyl (AM) resin by using DIC/HOBt to give 7 (see 
Scheme 2, page 61). Subsequent PyBOP-mediated22 coupling of Fmoc-Thr(tBu)-OH afforded 8 in 
low yields (<20%), which is probably caused by the relatively low reactivity of the Thr residue 
and/or the sulfonamide group. Alternatively, 8 can be obtained via coupling of the amino acid 
fluoride Fmoc-Thr(tBu)-F to 7.23 In our hands, the highest yield (64%) was obtained after 
prolonging the reaction time to 5h, and increasing the excess of Fmoc-Thr(tBu)-F and base to 9 
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and 18eq., respectively. Sequential elongation of 8, resulting in immobilized peptide 9, was 
effected by BOP/HOBt/DiPEA-mediated condensation with suitably protected Fmoc amino 
acids.24 With respect to residue Dab4, efforts were dedicated towards the incorporation of this 
Dab residue bearing a Mtt functionality, as the mild acidic removal of this group would be fully 
compatible with our approach. However, the synthesis of Fmoc-Dab(Mtt)-OH gave 
unsatisfactory low yields.25 This problem could be avoided by incorporation of an ivDde-
protected Dab residue. Compared with the more common Dde group, the ivDde group shows an 
increased stability towards piperidine treatment and is less prone to migration. The assembly of 
the linear polymyxin molecule 10 was completed by removal of the Fmoc-group in 9 and 
subsequent coupling of (S)-6-methyloctanoic acid using BOP/HOBt/DiPEA. The octanoic acid 
derivative was prepared as follows (Scheme 1): reduction of commercially available (R)-
citronellyl bromide with LiAlH4 was followed by ozonolysis with a reductive work-up (NaBH4)
afforded S-(+)-4-methylhexanol.26 Finally, S-(+)-4-methylhexanol was converted into (S)-6-
methyloctanoic acid as described.26c
SCHEME 1 | Preparation of the chiral fatty acid residue present in polymyxin B1.
In order to secure the final cyclization of the amino group of Dab4 with Thr10 in activated 14, the 
ivDde group in 10 was removed by hydrazinolysis (Æ11) and replaced with the MMT group 
(Æ12). Alkylation of 12 with ICH2CN afforded activated sulfonamide 13.22 Removal of the MMT 
group from Dab4 in 13 by treatment with TFA/TIS yielded the partially protected and 
immobilized peptide 14. Cyclization of 14 with concomitant release of the cyclic peptide from the 
solid support was effected with DiPEA in THF. Removal of the remaining side-chain protecting 
groups by acidolysis furnished 1 (Figure 2A). 
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SCHEME 2 | Synthesis of polymyxin B1 (1). Reagents and conditions: (i) 3-carboxypropanesulfonamide, 
DIC, HOBt, DMF; (ii) Fmoc-Thr(tBu)-F, DiPEA, CH2Cl2, 64%; (iii) Fmoc-based SPPS applying 
20% piperidine/NMP (Fmoc deprotection), amino acids/BOP/HOBt/DiPEA in DMF/NMP 
(coupling) and Ac2O/HOBt/DiPEA (capping); (iv) 1. 20% piperidine/DMF; 2. (S)-6-
methyloctanoic acid, BOP/HOBt/DiPEA, DMF/NMP; (v) 2% NH2NH2.H2O, DMF; (vi) MMTCl, 
DiPEA, NMP; (vii) ICH2CN, DiPEA, NMP; (viii) TFA/TIS/CH2Cl2 3/5/92 (v/v/v); (ix) 1. DiPEA, 
THF; 2. TFA/TIS/H2O 95/2.5/2.5 (v/v/v). 
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The high purity of the crude product is indicative of the potential of the safety-catch approach 
towards polymyxins. Semi-preparative HPLC purification afforded pure 1 (Figure 2B). The 
corresponding linear PMB1 was not present, as indicated by LCMS analysis of the crude product. 
The synthetic compound co-eluted with PMB1 that was isolated from a commercial sample of 
polymyxin B.2 In addition, MS/MS analysis revealed that the fragmentation pattern of 1 was, in 
every aspect, identical to the one reported recently.27 Following the same safety-catch procedure 
as for PMB1, the natural polymyxins PMB3 (3), PMB4 (4) and PMB5 (5) were synthesized for 
comparison of activity with PMB1 (1).
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FIGURE 2 | HPLC traces of PMB1 (1). (A) crude after cyclization and deprotection; (B) after HPLC 
purification. 
Having developed a convenient synthetic route towards the natural polymyxins B1 and B3-5, 
attention was directed towards the design and synthesis of non-toxic analogues. It has been 
proposed that the acyl chain and hydrophobic DPhe6/Leu7 dipeptide may contribute to the 
toxicity of PMB1.28 Based on this concept, both segments were varied independently to give two 
series of analogues. The first series comprised of those in which the (S)-6-methyloctanoic acid 
moiety was replaced with other acyl chains, including 1-adamantane acetic acid (15, Figure 3), 
synthesized using an identical procedure as for PMB1. In the second series, the dipeptide 
DPhe6/Leu7 was replaced with unnatural, commercially available Fmoc-protected dipeptide 
mimics: the β-turn inducing amino acid (S)-3-amino-1-carboxymethyl-caprolactame (Capro 16,
Figure 3),29 the five rigid moieties N-carboxymethylpiperazine (Cmpi 17), m-aminomethylbenzoic 
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acid (Mamb 18),30 p-aminomethylbenzoic acid (Pamb, 19), 4-phenylpiperidine-4-carboxylic acid 
(PhPip 20) and tranexamic acid (Tran 21)31 and finally the flexible δ-aminovaleric acid (Ava 22).  
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FIGURE 3 | Acyl chain (15) and dipeptide mimics (16-22) used for substitution of the original DPhe6-Leu7 
dipeptide in PMB1 (rightmost structure). 
The synthesis of all analogues was performed by slight adaptation of the procedure depicted in 
Scheme 2: double couplings were applied for the incorporation of the dipeptide mimics 16, 18, 19,
and 20. Application of the cleavage-cyclization strategy afforded analogues 24-33 in 37-67% 
purity based on HPLC analysis of the crude peptides (see Figure 4 for two representative 
examples). In contrast to a different on-resin cyclization reaction reported recently,32 these results 
nicely illustrate that the cleavage-by-cyclization reaction appears to be deprived of structural 
requirements and is generally applicable.  
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FIGURE 4 | Representative HPLC traces of crude PMB1 analogues; A Mamb-PMB1 29; B Ava-PMB1 33.
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2.3 | Biological Evaluation 
2.3.1 | Antibiotic activity 
After semi-preparative HPLC purification, natural PMBs and analogues were evaluated for their 
antibiotic activity against Escherichia coli ATCC 11775. As summarized in Table 1, the acyl chain 
modified derivatives (23 and 24) exhibit antimicrobial activities similar to 1. Contrarily, the 
shorter pentanoyl and butanoyl derivatives 25 and 26 are considerably less potent than analogues 
23 and 24, implying that stepwise shortening of the acyl chain results in an increase in MIC value. 
However, analogues containing rigid dipeptide mimics (i.e. compounds 27-30) as well as those 
bearing extended conformation mimicking elements (31 and 32) are devoid of any significant 
antimicrobial activity up to concentrations of 50Ǎg/mL. For PMB1 analogue 33, containing the 
flexible ǅ-aminovaleric acid moiety, a very modest MIC value was determined (500Ǎg/mL).  
TABLE 1 | Antimicrobial data on synthesized natural polymyxins and analogues. 
Polymyxin RA X-YA MIC (g/mL)B
1 (S)-6-methyloctanoyl DPhe6-Leu7 0.3 
3 C8 DPhe6-Leu7 0.6 
4 C7 DPhe6-Leu7 0.3 
5 C9 DPhe6-Leu7 0.3 
23 Ada 15 DPhe6-Leu7 0.9 
24 C6 DPhe6-Leu7 0.7 
25 C5 DPhe6-Leu7 11 
26 C4 DPhe6-Leu7 23 
PMB1 Analogue 
27 (S)-6-methyloctanoyl Capro 16 -c
28 (S)-6-methyloctanoyl Cmpi 17 -c
29 (S)-6-methyloctanoyl Mamb 18 -c
30 (S)-6-methyloctanoyl Pamb 19 -c
31 (S)-6-methyloctanoyl PhPip 20 -c
32 (S)-6-methyloctanoyl  Tran 21 -c
33 (S)-6-methyloctanoyl Ava 22 500 
A See Figure 1 for general polymyxin structure and Figure 3 for structures of 15-22; B
minimal inhibitory concentration against E. coli ATCC 11775; C no 100% inhibition detected 
at concentrations up to 50g/mL. 
2.3.2 | LPS Affinity 
The affinity for LPS was evaluated using a displacement assay.33 In this assay, affinity of PMB 
analogues 4, 5, 24-26 and 28-33 was determined by competitive binding to LPS in the presence of 
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dansylated polymyxin B (DPX). In short, to an LPS solution in which the LPS was saturated with 
DPX, aliquots of PMB analogue were added. Displacement of DPX from LPS by the PMB 
analogues was observed as decrease in fluorescence. In Figure 5, the DPX displacement curves of 
the polymyxins that differ in the length of the acyl chain are compared. Both ‘natural’ PMBs 2 
and 3, and the synthetic PMBs 4 and 5 have somewhat less affinity for LPS compared to 
commercial PMB.34 Shortening of the acyl chain (analogues 24-26) results in a decreased affinity 
for LPS (Figure 5),35 an observation that can be correlated with their respective higher MIC values 
(i.e. C4-PMB (26) and C5-PMB (25) are the least potent). Figure 6 depicts the LPS affinities of 
polymyxin analogues 28-33 carrying ring substituents. 
FIGURE 5 | LPS affinity assay of PMB analogues differing in acyl chain length. n - natural (i.e. isolated 
from a commercial (natural) sample), s - synthetic. Concentration in M.  
Introduction of such ring substituents does not abolish affinity for LPS, but these analogues 
display lower affinity than PMBs 2-5. However, they are able to displace DPX from LPS to a 
similar extent as do the PMB analogues with shortened acyl chains (24-26). The regioisomers 
Pamb-PMB1 (30) and Mamb-PMB1 (29) have the highest and lowest affinities, respectively. 
Interestingly, Pamb-PMB1 (30) and PMBs 3-5 appear to possess similar displacement capacities, 
although their MIC values are rather different (< 1Ǎg/mL for PMBs 3-5 whereas 30 is not active 
up to 50Ǎg/mL). 
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FIGURE 6 | LPS affinity assay of ring-substituted PMB1 analogues and commercial PMB sulfate for 
comparison. Concentration of polymyxin analogue in M.
2.4 | Conclusion 
A SPPS route towards the cyclic CAP polymyxin B1 and analogues thereof has been presented, 
based on a safety-catch strategy. The method has the advantage that relatively pure polymyxins 
are acquired after the final cleavage/cyclization process, obviating extensive purification 
procedures. Antibacterial assays showed that analogues 23-26, in which the (S)-6-methyloctanoyl 
moiety is replaced with other acyl chains, exhibit distinct antimicrobial activity. Shortening the 
length of the acyl chain below C6 leads to a significant drop in activity, which appears to correlate 
with decreased LPS affinities compared to natural polymyxins B,36 as seen for compounds 24-26.
Analogues 27-33, in which the hydrophobic ring segment DPhe6/Leu7 is substituted were 
basically devoid of antimicrobial activity and for these compounds, display decreased affinity in 
the displacement assay. Whether this impaired affinity is due to the loss of a hydrophobic site 
that interacts with the lipid chains of Lipid A or because these analogues are unable to adopt a 3D 
structure that positions the Dab side chains in proximity of Lipid A’s phospate groups for 
efficient electrostatic interactions, is not clear. There is no evidence that either of these two 
possible causes of loss of LPS affinity is responsible for the antibacterial inactivity; although the 
natural PMB2 and B3 and synthetic PMB4 and B5 compared to Pamb-PMB1 30 display quite 
similar LPS affinity, their respective MIC values are rather different (<1Ǎg/mL vs. >50Ǎg/mL). 
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From this, it appears that an intact ring segment is more important for antibacterial activity than 
the hydrophobic acyl chain (although there is a minimal chain length required for activity in the 
low Ǎg/mL range). 
In general, nature appears to have optimized the ring structure of the polymyxin series of 
antibiotics to a large extent, as only small variations in the ring section are found in natural 
compounds (Table 1) and tolerated in synthetic polymyxins1d,37 and the closely related polymyxin 
B nonapeptide (PMBN);38 with a few exceptions, modulation of the hydrophobic segments in 
polymyxin B1 leads to analogues with slightly decreased LPS affinity, but a significant loss in 
antibiotic activity. 
2.5 | Experimental Section 
2.5.1 | General
Analytical and semi-preparative HPLC was performed on an ÄKTA Explorer chromatography system 
(Amersham Pharmacia Biotech). The peptides were analyzed using a Zorbax SB C18 column (4.6x150mm, 5Ǎ
particle size, denoted as column 1 or an Alltech Alltima C18 4.0x250mm, 5Ǎ particle size, column 2). The 
following buffers were employed: (A) 0.1% TFA in 5% aq. MeCN and (B) 0.1% TFA in 80% aq. MeCN. 
MALDI-TOF analyses were performed on a Bruker Biflex III mass spectrometer. ESI-MS analyses were 
performed on a Q-TOF mass spectrometer (Micromass) at a cone voltage of 20V. 
2.5.2 | SPPS
Loading of AM resin with SCL and Fmoc-Thr(tBu)-F (8) 
Loading of the AM resin with SCL (3-carboxypropanesulfonamide) and subsequent preparation using 
DAST and coupling of Fmoc-Thr(tBu)-F was accomplished following the procedure of Ingenito et al.23 with
some modifications. Loading of the safety-catch resin (2g, 0.72mmol) was accomplished with DiPEA 
(2.25mL, 11mmol) and Fmoc-Thr(tBu)-F (2.65g, 7.7mmol) in CH2Cl2 (12mL) and the reaction time was 
extended to 5h to give 8 with a loading of 64%. 
SPPS of linear polymyxin B1 (10) 
The acylated decapeptide 10 was synthesized on an ABI 433A (Applied Biosystems) peptide synthesizer. 
The synthesis was performed on 100Ǎmol scale starting from 8 (0.43g, 0.23mmol/g). Cleavage of Fmoc 
groups was effected with 20% piperidine/DMF. Single couplings were performed using Fmoc-amino acids 
(5eq.) in NMP with BOP/HOBt/DiPEA as activator system. Residues 3, 4, and 5 were doubly coupled using  
2x4eq. Capping was performed after each coupling step by acetylation (Ac2O/HOBt/DiPEA) in NMP. 
On-resin protective group manipulation (12) 
Immobilized peptide 10 (100Ǎmol) was suspended into a solution of 2% NH2NH2.H2O in DMF (5mL) and 
shaken for 3min. The mixture was filtered and the resin rinsed with DMF and CH2Cl2. This procedure was 
repeated twice to give resin 11. Subsequently, the resin was suspended in NMP (1mL), DiPEA (0.1mL, 
0.5mmol) and MMTCl (0.11g, 0.35mmol) were added and the mixture was shaken for 4h. The resin was 
filtered, washed with CH2Cl2 and MeOH to give 12.
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Activation of SCL (13) 
A solution of ICH2CN (0.57mL, 7.9mmol) in NMP (1mL) was passed through a basic alumina plug under 
the exclusion of light. The resin 12 (100Ǎmol) was suspended in the obtained solution and subsequently 
DiPEA (0.2mL, 1mmol) was added. The suspension was shaken for 16h under the exclusion of light. The 
activated resin 13 was filtered and washed with NMP and CH2Cl2.
Removal of MTT protecting group (14) 
The activated resin 13 was suspended in TFA/TIS/CH2Cl2 (3mL, 3/5/92, v/v/v) and shaken for 30min. 
This procedure was repeated with 10min periods until the filtrate became colourless. After washing with 
CH2Cl2, resin 14 was washed with CH2Cl2 and used immediately in the cyclization reaction. 
Polymyxin B1 (1) 
To a suspension of 14 (100Ǎmol) in freshly distilled THF (3mL), DiPEA (0.17mL, 0.85mmol) was added. The 
obtained cyclization/cleavage mixture was shaken for 24h at RT. The resin was filtered and washed with 
CH2Cl2, MeOH and CH2Cl2, respectively. The filtrate and washing solutions were concentrated in vacuo to 
afford the protected cyclic peptide. The residue was suspended in a mixture of TFA/TIS/H2O (5mL, 
95/2.5/2.5 v/v/v) and shaken for 2h. The deprotected polymyxin was precipitated in Et2O. The precipitate 
was centrifuged and the solvent was decanted to give 22.9mg of crude PMB1 (Rt 9.92min, column 1, purity 
50%). The crude cyclic peptide was purified using HPLC (linear gradient of 0-100% B in 20min) and 
lyophilized to furnish pure 1. Yield after purification: 1.9mg (1.5Ǎmol, 1.5%). ESI-MS: 1203.8 [M+H]+, 602.4 
[M+2H]2+, 402.3 [M+3H]3+. See also Table 2 and Figure 7 (part of the ROESY NMR spectrum). 
Synthesis of PMB1 derivatives (3-5, 23-33) 
Derivatives 3-5 and 23-33 were synthesized through a similar reaction sequence as was 1, implementing  the 
modifications in amino acid sequence or acyl chain composition. Analytical data: see Table 2. Exact 
concentrations of polymyxin solutions were determined by comparison of the LC UV 214nm peak area with 
that a solution of PMB1 of which the exact content was known. This content was calculated by integration of 
the phenyl ring proton 1H NMR signals and comparison with the internal reference tetramethylsilane proton 
signals of known concentration. Part of the ROESY NMR spectrum of 29 is found in Figure 8. 
2.5.3 | Antibacterial Assay
The bacteria (E. coli ATCC 11775) were grown on nutrient agar plates and kept at 40C. Lyophilized peptides 
were dissolved in Luria-Bertani (LB) broth to give a concentration of 80ǍM and filtered using 0.22Ǎm filter 
discs. An overnight culture in LB broth was adjusted to 5x106 CFU/mL and inoculated into the micro titre 
plate wells containing each 100ǍL of a serial 2-fold dilution (50-0.1Ǎg/mL) of the tested peptide in LB broth. 
After incubation for 24h at 370C, absorbance was measured at 600nm using a ǍQuant micro plate 
spectrophotometer (Bio-Tek Instruments). The MIC value of Ava-containing polymyxin 33 was determined 
separately. Hereto, the serial 2-fold dilution assay was adjusted to concentrations ranging from 1000 to 
2Ǎg/mL. Analogue 26 was tested in quadruplo; all other peptides were assayed in duplo. 
2.5.4 | LPS Affinity Assay
Affinity for LPS (Sigma L6761 S. enteritidis ATCC 13076 or Sigma L6529 from E. coli O55:B5 for 24-26, 28 and 
31; using commercially available PMB no difference between these two LPS preparations was found) was 
assessed in 2-fold using a competitive displacement assay employing commercially available dansylated 
polymyxin B. The DPX background fluorescence was determined by addition of an aq. DPX solution (5ǍL, 
100ǍM) to HEPES buffer (5mM, pH 7.2, 1mL) at 340nm excitation and 495nm emission wavelenghts; this 
addition was repeated 5-10 times. Saturation of LPS with DPX was determined by measuring fluorescence of 
a mixture of DPX solution (5ǍL, 100ǍM) and LPS solution (3Ǎg/mL in 5mM HEPES buffer pH 7.2, 1mL). 
Aliquots of 5ǍL of DPX solution were continuously added to the LPS solution until the fluoresence leveled 
off and the increase was only a result of the change in background. The amount of DPX to be added to the 
LPS solution to give 85-90% of saturation (Z-amount) was calculated from these data. For determination of 
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the amount of displacement of DPX, this Z-amount of DPX solution was added to 1mL LPS solution and 
equilibrated at RT for 10-15min. Aliquots of synthetic polymyxin analogue (5ǍL, 100ǍM in water) were 
added and the fluorescence measured after 30-60s until the maximum displacement was reached.  
TABLE 2 | Data on synthesized polymyxins. 
# Modifi-
cation
Scale
(mol)
Crude 
(mg)
Rt (min, 
column)
Crude 
Purity
Pure (mg, 
mol)
Yield 
(%)
MS
1 PMB1 100 22.9 9.92 (1) 50% 1.9, 1.5 1.5 1203.8A
3 PMB3 50 n/d 9.87 (1) 53% 2.9 3.1 1188.8A
4 PMB4 20 n/d 9.85 (1) 60% n/dC n/d 1174.8A
5 PMB5 20 n/d 9.93 (1) 62% n/dC n/d 1202.7A
23 Ada 50 18.4 9.50 (1) 44% 2.8, 2.3 4.5 1239.8B
24 C6 50 14.1 8.42 (1) 48% 2.5, 2.2 4.3 1161.7B
25 C5 50 17.9 8.01 (1) 46% 3.3, 2.9 5.8 1147.7B
26 C4 30 6.5 7.98 (1) 38% 1.2, 1.0 3.5 1133.9B
27 Capro 45 n/d 9.00 (2) 42% n/dC n/d 1112.2A
28 Cmpi 45 n/d 8.72 (2) 51% n/dC n/d 1068.7A
29 Mamb 100 32.7 10.83 (2) 67% 9.8, 9.1 9.1 1076.6B
30 Pamb 40 4.7 8.43 (1) 37% n/dC n/d 1076.6B
31 PhPip 40 10.9 8.45 (1) 49% 1.8, 1.6 3.9 1130.7B
32 Tran 40 3.9 8.33 (1) 49% n/dC n/d 1082.6B
33 Ava 100 21.4 10.6 (2) 67% 2.8, 2.7 2.7 1042.6B
A ESI-MS [M+H]+; B MALDI-MS; C Synthesis under unoptimized conditions;  n/d - not determined 
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FIGURE 7 | Part of the 600MHz PMB1 (1) ROESY spectrum in 43% (v) TFE-d3/H2O, 298K, pH 4, mixing time 
200msec. Intraresidual NOE contacts of amide NH peaks with other atoms are given in regular 
face; interresidual NOEs are denoted in bold/italic face and are connected with lines to the 
corresponding signals, residues are depicted by their numbers; MOA is the 6-methyloctanoyl 
chain. Thus, the amide proton of residue 6 (i.e. DPhe6NH) has interresidual NOE contacts with 
the two 5ş protons (Dab5Hşa and Hşb) and the amide proton of residue 2 (Thr2NH) has 
intraresidual NOE contacts with Thr2HŠ, HŞ and Hş atoms (denoted in the spectrum as 2Š, 2Ş
and 2ş, respectively). 
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FIGURE 8 | Part of the 600MHz Mamb-PMB1 (29) ROESY spectrum in 43% (v) TFE-d3/H2O, 298K, pH 4, 
mixing time 200msec. Intraresidual NOE contacts of amide NH peaks with other atoms are 
given in regular face; interresidual NOEs are denoted in bold/italic face and are connected 
with lines to the corresponding signals. Residues are depicted by their numbers; the Mamb 
moiety replaces both residues 6 and 7 in PMB1 and is denoted with M; MOA is the 6-
methyloctanoyl chain. For example, the amide proton of residue 3 (i.e. Dab3NH) has 
interresidual NOE contacts with 2Ş and 2ş protons (Thr2HŞ and Hş) and intraresidual NOE 
contacts with Dab3HŠ, HŞ and the two inequivalent Hş atoms (denoted in the spectrum as 
3Š, 3Ş and 3ş, respectively). The Mamb residue covers residues 6 and 7. 
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3.1 | Introduction 
Polymyxins, potent antibiotics of the class of cationic antimicrobial peptides, are receiving 
increasing attention due to their unique combination of antibacterial and endotoxin-neutralizing 
properties.1 Consequently, their chemical properties have been the subject of a number of studies, 
carried out mostly in the second half of the last century. These studies supply data on the stability 
of formulations of polymyxins B,2,3 E,4,5 and M6 (see Table 1). Polymyxins B and M were found to 
be stable in neutral and mildly acidic media, but became inactivate after exposure to basic or 
strongly acidic conditions.2a,7,8 This decrease in activity in both basic and acidic solutions were 
hypothesized to be the result of acyl or aminoacyl migration.8 Studies on model systems 
established the possibility of both migrations in Nα-(amino)acylated Dab (α,γ-diaminobutyric 
acid) residues under basic and acidic conditions.7,8,9
TABLE 1 | Composition of polymyxins B, E and M. Different acyl chains (R) can be connected to the Dab1 
residue – see Chapter 2. For polymyxin B1, R=(S)-6-methyloctanoyl; for polymyxin B3 
R=octanoyl.
Polymyxin AA6 AA7
B DPhe Leu 
E DLeu Leu 
M DLeu Thr 
3.2 | Isomerization in Polymyxins 
3.2.1 | Isolated polymyxin B1 
In a recent analytical study by Orwa et al. devoted to the stability of single polymyxins isolated 
from commercial samples (e.g. a commercial sample of polymyxin B contains at least 7 
compounds in varying amounts, see Chapter 2 Figure 1),10 formation of degradation products 
was observed upon exposure to a range of conditions.11 Interestingly, a number of these products 
showed different retention time on HPLC but possessed a molecular weight identical to that of 
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the substrate. For example, when polymyxin B1 (PMB1, Table 1) was subjected to an acid stability 
test, a side-product was formed with a longer Rt than PMB1 itself, but with identical molecular 
weight (Figure 1).  
FIGURE 1 | TIC diagram of isolated PMB1 after acid stability test for 6d at pH 1.4, showing the presence 
of a side-product, and MS spectra of the two peaks. Peak at 602.6 represents [M+2H]2+.
Reprinted with permission from A. Van Schepdael, personal communication.
Interestingly, subtle differences were found (see Figure 2) in the MS/MS spectra of both peaks. 
For example, peaks present in both spectra are different in relative intensity, and a number of 
peaks are absent in the side-product’s spectrum, including 241.0, 414.0, 432.3, 482.4, 863.3 and 
963.4. The fatty acyl group (FA, in PMB1 this is (S)-6-methyloctanoyl) seems to be involved in all 
these fragments as in PMB1 these peaks represent FA+Dab1 (241.0), M-(FA+Dab1+Dab5) (863.3) 
and M-(FA+Dab1) (963.4).10b-c,12 Peaks 482.4 (2+ ion of 963.4), 432.3 (2+ ion of 863.3) and 414.0 
(432.3-H2O) also relate to these fragments. In this study, it was concluded that this isomeric side-
product arose from epimerization of PMB1.11 However, besides the fact that in this study no data 
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was supplied to justify this theory (no attempts were made to localize the site of isomerization), 
amino acid epimerization is highly unlikely under acidic conditions as this process proceeds 
through an anionic species.13
FIGURE 2 | TIC diagram of isolated PMB1 after acid stability test, showing the presence of a side-product,
     and MS/MS spectra (of the [M+2H]2+ ion) of the two peaks. Reprinted with permission from A. 
Van Schepdael, personal communication.
3.2.2 | Synthetic polymyxins 
As isolation of substantial amounts of every individual polymyxin from a commercial PMB 
sample requires an extremely time-consuming purification procedure,10b the chemical synthesis 
of PMB subfamily members was undertaken (Chapter 2). In the course of these studies, formation 
of a small amount (typically 5-10%) of a side-product with identical molecular weight but 
different LC retention time was encountered, reminiscent of the isolated PMB1 case (vide supra). 
Remarkably, after HPLC repurification, concentration in vacuo to remove solvents and 
redissolution of e.g. synthetic polymyxin B3 (PMB3), LCMS revealed the side-product had formed 
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again in a similar (5-10%) amount (Figure 3). Peaks in Figure 3 marked with arrows arose from 
two separate compounds both containing [M+H]+ 1190.0 and [M+2H]2+ 595.5 as major ions. 
Subjection of both peaks present in the mixture to MS/MS analysis displayed differences in 
abundances of a series of peaks between the spectra of PMB3 and the side-product (Figures 4 and 
5). 
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FIGURE 3 | LC diagram of purified PMB3, showing the presence of a side-product with identical molecular 
weight. 
FIGURE 4 | [M+2H]2+ MS/MS spectrum acquired for PMB3 and proposed fragmentation routes I and II.10b-c,12
The structures of four ions offering information about the FA residue or the ring amino acids 
DF6 and L7 are shown (FA=fatty acyl (i.e. octanoyl), amino acids in one letter code (X=Dab)). 
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FIGURE 5 | [M+2H]2+ MS/MS spectrum obtained from the side-product formed during PMB3 synthesis. 
These differences are similar to those seen in the case of PMB1 and the corresponding side-
product (vide supra); comparable peak disappearance in the side-product’s MS/MS relating to 
fragments containing FA is found in the absence of fragments 227.0, 863.2, 963.3 and the doubly 
charged ions 432.3 and 482.4 (see Table 2 in the Experimental section). This indicates that a 
similar isomerization process has taken place in both isolated PMB1 and synthetic PMB3. As acyl 
migration between Nǂ and NǄ positions in Dab residues were found possible to occur in 
comparable systems (vide supra) through an energetically favorable 6-membered ring transition 
state, it was reasoned that acyl migration at Dab1 had taken place rather than epimerization.  
3.3 | Synthesis & Analysis of the Acyl-Migrated Product 
To obtain proof regarding the structure of the observed side-product resulting from NǂÆNǄ acyl 
migration, the acyl-migrated product of PMB3 was synthesized. This regioisomer, the new 
polymyxin analogue Nγ-PMB3 (Figure 6B), was obtained following the safety-catch procedure 
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introduced in Chapter 2. Key step in this synthesis is the on-resin cyclization of the linear 
polymyxin with concomitant cleavage from the resin, which can only occur after activation of the 
resin by alkylation. This procedure generally yields a crude product of high purity that is not 
contaminated with its linear counterpart, obviating a tedious purification procedure. The 
reported procedure was slightly altered, applying Boc-Dab(Fmoc)-OH instead of Fmoc-Dab(Boc)-
OH as the last amino acid residue to achieve acylation at the Nγ position of Dab1. 
FIGURE 6 | Structures of PMB3 (A) and its regioisomer, Nγ-PMB3 (B). 
Upon co-injection of the HPLC-purified, side-product-containing PMB3 mixture (Figure 3) with 
Nγ-PMB3, the Nγ-PMB3 retention time in LC was found to be identical with the one observed for 
the side-product (Figure 7). Moreover, comparison of the MS/MS spectra of the PMB3 isomeric 
side-product with the synthetic NǄ-PMB3 showed that they were identical (Figures 5 & 8).  
FIGURE 7 | LC chromatogram of crude PMB3 mixture co-injected with Nγ-PMB3. Peak A: PMB3, peak B:
Nγ-PMB3 coincides with the obtained side-product as determined by MS/MS.
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FIGURE 8 | MS/MS spectrum obtained from [M+2H]2+ of synthetic Nγ-PMB3.
Based on these data it was concluded that the formed side-product corresponds to the structure 
in Figure 6B, being the Nγ-regioisomer of the desired polymyxin resulting from NÆN’-acyl 
migration in the Dab1 residue. 
3.4 | Determination of Favored Isomer 
Acyl migration takes place from both Nα- and Nγ-acylated single Dab residues, in both cases 
favoring the Nα-product under slightly acidic conditions to yield approx. 60% Nα-product.7a To
examine their chromatographic behavior, both Nα- and Nγ-octanoyl-Dab were synthesized by 
SPPS and treated thereafter in a similar way as was PMB3. In the final product mixture after 
synthesis of Nγ-octanoyl-Dab, only a small amount of this compound was obtained, accompanied 
by the major product Nα-octanoyl-Dab, whereas no Nγ-octanoyl-Dab was found in the synthesis 
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of Nα-octanoyl-Dab (by comparison of LCMS chromatograms: both [M+H]+ 244.5, C18 RP 
column, 15Æ90% MeCN/0.1% aq. TFA in 26min; Nα Rt 8.79min, Nγ Rt 9.15min). 
In order to examine the scope of the polymyxin NÆN’-acyl migration reported here, a stability 
study of PMB3 and Nγ-PMB3 was performed as a function of temperature (RT and 600C) and pH 
(1.4, 4.4 and 7.4). The obtained LCMS/MS chromatograms of these samples showed that acyl 
migration does not take place at RT. The formation of Nγ-PMB3 from PMB3 at 600C at the 
different pH values is presented in Figures 9A-C. 
FIGURE 9 | Profiles showing the LC peak areas of PMB3 and Nγ-PMB3 in time at 600C as a function of pH. 
A,B,C starting from PMB3; D,E,F starting from Nγ-PMB3. pH 1.4 (A,D), 4.4 (B,E) and 7.4 (C,F).
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The NαÆNγ acyl migration reached a maximum in the medium with pH 1.4 after approx. 48h, by 
which time ~7% Nγ-PMB3 had formed (Figure 9A). Nγ-PMB3 is formed fastest at neutral pH, 
which can be explained by the fact that at this pH value the Nγ of Dab1 is more nucleophilic.  
The formation of PMB3 out of Nγ-PMB3 (i.e. NγÆNα migration, Figures 9D-F) occurred 
most rapidly at low pH and equilibrated after approx. 48h. For pH 1.4, at this point ~20% of the 
Nγ-PMB3 was left. Conversion of either polymyxin went most rapid at pH 7.4 (Figures 9C and F). 
It should be noted that the decrease in PMB3 and Nγ-PMB3 levels might be partially ascribed to 
the formation of other degradation products that were not identified. 
3.5 | Biological Evaluation 
To investigate whether this NÆN’-acyl migration has an effect on the potency of the polymyxin 
as antibiotic, minimal inhibitory concentrations (MIC) values were determined against Escherichia 
coli ATCC 11775 using a 2-fold serial dilution assay (see Chapter 2). PMB3 was found to have a 
MIC value of 0.6ǍM, whereas the antibacterial potency of Nγ-PMB3 had decreased to a MIC 
value of 2.5ǍM, showing that, at least in PMB3, Dab1 NαÆNγ acyl migration has a negative effect 
on antibacterial activity. 
3.6 | Summary 
The structure of a side-product found in the synthesis of polymyxin B3 was elucidated. This side-
product, with a mass identical to PMB3 but with different LC retention time, reappeared after 
purification of PMB3 and resulted from isomerization of the parent compound under acidic 
conditions. Acyl migration was hypothesized to have taken place at the alkanoylated Dab1 
residue. Although the rare amino acid Dab occurs in some other natural products (e.g. in the 
peptide antibiotics friulimicins,14 syringomycin,15,16 syringopeptins,15,17 gavaserin and saltavalin,18
cepacidine A,19 pseudomycins,20 xylocandin,21 fuscopeptins,22 and tolaasins23), none of these 
compounds contain an N-terminally alkanoylated Dab residue,24 providing no precedent for such 
a hypothesized NÆN’ acyl shift. LC and MS/MS analyses showed the side-product to be 
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identical with the synthetic PMB3 regioisomer having the Nα-Dab1 acyl chain migrated to its Nγ
position. Analogously, this isomerization most likely also occurred during the acid stability test 
of isolated PMB1, rather than epimerization as proposed by Orwa et al.
3.7 | Experimental Section 
3.7.1 | SPPS 
PMB3 was prepared on 50Ǎmol scale as reported previously (see Chapter 2). Nγ-PMB3 was prepared 
analogously on 50Ǎmol scale, except for the coupling of the last residue to the peptide sequence. This moiety 
was incorporated using Boc-Dab(Fmoc)-OH instead of Fmoc-Dab(Boc)-OH. After liberating the peptides 
from the solid support, the compounds were purified using an ÄKTA ExplorerTM LC system equipped with 
an Alltima semi-preparative C18 column (250 x 10mm, 5 Ǎm particle size) employing gradients of buffers A 
(0.1% TFA in 5% (v) MeCN/H2O) and B (0.1% TFA in 80% (v) MeCN/H2O) and simultaneous detection at 
214 and 254nm. Collected product fractions were combined and evaporated or lyophilized using a LC1010 
vacuum centrifuge (preventing isomerization) to yield PMB3 (1.9mg, 3.2%) and Nγ-PMB3 (2.1mg, 3.5%) 
respectively. ESI-MS (both compounds): [M+H]+ 1190.0, [M+2H]2+ 595.5. LC: PMB3 Rt 14.14min, NǄ-PMB3 
Rt 17.05min. 
3.7.2 | LCMS and MS/MS Analyses 
The LC apparatus consisted of a Spectra HPLC system equipped with a YMC-Pack Pro C18 column (5μm, 
250x2.0mm, Waters), immersed in a water bath at 30°C, employing 0.01M aq. TFA/MeCN (77/23 (v/v)) as 
buffer. Mass spectra were recorded on a LCQ ion trap mass spectrometer equipped with an ESI interface 
operated in the positive ion mode at 5kV and capillary temperature of 210°C. Helium was used as collision 
gas at a pressure of 0.1Pa. MS acquisition over the mass range 500-1500 was performed on-line with UV 
detection at 215nm. The doubly-charged ions of the products in the sample were isolated mono-isotopically 
in the ion trap.  
3.7.3 | Stability Studies 
Appropriate amounts of 0.1M aq. H2KPO4 and 0.1M aq. HK2PO4 were mixed to pH 7.4. Similarly, buffers of 
pH 1.4 and pH 4.4 were prepared from 0.1M aq. H2KPO4 and 0.1M aq. phosphoric acid. For the stability 
study at different pH values and temperatures, reactions were initiated by diluting stock aqueous solutions 
of 0.25mg/mL PMB3 and Nγ-PMB3 with equal amounts of buffers pH 1.4, 4.4 or 7.4 to give solutions of 
0.125mg/mL. Aliquots in sealed vials were incubated at RT and at 60°C. Vials were removed at regular 
intervals and immediately frozen at -20°C until they were analyzed as a series. For pH 1.4 and pH 4.4 vials 
were removed after 1h, 24h, 48h and 144h. Those at pH 7.4 were removed after 1h, 3h and 6h. 
3.7.4 | Antibacterial Assay 
Antibacterial assays against E. coli ATCC 11775 were performed in 3-fold as previously described (Chapter 
2).
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TABLE 2 | Fragments found in MS/MS spectra of PMB3 and its isomer
FragmentA Origin PMB3 isomer
227.0 FA+Dab1 + - 
232.9 unknown + + 
260.9 DPhe6+Leu7 + + 
328.0 FA+Dab1+Thr2 - + 
361.0 DPhe6+Leu7+Dab8 + + 
410.1 428-H2O + + 
423 2+ ion of 845 + - 
428.1 FA+Dab1+Thr2+Dab3 + + 
432.3 2+ ion of 863 + - 
461 DPhe6+Leu7+Dab8+Dab9 + + 
464 2+ ion of 963-2H2O + - 
473 2+ ion of 963-H2O + - 
482.4 2+ ion of 963 + - 
495.3 unknownC - + 
527.4 2+ ion of 1090 (M-Dab)B–2H2O - + 
528.1 FA+Dab1+Thr2+Dab3+Dab4 + - 
536 2+ ion of 1090 (M-Dab)-H2O + + 
545.4 2+ ion of 1090 (M-Dab) + + 
569 2+ ion of M-3H2O + + 
578 2+ ion of M-2H2O + + 
586.5 2+ ion of 1172 (M-H2O) + + 
662.2 DPhe6+Leu7+Dab8+Dab9+Thr10+Dab4 + + 
711.3 729-H2O + + 
729 FA+Dab1+Thr2+Dab3+Dab4+Thr10+Dab + + 
744.3 762-H2O + + 
762.3 DPhe6+Leu7+Dab8+Dab9+Thr10+Dab4+Dab3 + + 
812 829-H2O + + 
829.3 M- DPhe6-Leu7-Dab + + 
845.3 863-H2O + + 
863 M-FA-Dab1-Dab5 + - 
945.4 963-H2O + - 
963.3 M-FA-Dab1 + - 
These fragments are designated present (+) or absent (-) for PMB3 but are applicable for its isomer on the 
premise that identical parts in both molecules give identical fragment peaks. A Approximate values  of 
peaks that are not denoted in spectra, or in which decimals differ by 0.1 are not given in decimal values; 
B M=1190; C might be 2+ ion of 990 (M-2Dab). 
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4.1 | Introduction
In addition to its potent antibiotic activity against Gram-negative bacteria, polymyxin B (PMB, 
see Chapter 2) is able to bind and neutralize endotoxin (or lipopolysaccharide, LPS). This 
neutralizing capacity may prevent a Gram-negative bacterial infection from reaching the state of 
sepsis or the aggravated, often lethal form septic shock.1 Furthermore, PMB is able to sensitize the 
Gram-negative bacterial outer membrane. In an attempt to impose these favorable features of 
PMB onto another antibiotic, a conjugate with the ristomycin A aglycon2 was prepared. The 
resulting compound was cidal to both Gram-positive and Gram-negative bacteria. However, 
PMB exerts toxicity and is therefore restricted to topical use. 
The polymyxin B nonapeptide (PMBN 1, Figure 1), a truncated form of PMB without the 
fatty acyl chain and the Dab1 residue, was reported to have lost both toxicity and antibacterial 
activity. It still sensitizes Gram-negative bacteria to other drugs3 and neutralizes LPS (indicating a 
strong binding to LPS), albeit to a somewhat lower extent than PMB.4
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FIGURE 1 | Structure of polymyxin B nonapeptide (PMBN). 
It was envisaged that conjugation of PMBN to other members of the cationic antimicrobial 
peptide (CAP) class of antibiotics would favorably influence their biological activities. The 
membranolytic CAPs tritrpticin (TTC)5 and KFF6 (Table 1), known to be rather unselective in 
their lytic actions in the sense that they also lyse red blood cells (RBC), might be rendered less 
hemolytic (more selective) by conjugation to non-hemolytic PMBN. Furthermore, the PMBN 
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moiety could attribute to bacterial uptake and enhance antimicrobial activity by sensitizing the 
outer membrane to these CAPs.7
TABLE 1 | Linear CAPs used in this study
Abbreviation SequenceB Target
BF2 TRSSR AGLQF PVGRV HRLLR K DNA/RNA 
  DRCA GKPRP YTPRP TSHPR PIRV DnaK
KFF KFFKF FKFFKa Membrane 
TTC VRRFP WWWPF LRRa Membrane 
A Drosocin analogue (Ser7ÆThr)DRC nG. B a = C-terminal carboxamide
Linear CAPs with targets in the inside of the bacterium, such as buforin II (BF2, binds to nucleic 
acids)8 and drosocin (DRC, targets the bacterial heat shock protein DnaK)9 would also benefit 
from conjugation to PMBN. Besides the aforementioned features of sensitization and selectivity, 
these particular CAPs might experience enhanced uptake through the inner membrane to arrive 
at the cytosol and thus show enhanced antibacterial activity. Finally, linear CAPs conjugated to 
PMBN are expected to be endowed with LPS neutralizing activity arising from the polymyxin 
moiety.
4.2 | Design & Synthesis 
Conjugates of PMBN with the linear CAPs listed in Table 1 were designed to consist of two 
separate moieties connected via a disulfide linkage (Figure 2). This linkage enables disconnection 
of the two moieties by reductive activities present in the bacterial cell10 and was implemented to 
overcome possible interference of PMBN with the antimicrobial actions of the linear CAPs. This is 
especially important in the case of conjugates with BF2 and DRC that target internal structures. 
Construction of this disulfide-linked type of PMBN/CAP conjugates calls for separate syntheses 
of thiol-functionalized PMBN and linear CAP parts. The thiol function in the linear CAP part is 
equipped with a 2-pyridylsulfenyl (SPy) leaving group, which enables selective heterodisulfide 
formation (vide infra).11
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FIGURE 2 | Schematic representation of disulfide conjugates of CAPs with PMBN. The disulfide bridge is 
located at the C-terminus of the CAP. 
4.2.1 | Synthesis of a thiol-functionalized PMBN derivative 
An important consideration in the design of a PMBN derivative that can be used in conjugation is 
the position of the thiol modification; it is known that modification of specific residues in PMB(N) 
results in loss of LPS affinity.12 The fact that, from PMB, the fatty acyl (FA)-Dab1 moiety can be 
removed without abolishing LPS affinity (yielding PMBN), indicates that the PMBN N-terminal 
Thr residue can serve as attachment point for conjugation. This approach yields defined 
conjugates (Figure 2).7,13 Thus, a Cys residue was added to the N-terminal Thr residue to provide 
a thiol function for participation in disulfide conjugation.  
The convenient route towards the synthesis of natural polymyxins reported in Chapter 2 
was slightly adapted for the synthesis of this new polymyxin derivative. Starting from Thr-
loaded resin 2 (Scheme 1), Boc-Cys(Tr)-OH was coupled as last residue to the linear, protected 
PMBN to give 3a. Resin 3a was then alkylated with ICH2CN/DiPEA (Æ4a) and subsequently 
treated with acid to liberate the Dab4 side chain. Although the N-Mtt group in 4a was expected to 
be more acid labile than the S-Tr group, it was not possible to detect full orthogonality between 
the N-Mtt and S-Tr (Ellman test) groups in test reactions. Therefore, both groups were removed 
to yield 5a, in which two nucleophiles can now take part in the subsequent ‘cleavage-by-
cyclization’ reaction: attack of the Dab4 side chain amine on the Thr carbonyl yields the correctly 
cyclized polymyxin derivative 6a directly. Nucleophilic attack of the Cys1 side chain yields the 
internal thioester instead (Scheme 2). If formed, this thioester could undergo conversion through 
a ‘native chemical ligation’-like mechanism (SÆN acyl migration) to give the correct product 6a
as well.  
-S-S-
LPS affinity moiety
(PMBN)
Antibacterial moiety
(CAP)
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SCHEME 1 | Synthesis of CPMBN. Reagents & conditions: i. Fmoc-based SPPS (see Chapter 2); ii. ICH2CN, 
DiPEA, NMP; iii. TFA/TIS/CH2Cl2 5/3/92 (v/v/v) iv. DiPEA, THF; v. TFA/TIS/H2O 95/2.5/2.5 
(v/v/v); vi. HPLC purification. 
SCHEME 2 | Formation of 6a through conversion of an internal thioester formed from 5a via a native 
chemical ligation (NCL)-like mechanism. 
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After subjection to cyclization conditions and deprotection, Cys1-modified PMBN (CPMBN) 7
was obtained in a crude cyclization yield of 25%. 
Unfortunately, the CPMBN 7 obtained via this route was contaminated with a small amount of 
undesired linear CPMBN, which is likely to have resulted from hydrolysis of unrearranged 
internal thioester. The formation of this hydrolysis product, together with the fact that both 6a
and 7 are susceptible to the formation of disulfide-linked homodimers during storage, led to 
adjustement of the synthesis of 7. The Cys side chain S-Tr group was replaced by an S-StBu 
group giving 3b (Scheme 3). This peptide was carried through a similar reaction sequence as was 
3a in Scheme 1A.  
SCHEME 3 | Alternative synthesis of CPMBN 7. Reagents & conditions: i. ICH2CN, DiPEA, NMP; ii. 
TFA/TIS/CH2Cl2 5/3/92 (v/v/v) iii. DiPEA, THF; iv. TFA/TIS/H2O 95/2.5/2.5 (v/v/v); v. 0.1M 
TCEP.HCl, pH 4.5; vi. HPLC purification.
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This S-StBu strategy had a similar crude cyclization yield as the S-Tr strategy, but with the 
advantage that the Dab4 side chain can be liberated selectively (Æ5b), and the cyclized product 
6b could be stored conveniently without risk of oxidation. The Cys protecting group in 6b was 
removed quantitatively, as gauged by LCMS, by the action of tris(carboxyethyl)phosphine 
(TCEP),14 after which the compound was purified by HPLC to give fully deprotected 7.
4.2.2 | Synthesis of thiol-functionalized linear CAP moieties 
Four linear CAPs differing from each other regarding secondary structure, target and 
composition were selected for conjugation (see Tables 1 and 2). In short, buforin II (BF2) and a 
modified drosocin analogue (DRC, Chapter 1) with increased serum stability were selected as 
CAPs targeting structures inside the bacterial cell. Tritrpticin (TTC) and the synthetic peptide 
(KFF)3K (denoted KFF) act through lysis of the bacterial inner membrane. Two of these CAPs 
(BF2 and KFF) display α-helical structures upon interaction with the bacterial membrane, 
whereas the structures of DRC and TTC were found to be largely extended. The selected CAPs 
were equipped with a C-terminal Cys(Tr) residue to provide the thiol function for disulfide 
formation with CPMBN 7. Additionally, a δ-aminovaleric acid (Ava) linker was incorporated 
separating the Cys residue from the CAP to circumvent sterical interference from the linear CAP 
with the interaction of PMBN with LPS. The linear peptides were synthesized through standard 
automated Fmoc-based SPPS protocols using HCTU as coupling reagent and cleaved from their 
resins in the presence of 2,2’-dithiobispyridine to obtain CAPs 8-11 with a 2-pyridylsulfenyl (SPy) 
leaving group attached to the side chain of the Cys residue (Table 2).11
TABLE 2 | Modified peptides
A of the unmodified CAPs;  B  X = Ava, SPy = 2-pyridylsulfenyl, a = carboxamide
# From CAP StructureA SequenceB
8 BF2 α-helical TRSSR AGLQF PVGRV HRLLR KXC(SPy)a 
9 DRC extended GKPRP YTPRP TSHPR PIRVX C(SPy)a 
10 KFF α-helical KFFKF FKFFK XC(SPy)a 
11 TTC extended VRRFP WWWPF LRRXC(SPy) 
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4.2.3 | Conjugation 
Having CPMBN 7 and CAPs 8-11 in hand, attention was focussed on their conjugation. Selective 
asymmetric disulfide formation was accomplished through the use of the SPy leaving groups in a 
neutral aqueous environment, as monitored by LCMS; once expelled, the SPy group does not 
take part in disulfide formation due to its inactivity at pH 7. Using an excess of CAP, all CPMBN 
was found consumed after 16h of reaction (Figure 3). HPLC purification of the mixtures yielded 
conjugates 12-15 (Table 3). 
FIGURE 3 | Representative LC chromatograms (214nm, 10Æ90% MeCN in 0.1% aq. TFA in 17min) of crude 
conjugation mixtures showing the formation of 13 (left panel, Rt 7.77min) and 14 (right panel, 
Rt 9.17min) after 16h reaction; in all cases, all CPMBN 7 was found consumed. Peaks of Rt 
<5min arise from injection.
TABLE 3 | Conjugates prepared.
Compound Name SequenceA ESI-MS
12 BF2-CPMBN TRSSR AGLQF PVGRV HRLLR KXC-(SS)-CPMBN 1851.8 [M+2H]2+
13 DRC-CPMBN GKPRP YTPRP TSHPR PIRVX C-(SS)-CPMBN 1740.2 [M+2H]2+
14 KFF-CPMBN KFFKF FKFFK XC-(SS)-CPMBN 2683.0 [M+H]+      
15 TTC-CPMBN VRRFP WWWPF LRRXC-(SS)-CPMBN 1575.5 [M+2H]2+
A X = Ava, SPy = 2-pyridylsulfenyl, -(SS)- indicates disulfide bond, CPMBN is cysteine-modified PMBN
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4.3 | Biological Evaluation 
4.3.1 | Antibacterial activity 
The biological activities of conjugates 12-15 against E. coli ATCC 11775 were assessed. For none of 
the conjugates, 100% inhibition (i.e. MIC value, Figure 4) was reached beneath concentrations of 
100ǍM. Conjugates 12 and 13 were found to be completely devoid of activity while 14 and 15 did 
kill bacteria. KFF (as in conjugate 14) alone displays only very modest activity (MIC 300ǍM);
extrapolation of the activity curve of 14 in Figure 4 coincides with a similar MIC value. 
Attachment of the CPMBN moiety apparently does not interfere with the antibiotic action of KFF; 
it however slightly impairs the antibacterial activity of TTC (active in the low mM range).15
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FIGURE 4 | Antimicrobial effects of C-terminal PMBN/CAP conjugates against E. coli ATCC 11775.
4.3.2 | Hemolytic activity 
To assess the affinity of conjugates 12-15 for membranes of different composition (i.e. selectivity), 
hemolysis of red blood cells (RBC) was determined. No hemolysis was detected for compounds 
12 and 13 up to concentrations of 250ǍM. This feature appears to be inherited from the three 
parent compounds DRC, BF2 and PMBN, which are known to lack hemolytic activity. 
Unfortunately, the antimicrobial conjugates (14 and 15) have retained the hemolytic activity of 
their parent compounds TTC and KFF; at the highest concentration tested (250ǍM), conjugates 14
and 15 accounted for 65% and 100% hemolysis, respectively.  
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4.3.3 | LPS binding affinity 
The affinity for LPS of compounds 12-14 by virtue of their PMBN moieties was assessed in a LPS 
displacement assay (see Chapter 2).16,17 In this assay, competitive binding of the conjugates with 
dansylated polymyxin B (DPX) to LPS is observed as decrease in fluorescence. Using 
commercially available LPS from Salmonella enteritidis, comparison of LPS affinity of these 
conjugates with that of commercially available PMB sulfate is shown in Figure 5. The linear CAP 
parts in 12-14 do not abolish LPS binding by the PMBN moiety; all conjugates are able to displace 
DPX from LPS.  
The order of activity in the displacement assay (conjugate of KFF > BF2 > DRC) reflects 
the ‘grand average of hydropathicity’ (GRAVY)18 value ranking of the CAP parts, being 
KFF(0.120) > BF2(-0.638) > DRC(-1.574). These values imply that KFF has the highest overall 
hydrophobic character and DRC lowest. KFF-containing conjugate 14 displays the highest LPS 
affinity of the conjugates assayed, and its affinity even surpasses that of commercial PMB and 
that of DPX.19 The enhancing effect of KFF on PMBN’s LPS binding might be explained by the 
fact that the KFF amphiphilic ǂ-helix formed upon contact with LPS creates a large hydrophobic 
area that allows interactions with the lipid chains of LPS (cf. the N-terminal acyl chain in PMB).  
FIGURE 5 | Inhibition of DPX fluorescence by conjugates and PMB. A See Experimental section for 
calculations.
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In fact, compound 14 is unique in the sense that there are no literature reports on polymyxin B-
based4,12,20 or other CAP-inspired compounds20b,21 that exert displacement activity higher than 
PMB. The percentage of maximal inhibition of DPX LPS binding can be calculated from the 
reciprocals plot (see Experimental Section, and Figure 5). In agreement with earlier reports, PMB
is capable of displacing all DPX; in the same report, PMBN was calculated to be able to displace 
DPX for a maximum of 77%.16
4.4 | Conclusion 
Disulfide conjugates of PMBN with linear CAPs were prepared to evaluate whether or not the 
favorable features of PMBN (sensitization/LPS scavenging/selectivity) could be imposed onto 
the antibiotic part. Through a cleavage-by-cyclization strategy, a Cys-modified derivative of 
PMBN was obtained. The Cys side chain was used in subsequent conjugation with a number of 
linear CAPs. Conjugation of PMBN to the membrane-active CAPs KFF and TTC did not abolish 
the hemolytic activity of the parent linear CAPs, nor did it improve the antibacterial actions of 
these linear CAPs. Antibacterial activity was absent in PMBN conjugates with BF2 and DRC, both 
acting on targets inside the bacterium. It can be speculated that the disulfide bond in these 
conjugates is not reduced inside the bacterium, leading to steric hindrance. Alternatively, the 
modification of their C-termini might simply be the cause of inactivity: C-terminal derivatization 
of DRC has not been reported in literature, and the only C-terminally modified BF2 derivative22
was not evaluated for antimicrobial potency. Finally, the affinity of the conjugates for LPS 
effected by the PMBN moiety was compared with that of PMB and a fluorescent PMB derivative 
(DPX) in competition experiments. All conjugates showed affinity for LPS, and the KFF conjugate 
14 was found to possess a higher affinity for LPS than PMB and DPX, indicating that KFF 
contributes to LPS affinity.  
4.5 | Experimental Section 
4.5.1 | Synthesis 
Cys1-modified polymyxin B nonapeptide CPMBN (7).  
Compound 6b was prepared via the procedure discussed in Chapter 2, which was slightly modified. In 
short, Boc-Cys(StBu)-OH was used as last amino acid. After completion of the synthesis of the linear 
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CPMBN, the resin was alkylated with ICH2CN, and the product was cyclized and cleaved under the agency 
of DiPEA. All acid-labile protecting groups were removed with 95% TFA. Reductive removal of the 
Cys(StBu) protecting group was achieved by dissolving compound 6b under Ar atmosphere in 0.1M aq. 
TCEP.HCl (brought to pH 4.5 with Na3PO4.12H2O) and stirring overnight. LCMS showed disappearance of 
6b and formation of 7; this compound was purified by HPLC (gradients of MeCN in 0.1% aq. TFA), 
concentrated in vacuo and stored at -200C under Ar.
Preparation of 2-pyridylsulfenylated CAPs (8-11) 
After completion of the SPPS of the linear peptides (Fmoc-based automated synthesis using HCTU as 
activator), adding Ava and Cys(Tr) to the C-terminus, the peptides were cleaved from their resins using 
TFA/TIS/H2O 95/2.5/2.5 (v/v/v) and 2,2’-dithiobispyridine (20eq.) for 1h. Peptides were precipitated in 
Et2O, centrifuged, decanted and washed three times with Et2O to remove the yellow color. Peptides were 
purified by HPLC and lyophilized. Analytical data: see Table 3.
Preparation of C-terminal conjugates (12-15)
Linear cationic peptides containing Cys(SPy) (ca. 1.5-2.5eq.) were dissolved in aq. 1M NH4OAc to which 
CPMBN 7 (0.7-1.2Ǎmol) was added. The pH was adjusted to pH 7 with AcOH and the mixture stirred 
overnight. LCMS analysis of the crude mixtures showed complete consumption of CPMBN in each case. The 
crude conjugates were purified by semi-preparative HPLC to yield pure compounds 12 (1.6mg, 0.51μmol), 
13 (2.9mg, 0.83μmol), 14 (2.1mg, 0.57μmol) and 15 (2.7mg, 1.01μmol). Analytical data: see Table 3. 
TABLE 3 | Data on synthetic peptides and conjugates used in this study. 
# Compound Rt (min) ESI-MS HRMS (calcd.) 
6b CPMBNStBu 8.59A 1155.0 [M+H]+ n/d
7 CPMBN 7.99A 1066.4 [M+H]+ 1065.584 (1065.576) 
8 BF2-Ava-Cys(SPy) 8.57A 2742.8 [M+H]+ 2744.517 (2744.507) 
9 DRC-Ava-Cys(SPy) 8.13A 2525.8 [M+H]+ 2522.332 (2522.326) 
10 KFF-Ava-Cys(SPy) 9.92A 1725.2 [M+H]+ 1723.891 (1723.877) 
11 TTC-Ava-Cys(SPy) 12.61A 2215.0 [M+H]+ n/d
12 BF2-Ava-Cys(SS)-CPMBN 8.27B   1851.8 [M+2H]2+ 3699.072 (3699.066) 
13 DRC-Ava-Cys-(SS)-CPMBN 7.77B   1740.2 [M+2H]2+ 3476.873 (3476.872) 
14 KFF-Ava-Cys(SS)-CPMBN 9.17B 2683.0 [M+H]+ 2678.401 (2678.393) 
15 TTC-Ava-Cys(SS)-CPMBN 8.20C     1575.5 [M+2H]2+ D 3166.679 (3166.665) 
A LC Rt 10Æ90% MeCN in 0.1% aq. TFA in 20min; detection at 214nm. B LC Rt 10Æ65% MeCN in 0.1% aq. TFA in 9.7min; 
detection at 214nm. C LC Rt 10Æ65% MeCN in 0.1% aq. TFA in 13.4min; D Calculated 1583.8; this is the main peak, 
originating from fragment M-16, presumably caused by loss of an NH2 group during ionization. LC detection in all cases 
at 214nm, n/d – not determined. 
4.5.2 | Antimicrobial Assay 
From an overnight culture of ~109-1010 E. coli ATCC 11775, a suspension of 5x106 CFU/mL in iso-sensitest 
broth (ISB) was prepared. The conjugates were dissolved in ISB to give 0.2mM solutions. Using a 96-well 
plate, in duplo, all conjugates where dispensed using 2-fold serial dilution down from 100 to 0.21ǍM.
Suspensions were incubated for 18-24h at 370C while shaking gently. The absorbance at 600nm was 
measured from which the MIC value was determined. 
4.5.3 | Hemolysis Assay 
Freshly drawn blood samples were centrifuged for 10min after which the erythrocyte pellet was washed 
with 0.85% saline. The RBC were diluted with saline to 1/25 packed volume of cells. The compounds were 
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dissolved in a minimal amount of DMSO (max. 30% (v)) and diluted further with saline to give a 0.75mM 
solution. Two-fold serial dilution of the compounds was applied in triplo against 1% Triton X-100 in saline 
as positive control. After addition of 50ǍL RBC solution, the plate was incubated at 370C for 4h, centrifuged 
(5min at 100C) and 50ǍL of each well was dispensed into a new plate. The percentage of hemolysis was 
determined from the absorbance at 405nm.  
4.5.4 | Displacement Assay 
Affinity for LPS (Sigma L6761 S. enteritidis ATCC 13076) was assessed in 2-fold using a competitive 
displacement assay employing commercially available dansylated polymyxin B (DPX). The DPX 
background fluorescence was determined by addition of an aq. DPX solution (5ǍL, 100ǍM) to HEPES buffer 
(5mM, pH 7.2, 1mL) at 340nm excitation and 495nm emission wavelengths; this addition was repeated 5-10 
times. Saturation of LPS with DPX was determined by measuring fluorescence of a mixture of DPX solution 
(5ǍL, 100ǍM) and LPS solution (3Ǎg/mL in 5mM HEPES buffer pH 7.2, 1mL). Aliquots of 5ǍL of DPX 
solution were continuously added until the fluorescence levelled off and the increase was a result only of 
the change in background. The amount of DPX to be added to the LPS solution to give 85-90% of saturation 
(Z-amount) was calculated from these data. For determination of the amount of displacement of DPX, 2 
times the Z-amount of DPX solution was added to 2mL LPS solution and equilibrated at RT for 10-15min. 
Aliquots of synthetic polymyxin analogue (5ǍL, 400ǍM in water) were added and the fluorescence 
measured after 30-60s until the maximum displacement was reached.  The maximum inhibition by a given 
compound was determined from the extrapolated y intercept of a plot of the reciprocal of % fluorescence 
inhibition as a function of the reciprocal of the compound concentration.16
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5.1 | Introduction
Quaternary ammonium compounds (QACs) are readily accessible cationic substances in which 
the hydrophobicity can be adjusted easily. QACs such as cetylpyridinium chloride or 
cetyltrimethylammonium bromide (CTAB, Figure 1) are widely used as disinfectives.1 These 
compounds exhibit antibacterial activity from their interference with, or destruction of the 
bacterial cytoplasmic membrane.2 At low concentrations in water, CTAB forms gels with worm-
like micelle structures.3
FIGURE 1 | Structure of the QAC cetyltrimethylammonium bromide (CTAB).
Ionic liquids4 based on quaternary imidazolium salts display amphiphilicity like CTAB. Gelation 
could be induced in imidazolium-based ionic liquids by addition of organogelators5 or mesogens 
(molecules that can exhibit a liquid-crystalline phase).6 Interestingly, addition of water in low 
concentrations (~5-40% (wt)) to the ionic liquid N-decyl-N’-methyl imidazolium bromide was 
found to induce nearly instantaneous formation of a lyotrophic (i.e. concentration-dependent) 
liquid-crystalline gel phase.7 The obtained so-called ‘ionogels’ resisted flow against gravity for an 
indefinite period of time. As N-alkyl-N’-methyl imidazolium QACs are expected8,9 to show 
antibacterial activity, their encapsulation into gravity-stable gels leads to interesting antibiotic 
formulations that might be useful for personal (topical) decontamination purposes.10 This 
Chapter describes the synthesis and the antibiotic activity of an array of N-alkyl-N’-methyl 
imidazolium (MIM) bromides 1-9 and 15-18 (Table 1) as well as N-alkyl-N-methyl pyrrolidinium 
(MPD) bromides 10-14, and of their encapsulation in stable gels obtained by mixing with polar 
liquids.  
N
Br
CTAB
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5.2 | MIM and MPD QACs
5.2.1 | Syntheses
N-alkyl-N’-methyl imidazolium (MIM) salts were readily obtained through established synthesis 
procedures, performing the alkylation of N-methylimidazole with n-alkyl bromides equimolarly, 
neat or in MeCN,11 at 1500C for 30min in a microwave oven (Scheme 1). After extraction and 
vacuum drying at 700C, compounds 1-9 were obtained in 85-90% yield and were found to be pure 
apart from some residual H2O. The physical appearances of these MIM salts changed with alkyl 
chain length. Compounds 1-6 were obtained as ionic liquids whereas 7-9 were solids.  
                          
N N
N
or
alkyl bromide
neat or MeCN
mircowave, 1500C, 30min
alkyl bromide
MeCN, 500C, o/n
N N
N
or
R
R
Br
Br
R = alkyl
MIM 1-9
R = alkyl
MPD 10-12
SCHEME 1 | Preparation of N-alkyl-N’-methyl imidazolium (MIM) and N-alkyl-N-methyl pyrrolidinium (MPD) 
bromides. For the R (alkyl) groups, see Table 1 below. 
                        TABLE 1 | Synthesized QACs.A
Compound  Compound  
1 C7MIM Br 10 C10MPD Br 
2 C8MIM Br 11 C11MPD Br 
3 C9MIM Br 12 C12MPD Br 
4 C10MIM Br 13 C13MPD Br 
5 C11MIM Br 14 C14MPD Br 
6 C12MIM Br 15 C9MIM2 2Br 
7 C13MIM Br 16 C10MIM2 2Br 
8 C14MIM Br 17 (C10MIM)2 SO4
9 C16MIM Br 18 (C10MIM)3 PO4
A MIM = N-alkyl-N’-methyl imidazolium, MPD = N-alkyl-N-
methyl pyrrolidinium, where ‘N-alkyl’ refers to the linear Cx alkyl group.
N N N N
N N
N
n
n
n
1-9 MIM compounds
10-14 MPD compounds
15 n=5
16 n=6
N N
7
17 n=2, X=SO4
2-
18 n=3, X=PO43-n
n+
X
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Non-aromatic N-alkyl-N-methyl pyrrolidinium (MPD) bromides were prepared through 
overnight reaction of N-methylpyrrolidine and n-alkyl bromide in MeCN at 500C (Scheme 1). 12,13
Pure MPD salts 10-14 (Table 1) were obtained by either spontaneous crystallization or after 
precipitation upon addition of Et2O. Application of the microwave-based synthesis of these 
bromides gave rise to the formation of unidentified impurities that could not be removed easily. 
All MPD bromides were obtained as crystalline white solids in yields of 70-95%. The choice of 
limiting the array of MPD salts to the ones containing C10 to C14 alkyl chains was based on the 
data obtained from MIC determinations of analogous MIM compounds (vide infra).
Next, dicationic MIM salts 15 and 16 (structure see Table 1), in which the two cationic 
sites are connected through a hydrophobic stretch were prepared from N-methylimidazole and 
linear ǂ,ǚ-dibromoalkanes (0.5eq.) applying the microwave approach. Finally, the ‘bis-MIM’ 
sulfate 17 and ‘tris-MIM’ phosphate 18 were prepared by conversion of compound 4 with either 
Ag2SO4 or Ag3PO414 and were included to examine the effect of a multivalent anion. 
5.2.2 | Biological Evaluation 
The minimal inhibitory concentration (MIC) values of all MIM compounds were determined 
against Escherichia coli ATCC 11775. Results are found in Table 2 and show an obvious 
relationship between length of n-alkyl chain and antimicrobial activity. QACs with alkyl chains < 
10 carbon atoms did not display any antimicrobial activity up to 200ǍM. On the other hand, 
lengthening the alkyl chain >14 atoms did not increase the MIC value, a finding that agrees with 
earlier reports.9a
TABLE 2 | MICA and MHCB values of MIM and MPD QACs.
A Minimal inhibitory concentration against E. coli ATCC 11775; B Minimal hemolytic 
concentration; n/d - not determined. It should be noted that for MIM and MPD QACs 
different bacterial growth media were used (see Experimental section). 
# MIC (M) MHC (M) # MIC (M) MHC (M)
1 >200 n/d 10 >1000 >1000
2 >200 n/d 11 500 >1000
3 >200 1000 12 250 500 
4 200 n/d 13 125 250 
5 100 125 14 62.5 125 
6 50 n/d 15 >1000 n/d 
7 25 125 16 1000 n/d 
8 12.5 n/d 17 250 n/d 
9 12.5 31 18 31 n/d 
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Dicationic MIM species 15 and 16 are virtually devoid of antibacterial activity, which can be 
explained by the fact that a terminal hydrophobic tail is needed to penetrate the membrane, a 
feature absent in 15 and 16. Furthermore, no conclusion can be drawn from the MIC values 
regarding the effect of multivalent anions; compounds 4 (bromide) and 17 (sulfate) have MIC 
values in the same range whereas 18 (phosphate) is >6 times as active as 4.15 Similarly, the MIC 
values of the MPD bromides were determined against E. coli ATCC 11775. As expected, the same 
trend was observed as with the MIM salts: a longer alkyl chain constitutes higher antimicrobial 
activity.16 Additionally, hemolytic indexes were determined of some of these compounds. MIM 
compounds 3, 5, 7 and 9 and the MPD bromides were tested for their potency to lyse erythrocytes 
and were found to have MHC (minimal hemolytic concentration, see Table 2) values that were 
close to the MIC values (1.25-5 fold (MIM) or 2-fold (MPD) the MIC values). 
5.3 | Gel Formation 
Having established the antimicrobial potency of the synthesized MIM and MPD bromides, 
attention was focussed on the gel formation of selected salts by mixing with water and two other 
polar liquids (ethylene glycol and glycerol).17
5.3.1 | Water-based gels (W-gels)
Following the procedure in which 4 showed phase transition upon mixing with ~5-40% (wt) H2O, 
water-based gels (W-gels) of MIM bromides 4-7 were prepared. In case of MIM bromides 4-7 (see 
Table 3) homogeneous gels were obtained after addition of H2O at percentages ranging from 10-
35% (wt) and homogenization by centrifugation. Obtaining homogeneous gels containing the 
lowest percentages of additive and longest alkyl chains required additional heating and/or 
sonication. For the MPD bromides (10-14, Table 3), gels with water (W-gels) could also be 
prepared with percentage of additive ranging from 10-50% (wt). In contrast, commercially 
available CTAB (19) did not form a W-gel. Both MIM and MPD bromides appear to follow a 
trend in which gel formation of compounds containing longer alkyl chains requires a higher 
percentage of additive. Some of the prepared W-gels (C14MIM gels 8) were found unstable (i.e.
remained no longer in gel phase) when exposed to the air movements in a fume hood (vide infra), 
very likely due to a decrease in % (wt) of H2O. Gels based on ethylene glycol or glycerol, with 
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boiling points higher than that of water, were therefore expected to be more stable under such 
conditions. 
TABLE 3 | Gels of selected QACs containing water (W).
  Additive (H2O wt%) 
# Composition a. 10% b. 16% c. 25% d. 35% 
4 C10MIM Clear gel Clear gel Clear gel Clear gel 
5 C11MIM Clear gel Clear gel Clear gel Clear gel 
6 C12MIM Clear gel Clear gel Clear gel Clear gel 
7 C13MIM Solid Clear gel Clear gel Clear gel 
8 C14MIM Solid Inh. Clear gel Clear gel 
9 C16MIM Solid Solid Solid Solid
e. 20% f. 30% g. 40% h. 50% 
10 C10MPD Clear gelA Clear gel Fluid Fluid 
11 C11MPD Inh. Clear gel Clear gel Clear gel 
12 C12MPD Inh. Clear gel Clear gel Fluid 
13 C13MPD Solid Inh. Clear gel Clear gel 
14 C14MPD Solid Inh. Clear gel Clear gel 
19 CTAB Solid  Solid  Solid   Solid 
A A gel with 10% additive could also be constructed from this compound (10a);
Inh. – inhomogeneous. 
5.3.2 | Ethylene glycol-based gels (E-gels)
Compounds 4, 5, 10 and 19 could not be transformed into a gel with ethylene glycol (E-gel) in a 
range of 10-40% (wt). Whereas gelation of 9 was not induced with H2O, 35% (wt) ethylene glycol 
caused gel formation.  
TABLE 4 | Physical appearances of QACs upon addition of ethylene glycol (E).
 Additive (ethylene glycol wt%) 
Compound i. 10% j. 20% k. 30% l. 40% 
4 C10MIM Fluid Fluid Fluid Fluid 
5 C11MIM Fluid Fluid Fluid Fluid 
6 C12MIM Inhomogeneous Clear gel Fluid --- 
7 C13MIM Inhomogeneous Inhomogeneous Clear gel Clear gel 
8 C14MIM Solid Inhomogeneous Inhomogeneous Clear gel 
9 C16MIM Solid Solid Inhomogeneous Clear gelA
10 C10MPD Fluid Fluid Fluid Fluid 
11 C11MPD Clear gel Clear gel --- --- 
12 C12MPD Clear gel Clear gel Fluid --- 
13 C13MPD Inhomogeneous Clear gel Clear gel --- 
14 C14MPD Solid Inhomogeneous Clear gel Fluid 
19 CTAB Solid Solid Solid Solid 
A 35% (wt) instead of 40% (wt) of ethylene glycol was used. --- not prepared. 
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In contrast to some of the C14MIM W-gels, the E-gel 8l proved to be stable towards air movements 
in a fume hood. Although the trend observed for W-gels regarding % additive/alkyl chain length 
also applies to E-gels, a higher % (wt) of additive was necessary to form homogeneous E-gels 
with increasing alkyl chain length as compared to W-gels.
5.3.3 | Glycerol-based gels (G-gels)
Preparation of MIM and MPD gels containing glycerol (G-gels) yielded similar trends as did the
E-gels; all three 4, 5 and 10 would not form a gel with 10-40% glycerol (Table 5). In general, 
higher percentages of glycerol were needed to form gels than was necessary with ethylene glycol. 
C16MIM 9 could not be transformed into a G-gel, nor could CTAB 19.
TABLE 5 | Physical appearances of QACs upon addition of glycerol (G).
 Additive (glycerol wt%) 
Compound m. 10% n. 20% p. 30% q. 40% 
 4 C10MIM Fluid Fluid Fluid Fluid 
 5 C11MIM Clear gel  Fluid Fluid --- 
 6 C12MIM Inhomogeneous Clear gel Clear gel --- 
 7 C13MIM Inhomogeneous Inhomogeneous Clear gel Clear gel 
 8 C14MIM Solid Inhomogeneous Inhomogeneous Clear gel 
 9 C16MIM Solid Solid Solid Solid 
10 C10MPD Fluid Fluid Fluid Fluid 
11 C11MPD Clear gel Clear gel --- --- 
12 C12MPD Inhomogeneous Clear gel Clear gel Fluid 
13 C13MPD Inhomogeneous Inhomogeneous Clear gel Fluid 
14 C14MPD Solid Solid Inhomogeneous Clear gel 
19 CTAB Solid Solid Solid Solid 
* Inhomogeneity is due to inability to mix QAC and additive thoroughly (‘partly gelated’). --- not 
prepared.
5.4 | Gel Stability 
Gel stability against a range of external factors determines their potential applicability. 
Preliminary results of studies towards the resistance of gels against gravity, temperature and 
water are discussed in the following paragraphs.
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5.4.1 | Gravity 
The W-gels 4b, 5b and 6b, as well as 7c and 8c were examined for their ability to resist flow 
against gravity.18 They were found to be resistant against gravity for at least 5 consecutive days, 
whereas the other MIM W-gels were stable for at least 6h (the longest period examined for these 
gels). MPD W-gels all were gravity-stable (at least 5 days), as were both all MIM and MPD E-gels. 
In the G-gel series, only MIM gel 6p and MPD gel 12n were found to be gravity- sensitive.  
5.4.2 | Temperature 
When examined for thermal stability, nearly all gels proved to be stable (i.e. did not become fluid, 
Table 6) up to temperatures of 60-650C for 30min. Exceptions were W-gels 4b and 4c (already 
becoming fluid at slightly elevated temperatures within seconds), and 10a and 11f that liquefied 
after heating to 650C after a few minutes. Increase in stability is observed in gels of 5 and 6 with 
increasing % (wt) of H2O; the 30% versions are more stable than are their 16% counterparts. The 
results obtained with E-gels show that none of the MIM gels tested are stable except C16MIM 9l,
whereas those composed of the corresponding MPD salts easily seem to handle heating to 60-
650C for 30min. G-gels all appeared to be stable under the conditions given. 
5.4.3 | Water resistance 
Water resistance is an important aspect regarding applicability. It is undesirable for antimicrobial 
gels used as protective coatings outdoors to be easily removed e.g. at the event of rain. In this 
light, preliminary studies on the ‘water-stability’ of the prepared gels show that C16MIM gel 9l is 
a promising candidate. This particular gel, when dispensed on a vertical glass plate, showed the 
ability to withstand a one-minute, continuous drop-wise flow of 20mL/min of tap water. 
Although 9l was not completely unaffected by this treatment, the water stability observed was 
not found in the vast majority of the gels reported in this study. 
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TABLE 6 | Visual effects upon heating of selected gels. 
A Temperature reached; B No apparent changes after prolonged heating to 3600s; + no apparent 
changes; - becomes fluid; +/- becomes partially fluid at time indicated.
5.5 | Biological Evaluation of Gels 
Selected gels were assayed for their antimicrobial potency using an ISO standardized film 
adherence method.19 In this method, small glass plates are coated with a thin layer of gel. A 
bacterial suspension containing Gram-negative Escherichia coli ATCC 8739 or Gram-positive 
Staphylococcus aureus ATCC 6538P was then added to the coating, covered, and incubated for 24h 
at 370C. Surviving colonies were replated and counted. Results are summarized in Tables 7-10 
below (key: see Table 10) and show that all W-, E- and G-gels tested killed >99.9% of E. coli; a 
selection of the gels also eradicated Gram-positive S. aureus for >99.9%. 
Gel Composition T (0C)A t (s) Observation 
4b C10MIM / 16% W 24 5 - 
4c C10MIM / 30% W 24 5 - 
5b C11MIM / 16% W 42 90 +/- 
5c C11MIM / 30% W 65   1800B + 
6b C12MIM / 16% W 65 600 +/- 
6c C12MIM / 30% W 65 1800 + 
7c C13MIM / 30% W 65 1800 + 
8c C14MIM / 30% W 65 1800 + 
10a C10MPD / 10% W 65 360 +/- 
11f C11MPD / 30% W 65 510 +/- 
12f C12MPD / 30% W 65 1800 + 
13g C13MPD / 40% W 65 1800 + 
14f C14MPD / 30% W 60 1800 + 
6k C12MIM / 30% E 65 360 +/- 
7k C13MIM / 30% E 65 1200 +/-
8l C14MIM / 40% E 40 30 - 
9l C16MIM / 35% E 65 1800 + 
11i C11MPD / 10% E 65 360 +/- 
12j C12MPD / 20% E 60 1800 + 
13k C13MPD / 30% E 60 1800 + 
6n C12MIM / 20% G 65 1800 + 
7p C13MIM / 30% G 65 1800 + 
8q C14MIM / 40% G 65 1800 + 
11m C11MPD / 10% G 60 1800 + 
12p C12MPD / 30% G 60 1800 + 
13p C13MPD / 30% G 60 1800 + 
14q C14MPD / 40% G 65 1800 + 
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TABLE 7 | Antibacterial evaluation of selected MIM W-gels.
 E. coli ATCC 8739 S. aureus ATCC 6538P
# Composition t0 (log CFU)A,B t24 (log CFU)A,C t0 (log CFU)A,B t24 (log CFU)A,C 
Negative control 5.11    6.49 4.87   5.06 
4b C10MIM/16% 5.11   <1.0D 4.87   <1.0D
5b C11MIM/16% 5.11 <1.0 4.87 <1.0 
6b C12MIM/16% 5.11 <1.0  4.87 <1.0 
7c C13MIM/30% 5.11 <1.0 4.87 <1.0 
8c C14MIM/30% 5.11 <1.0 4.87 <1.0 
TABLE 8 | Antibacterial evaluation of selected MPD W-gels.
 E. coli ATCC 8739 
# Composition t0 (log CFU)A,B t24 (log CFU)A,C
Negative control 4.54   5.91 
10e C10MPD/20% 4.54   <1.0D
11e C11MPD/20% 4.54 <1.0 
12g C12MPD/40% 4.54 <1.0 
13h C13MPD/50% 4.54 <1.0 
14h C14MPD/50% 4.54 <1.0 
TABLE 9 | Antibacterial evaluation of selected MIM & MPD E-gels.
 E. coli ATCC 8739 
# Composition t0 (log CFU)A,B t24 (log CFU)A,C
Negative control 4.54   5.91 
7l C13MIM/40% 4.54   <1.0D
8l C14MIM/40% 4.54 <1.0 
11j C11MPD/20% 4.54 <1.0 
12i C12MPD/10% 4.54 <1.0 
13j C13MPD/20% 4.54 <1.0 
14k C14MPD/30% 4.54 <1.0 
TABLE 10 | Antibacterial evaluation of selected MIM & MPD G-gels.
 E. coli ATCC 8739 
# Composition t0 (log CFU)A,B t24 (log CFU)A,C
Negative control 4.54   5.91 
5n C11MIM/20% 4.54   <1.0D
6n C12MIM/20% 4.54 <1.0 
7q C13MIM/40% 4.54 <1.0 
8q C14MIM/40% 4.54 <1.0 
11n C11MPD/20% 4.54 <1.0 
12p C12MPD/30% 4.54 <1.0 
13p C13MPD/30% 4.54 <1.0 
Key for Tables 7-10: A Average of triplo measurement; B At time t=0; C At time t=24h; D <1.0 equals >99.9% 
eradication. CFU - colony forming units.
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5.6 | Conclusion 
Alkylated MIM and MPD bromides were synthesized and their antibiotic activity was 
determined against E. coli ATCC 11775. Increased activity was observed along with increasing 
chain length up to C14. The relatively high MIC values, in combination with their MHC values 
(only a factor ~2 higher than the MIC values) indicate a lack of cell-selectivity and do not allow 
for systemic use.2b
Unlike commercially available CTAB, most (ionic liquid and solid) MIM and MPD 
bromides could be brought into gel phase by addition of water, ethylene glycol, or glycerol. In 
general, the length of the alkyl chain appears to impose limitations on gel formation: whereas 
only an E-gel of C16MIM bromide 9 could be obtained, CTAB 19 would not form a W-, E-, or G-
gel in the range of 10-50% (wt), nor would C18MIM (not shown). Preliminary tests to assess the 
susceptibility of the gels to external factors showed that the majority of the gels resisted flow 
against gravity and could withstand a temperature of 60-650C for 30min. Gel 9l appeared to be 
also largely stable against running water. A selection of gravity-stable gels were assayed for 
antibacterial activity against E. coli ATCC 8739, and in some cases against S. aureus ATCC 6538P.
Both these Gram-negative and Gram-positive bacteria were eradicated for >99.9%. 
5.7 | Experimental Section 
5.7.1 | Syntheses 
MIM bromides (1-9). Typical procedure for the synthesis and analysis of MIM 
bromides: n-alkyl bromide (10mmol) and N-methylimidazole (1eq.) were 
stirred in a microwave oven (Personal Chemistry) at 1500C for 30min with the 
Absorption leve option set at ‘high’. The product was extracted in Et2O/H2O/
MeOH, removing all unreacted reagents, and the solvents were removed through lyophilization. The 
bromides were obtained as ionic liquids (1-6) whereas 7-9 were solids. Compounds were analyzed by 1H
NMR, 13C NMR and LCMS. All compounds were found to be pure except for residual water (~5-20% (wt) 
after vacuum drying for 24h at 700C; percentage increases along with alkyl chain). Yields: C10MIM 4: 83%, 
C11MIM 5: 90%, C12MIM 6: 87%, C13MIM 7: 88%, C14MIM 8: 87%. 1H NMR data was found to be consistent 
with the data published.9a Representative analysis for C14MIM Br 8: 1H NMR (MeOD): δ 9.01 (s, 1H, H2), 7.67 
(t, 1H, H3), 7.59 (t, 1H, H4), 4.23 (t, 2H, H5), 3.95 (s, 3H, H1), 1.90 (m, 2H, H6), 1.34 (bm, 22H, H7-17), 0.90 (t, 
3H, H18). 13C NMR (MeOD): δ 124.8, 123.5 (C3, C4), 50.6 (C5), 36.3 (C1), 32.8, 30.9, 30.5, 30.2, 29.9, 27.0, 23.5 
(C6-17), 14.2 (C18). LC (254nm): Rt 18.2min. ESI-MS: 265.2 [M–Me+H]+, 279.3 [M]+.
N N
n
Br -
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MPD bromides (10-14).Typical procedure for synthesis and analysis of MPD 
salts: alkyl bromide (15mmol) and N-methylpyrrolidine (1eq.) were stirred at 
500C for 16h, yielding a white precipitate in each case. The precipitate was 
filtered off, washed with Et2O (3x) removing all unreacted reagents and dried,    
yielding alkyl MPD bromides as white solids. Yields: C10MPD 10: 85%, C11MPD 11: 92%, C12MPD 12: 92%, 
C13MPD 13: 96%, C14MPD 14: 70%. All MPD salts were obtained as white solids containing some residual 
water (~8-20% (wt) after vacuum drying for 24h at 700C). C13MPD contains ~25% (wt) H2O as exception. 
Representative analysis for C10MPD Br 10: 1H NMR (DMSO-d6): δ 3.52 (m, 4H, H2), 3.38 (m, 2H, H4), 3.02 (s, 
3H, H1), 2.09 (bm, 4H, H3), 1.69 (bm, 2H, H5), 1.26 (bm, 14H, H6-12), 0.87 (t, 3H, H13). 13C NMR (DMSO-d6):
δ 63.4 (C2), 63.0 (C4), 47.4 (C1), 31.4, 29.0, 28.8, 28.6, 26.0, 23.0, 22.2, 21.1 (C3, C5-12), 14.0 (C13). ESI-MS: 212.0 
[M-Me+H+]+, 225.8 [M+]+, 565.5 [2M++TFA-]+.
MIM2 bromides (15, 16). Typical synthetic procedure: n-alkyl-α,ǚ-di-
bromides (3mmol) were treated according to the described microwave 
procedure using 10mmol of N-methylimidazole;  MeCN was added to a 
final volume of 3mL. After repeated of the extraction, residual N-methyl
imidazole was found to be present by NMR, and compounds were purified by gel filtration using an LH20 
column (88x2.8cm) and MeOH as eluent. Yields: C9MIM2 15: 64%, C10MIM2 16: 60%. Representative analysis 
for C9MIM2.2Br 15: 1H NMR (MeOD): δ 9.23 (s, 2H, 2xH2), 7.82 (t, 2H, 2xH3), 7.74 (t, 2H, 2xH4), 4.35 (t, 4H, 
2xH5), 4.05 (s, 6H, 2xH1), 1.95 (m, 4H, 2xH6), 1.37 (bm, 10H, 2xH7, 2xH8, H9). 13C NMR (MeOD): δ 124.9, 
123.6 (C3, C4), 50.7 (C5), 37.0 (C1), 31.0, 29.7, 29.5, 27.0 (C6-C9). 
Metathesis of C10MIM (17, 18)
Bromide 4 (0.5mmol) was dissolved in 1mL MeOH/H2O 1/1 (v/v), and Ag2SO4 (17) or Ag3PO4 (18), both 
1.0eq (taking into account the multivalent anions), were added under the exclusion of light. After stirring for 
72h, samples were filtered and solvents were evaporated. After standing for 14d in daylight, newly formed 
precipitate was filtered off. 31P NMR (D2O) of 18 showed a single peak. Materials were then subjected to 
antibacterial assays. 
5.7.2 | Gel formation 
W-gels (a-h) 
Gels of MIM compounds 4-8 were prepared by determination of the amount of residual H2O in a sample by 
1H NMR (acetone-d6) and then addition of H2O to obtain a gel with defined weight percentage of H2O (final 
concentrations of 10, 16, 25 and 35% (wt)). Gels containing MPD compounds 10-14 were obtained by 
determination of the H2O content through 1H NMR (DMSO-d6) and subsequent addition of H2O to obtain 
the gels (final concentrations of 10, 20, 30 and 40% (wt)). 
E-gels (i-l) and G-gels (m-p) 
Compounds were dried for 16h under vacuum at 700C. Ethylene glycol (E-gels) or glycerol (G-gels) was 
added to samples starting at 10% (wt), and increasing stepwise with 10% (wt) until a homogeneous gel 
would form (after gently heating/sonication and centrifugation if necessary) to a maximum of 50% (wt).  
5.7.3 | Antibacterial assay in solution 
E. coli ATCC 11775 were grown on nutrient agar plates and kept at 40C. Imidazolium salts were dissolved in 
Luria-Bertani (LB) and MPD salts in Brain-Heart Infusion (BHI) to give a concentration of 200ǍM and 
filtered using 0.22Ǎm filter discs. An overnight culture in LB broth was adjusted to 5x106 CFU/mL and 
inoculated into the micro titre plate wells containing each 100ǍL of a serial two-fold dilution (200ǍM-down) 
of the tested compound in LB/BHI broth. After incubation for 24h at 370C, absorbance was measured at 
600nm using a ǍQuant micro plate spectrophotometer. MIC values of compounds were measured in 3-fold 
and averaged. 
N
n
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5.7.4 | ISO Film adherence assay 
Antimicrobial activities of the gels were quantitatively established using the film adherence method using 
Gram-negative E. coli ATCC 8739 and Gram-positive S. aureus ATCC 6538P. At time t0, in 3-fold, object 
glasses were thinly coated in an area of 3cm2 with 2–5mg of the antimicrobial gel. Subsequently, bacterial 
suspension (50ǍL) containing approx. 1x105 CFU was applied onto the coating and covered with a plastic 
film. Test samples were incubated for 24h at 370C, after which the number of surviving bacteria was 
determined (i.e. t24): bacteria were removed with swabs from the glasses, suspended and plated in tryptic 
soy agar (TSA). The TSA plates were incubated for 3 days at 370C, after which the number of developing 
colonies was counted. The number of surviving bacteria were calculated in CFU and the antibacterial 
activity was calculated using log CFU @ t0 (negative control) – log CFU @ t24 (test sample). 
5.7.5 | Hemolysis Assay 
Minimal hemolytic concentration (MHC) values were determined by averaging the results of three 
measurements, according to the method described in see Chapter 1. 
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6.1 | Introduction
The use of fluorous techniques1 for the separation of reaction mixtures has found wide attraction 
in synthetic organic disciplines in recent years.2 An important development comprises the so-
called ‘light-fluorous’ strategy, developed by Curran and co-workers.1a,3 In this strategy, 
compounds differing in fluorine content are separated by chromatography using a fluorous 
stationary phase. For this purpose, an array of fluorinated handles have become available in 
recent years, including fluorous versions of the Z,4 Boc,5 tBu,6 Bn,7 THP,8 acyl-based,9 silyl-based,10
and alkoxyethylether11 protecting groups. 
6.2 | Fluorous Techniques in SPPS 
Although synthetic peptides containing up to 50 residues have become available via improved 
solid-phase synthesis techniques in recent decades, facile HPLC purification of the desired full-
length peptide (of n residues) is often hampered by the presence of incomplete sequences (e.g. n-1 
and n-2 sequences).  This is especially true for longer peptides as the chromatographic behavior 
of full-length and n-1 and n-2 sequences becomes less distinguishable with increasing number of 
residues, resulting in tedious and lengthy HPLC purification procedures along with unavoidable 
handling losses. This Chapter describes two approaches for application of fluorous strategies in 
the purification of synthetic peptides. 
6.2.1 | Fluorous chromatography 
Introduction of long, polyfluorinated alkyl groups increases both hydrophobicity and 
fluorophilicity of molecules. To verify that the ‘light-fluorous’ strategy relies on fluorophilic 
rather than hydrophobic properties of compounds, a test peptide GEPKPAG was equipped with 
two handles differing from each other only in fluorine content. Thus, in order to examine their 
influence on the chromatographic behaviour of the peptide, the peptide was equipped with 
either a lipophilic n-undecanoyl (C8H17(CH2)2COR) moiety or a fluorinated alkanoyl handle 
(C8F17(CH2)2COR) were introduced. 
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The three peptides GEPKPAG, L-GEPKPAG (lipophilic) and F-GEPKPAG (fluorophilic) were 
synthesized via standard Fmoc-based SPPS procedures and evaluated for their affinity towards a 
FluoPhase LC column, the stationary phase of which is coated with polyfluorinated alkyl chains. 
Elution of the three peptides occurred with a gradient of 20Æ100% TFE in 0.1% aq. TFA in 18min. 
GEPKPAG, a peptide that is neither lipophilic nor fluorophilic, was expected to have minimal 
retention on the FluoPhase column; indeed, it elutes in the injection peak (Rt < 2min, not shown). 
Peptide L-GEPKPAG shows a distinct retention time (Rt 7.21min, Figure 1, trace A), indicating 
there is a significant hydrophobic interaction with the FluoPhase column. Fluorophilic peptide F-
GEPKPAG however displays a significantly larger retention time than L-GEPKPAG (Figure 1, 
trace B), which is indicative of additional effects and confirms the proposed concepts of ‘light-
fluorous’ chromatography techniques. 
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FIGURE 1 | Chromatograms (5-18min) of peptides L-GEPKPAG (trace A) and F-GEPKPAG (trace B) on a 
FluoPhase C18 RP column, applying a gradient of 20Æ100% TFE/H2O + 0.05% TFA in 13min, 
with UV detection at 214nm.   
6.2.2 | Fluorous Strategies in SPPS 
The application of fluorous handles promises to be a valuable asset in stepwise solid-phase 
synthesis procedures. Target molecules, of which the purification from final product mixtures is 
hampered by the occurrence of closely eluting impurities, can be effectively isolated with the aid 
of fluorous-based separation.  
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SCHEME 1 | Schematic representation of tagging strategy. On-resin tagging of the desired product (1) 
yields a mixture after cleavage (2) from which the desired product can be selectively 
obtained through affinity separation (3). X = capped incomplete sequences. 
Two different approaches can be distinguished, that is, attachment of an appropriate fluorous 
protecting group to either the final products (tagging, Scheme 1) or to the intermediate unreacted 
species (capping). The success of fluorous capping in solid-phase chemistry was demonstrated by 
Seeberger et al.10b,c who were able to separate the desired products from the fluorous impurities 
after the solid-phase assembly of oligosaccharides.  
6.3 | Fluorous Tag: Design & Synthesis 
Recently, the first example of the use of a fluorous tag (a fluorinated derivative of the Z-
protecting group, i.e. FZ tag, Figure 2) in the purification of peptides obtained through solid-
phase peptide synthesis was disclosed.4a
FIGURE 2 | Structures of the designed FZ tag and derivatives for tuning of acid lability.
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Although the acid-lability of the FZ tag could be tuned by the introduction of additional 
substituents (FMZ and FEZ tags), the application of the FZ tag in Fmoc-based SPPS proved to be 
restricted. It requires the use of amino acids with highly acid-labile side-chain protecting groups 
and a highly acid-labile linker. It was reasoned that a base-labile fluorous protecting group 
would be an attractive alternative tag for standard Fmoc-based SPPS with acid-labile side-chain 
protections and standard linker/resin systems such as Wang and Rink amide resins. To this end, 
a fluorous version of the Msc (methylsulfonylethoxycarbonyl, Figure 3)12 protecting group for 
amines, introduced by Tesser and co-workers nearly 30 years ago,13 was designed and 
synthesized. The new fluorous protecting group was named FMsc (1), in analogy with FZ.  
FIGURE 3 | Structures of the Msc protecting group and the derived tag 1.
The FMscCl tagging reagent 5 was readily synthesised as follows (Scheme 2). In the first step, 
commercially available [1H,1H,2H,2H]-perfluorodecyl iodide 2 was substituted with 2-
mercaptoethanol to give 3. After oxidation of thioether 3 to the corresponding sulfone 4 (30% 
AcOOH/AcOH), target FMscCl 5 was obtained by chloroformylation of 4, in an excellent overall 
yield of 88%. 
SCHEME 2 | Reagents and conditions: (i) 2-mercaptoethanol, NaOH, tBuOH, reflux (91%); (ii) AcOOH (30% 
in AcOH), H2O, 97%; (iii) phosgene (20% in toluene), THF (quant.). 
CF3(CF2)7
I
S
OCF3(CF2)7
O O
Cl
O
S
OHCF3(CF2)7
iii
i
2 3
5 FMscCl
S
OHCF3(CF2)7
ii
4
O O
C8F17
S
O
O O O
S
O
O O O
1 FMsc tag Msc protecting group
Chapter 6  
122 
6.4 | Application of the FMsc Tag 
With reagent 5 in hand, the ease and efficiency of introduction and removal of the FMsc tag 1 was 
explored. Model peptide 6 (Table 1) was treated with FMscCl 5 (5eq.) and DiPEA (10eq.) in DMF 
to give the corresponding tagged peptide FMsc-6, as corroborated by LCMS (Figure 4, trace A). 
Treatment of FMsc-6 with 2% aq. NH3 for 15min furnished starting peptide 6 (Figure 4, trace B). 
FIGURE 4 | LC chromatograms (5-18min, C18 RP column, 5Æ90% MeCN/0.1% aq. TFA, detection at 
214nm) of peptide GEPKPAG; A. after on-resin tagging (FMsc-6); B. after detagging (6).
6.4.1 | Fluorous HPLC (FHPLC) purification 
On the basis of these results, we turned our attention to the application of the FMsc tag in the 
purification of peptides 7-9 (Table 1) obtained through SPPS. These peptides are difficult to 
isolate in pure form using reversed-phase HPLC.14,15 For instance, the assembly of 35-mer 9 by a 
standard SPPS protocol suffered from incomplete couplings leading to a tedious isolation 
procedure, as shown by the HPLC pattern of crude 9 (Figure 5E). 
TABLE 1 | Synthetic peptides used in this study. 
Peptide Sequence 
6 GEPKP AGa 
7 GCCSL PPCAL NNPDYa 
8 RQIKI WFQNR RMKWK Ka 
9 LSELD DRADA LQAGF SQFES SAAKL KRKYW WKNLK 
     a = C-terminal carboxamide 
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Peptides 7-9 were synthesised using standard Fmoc-based SPPS with either HCTU (7 and 8) or 
BOP/HOBt (9) as condensing agents, starting from Rink amide (7, 8) and Wang resins (9). In the 
latter case, the first amino acid was condensed with the resin using DIC and DMAP. Each 
condensation step was followed by capping (Ac2O, DiPEA, HOBt) of the residual unreacted 
amines. After completion of the synthesis of the respective oligopeptide sequences and removal 
of the final Fmoc group, the resin-bound peptides were tagged with FMscCl/DiPEA (5 and 10eq. 
respectively) in DMF. The peptides were then cleaved from the solid support with concomitant 
liberation of the side-chain functionalities using TFA/TIS/H2O (95/2.5/2.5, v/v/v). 
At this stage, we turned our attention to the purification of tagged 35-mer 9. As can be seen 
(Figure 5F), full length, FMsc-tagged 9 eluted significantly later from a fluorous HPLC (FHPLC) 
column than non-tagged impurities. Semi-preparative FHPLC with an aq. TFE gradient afforded 
FMsc-9 in 99% purity (Figure 5G). Detagging (2% aq. NH3, Figure 5H) finally afforded target 
peptide 9 in 21% overall yield (based on initial loading of the resin). Tagged peptides 7 (Figure 5) 
and 8 were purified with FHPLC and detagged with equal efficiency (Table 2).  
         
FIGURE 5 | Chromatograms (5-18min except B and C, 5-12min), UV detection at 214nm) of peptides 
purified by FHPLC. Left: peptide 7: A. Crude 7; B. Crude-FMsc-7, the apparent double peak 
is due to overloading of the column; C. FHPLC-purified FMsc-7; D. Pure 7 after detagging; 
shoulder is caused by S-S oxidation. Right: 35-mer 9: E. Crude 9; F. Crude FMsc-9; G. FHPLC-
purified FMsc-9; H. Pure 9 after detagging. HPLC methods (see Experimental section): 
A,D,E,H method X; F,G method Y. B,C method Z. Peaks with correct mass are indicated 
with arrows. Shift of retention time is due to different sample composition. 
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TABLE 2 | Data on detagged peptides purified by FHPLC. 
               ESI-MS
Peptide Yield (%)A Purity (%)D Tagged Detagged 
7 37 98 2252.0 1669.0 
8 10 94 2828.8 2246.6 
9 21 99  2343.0B     4099.121C
A Based on loading of the first amino acid; B [M+2H]2+; C HRMS (calcd. 4099.128); D purity determined by  
integration of LC peaks.
6.4.2 | Fluorous SPE (FSPE) purification 
In an alternative approach, it was investigated whether FMsc-tagged peptides 7-9 could be 
purified by fluorous silica gel extraction.16 As an example, crude FMsc-7 was applied to a 
fluorous solid-phase extraction (FSPE) cartridge. With the aim of removing non-tagged 
impurities, the cartridge was eluted first with 0.1% aq. TFA and then with 0.1% TFA in 
MeOH/H2O 1/1 (v/v). Subsequent elution of the cartridge with 0.1% TFA/MeOH afforded 
FMsc-7 in a significant enhanced purity after detagging (59% yield, 91% purity, Table 3). 
Although the purity of the final product was somewhat lower than was observed after FHPLC, 
the ease of execution and potential scale (~50mg crude FMsc-7 could be applied to the FSPE 
cartridge in one single run) makes this purification procedure an attractive alternative. In a 
similar way, FMsc-tagged 8 was purified and detagged (Table 3). In this case, the use of a mixture 
of 0.1% TFA in TFE/H2O 1/1 (v/v) proved to be more effective for elution of the fluorous 
peptide. In contrast, purification of FMsc-9 on a FSPE cartridge failed, arguably due to the 
relative low fluorine content (only 7% by weight compared to 14% in 7 and 11% in 8).
TABLE 3 | Data on detagged peptides purified by FSPE.
Peptide Crude Material (mg) Detagged Yield (%)A Purity (%)B EluentsC
7 45.9 59 91 MeOH/H2O
8 17.2 7 72 TFE/H2O
A Based on loading of the first amino acid; B purity determined through integration of LC peaks; 
C containing 0.1% TFA.
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6.5 | Fluorous Capping 
The described fluorous methods (FZ, FMsc) based on tagging of the desired product, discussed in 
the previous paragraphs, have the common disadvantage that the fluorous product obtained 
after purification by either FHPLC or FSPE must be subjected to one final detagging step, which 
leads to inevitable handling losses. Attachment of a fluorous handle to all incomplete sequences, 
i.e. the use of fluorous capping reagents,10b,c overcomes this last reaction step. However, 
substitution of commonly used Ac2O for capping in SPPS with a fluorous anhydride (e.g.
[1H,1H,2H,2H]-perfluoroundecanoic acid anhydride) brings about some practical issues: 
[1H,1H,2H,2H]-perfluoroalkanoic anhydrides with sufficient fluorine content are not 
commercially available, and the precursor acids are rather expensive for large-scale use. Besides, 
the reactivity of the fluorous capping reagent is unknown and might well differ from Ac2O.
To circumvent these issues, the following two-step fluorous capping strategy was 
designed. As outlined in Scheme 3, Ac2O in standard SPPS procedures (step A) has been replaced 
by azidoacetic acid anhydride (10) or azidoacetic acid/HCTU. After completion of the SPPS (A),
in which the N-terminal residue is incorporated as its Nǂ-Boc-protected derivative, the on-resin 
azides are reduced by phosphine treatment (B) and subsequently capped by reaction with a 
perfluoroalkyl acid or its anhydride (step C). As the last two steps are performed after automated 
synthesis, their progress can be easily followed by TNBS or Kaiser tests. 
SCHEME 3 | Outline of the two-step fluorous capping strategy. * or the corresponding anhydride/DiPEA if 
desired; the azidoacetic acid/HCTU/DiPEA conditions can be applied instead of compound 
10 as well. 
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After cleavage from the resin (D), fluorous affinity purification (FHPLC/FSPE, E) can be applied 
to obtain the desired product as the first, non-fluorous, peptide eluting. This way, the fluorous 
acylation step C is applied only once (after completion of the SPPS) as in the tagging approach, 
rather than after every coupling step as in the original capping approach. 
In a preliminary experiment, the peptide GEPKPAG was synthesized following the two-step 
fluorous capping strategy. During automated Fmoc-based SPPS, 0.85eq. of amino acid was used 
to ensure incomplete sequences. After each coupling, the resin was treated with azidoacetic 
acid/HCTU/DiPEA. After completion of the synthesis, treatment with PMe3/1,4-dioxane/H2O
yielded the free amines, as verified by TNBS test. Subsequent acylation with [1H,1H,2H,2H]-
perfluoroundecanoic acid/HCTU/DiPEA resulted in fluorous capped incomplete sequences. 
After cleavage from the resin, the crude material (14.2mg) was purified in a single run using 
FSPE. The FSPE cartridge, containing 0.7mL fluorous silica, was eluted with 4x5mL 10% aq. TFA, 
and the desired product was found primarily in the first 5mL fraction, with very low amounts in 
the other fractions. Importantly, no fluorous incomplete sequences were detected by LCMS in 
these fractions. The yield of the desired peptide was 28% of the theoretical maximum yield. 
Although this method does need optimization, it might eventually lead to a simple and time-
effective synthesis/purification procedure for peptides. 
6.6 | Summary 
In summary, the development and application of a new fluorous FMsc protecting group 1 was 
disclosed. Application of FMscCl 5 in Fmoc-based SPPS allows the generation of full-length 
peptides equipped with a base-labile fluorous tag. These peptides were purified by either FHPLC 
or FSPE, after which the tag is easily and quantitatively removed. Furthermore, a two-step fluorous 
capping approach towards a capping strategy was discussed along with preliminary results. In 
conclusion, fluorous strategies can be valuable tools enabling isolation of desired products from 
complex crude synthetic peptide mixtures. 
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6.7 | Experimental Section 
6.7.1 | HPLC methods
HPLC methods: X. Alltech Alltima C18 column (150x4.6mm), 5Æ90% MeCN/H2O+0.05% TFA in 17min at 
1.0mL/min; Y. Keystone Scientific Operations FluoPhase WP column (100x4.6mm), 20Æ100% TFE/H2O + 
0.05% TFA in 18min at 1.5mL/min; Z. Identical to method Y but gradient elution time is 12min. UV 
detection in all methods at 214nm.
6.7.2 | Syntheses
Acylated GEPKPAG dervatives
GEPKPAG was synthesized using automated Fmoc-based SPPS procedures using Rink amide resin and 
HCTU/DiPEA as coupling reagents. After completion of the synthesis, the last Fmoc group of GEPKPAG 
was removed and the resin was split into three batches (6.5Ǎmol each), two of which were treated with 
undecanoic acid/DiPEA (5 and 10eq. respectively) or [1H,1H,2H,2H]-perfluoroundecanoic acid/DiPEA (5 
and 10eq. respectively) in DMF for 2h. After acidic cleavage of all batches from the resins, three peptides 
were obtained; GEPKPAG, F-GEPKPAG and L-GEPKPAG. These peptides were analyzed by FHPLC 
(method Y): GEPKPAG Rt < 2min, L-GEPKPAG Rt 7.21min, F-GEPKPAG Rt 9.75min. 
([1H,1H,2H,2H]-perfluorodecyl)sulfidylethanol (3). Under nitrogen atmosphere,     
NaOH (0.50g, 12.5mmol, 1.5eq.) and 2-mercaptoethanol (1.41mL, 20mmol, 2.45eq.) 
were refluxed in tBuOH (30mL) for 30min. Next, [1H,1H,2H,2H]-perfluorodecyl iodide 2 (4.71g, 8.15mmol) 
was added and the mixture was stirred under reflux conditions for an additional 3h. After evaporation of all 
volatiles, the crude product was subjected to silica gel column purification, yielding 3.88g (7.41mmol, 91%) 
of pure 3. TLC (PE/EtOAc 1/1 (v/v)): Rf 0.70. 1H NMR (CDCl3): δ 3.75 (s, 1H, OH), 3.75-3.68 (m, 2H, H1), 
2.71-2.42 (m, 4H, H2, H3), 2.40-2.09 (m, 2H, H4). 13C NMR (CDCl3): δ 123.1-104.7 (CF), 59.5 (C1), 24.6 (C2), 
32.3, 31.9, 31.4 (C4), 22.4 (C3); 19F NMR (CDCl3): δ -5.03 (CF3), -38.1, -45.6, -46.7, -47.0, -50.1 (CF2). ESI-MS: 
547.1 [M+Na]+.
([1H,1H,2H,2H]-perfluorodecyl)sulfonylethanol (4). To a solution of 3 (3.12g, 
5.95mmol) in ice-cooled AcOH (1.6mL), 32% AcOOH in AcOH (3.26mL, 1.2eq) 
and water (1.1mL, 10eq) were added. If gel formation occurred, EtOAc (5mL) 
was added to dilute the reaction mixture. After 2h, TLC showed total conversion of the starting material and 
NaHCO3 (s) was carefully added to neutralize the mixture. Next, the mixture was extracted using a large 
excess of EtOAc (3x) and dried over MgSO4. After filtration and removal of solvents in vacuo, the crude 
product was purified by silica column chromatography. Compound 4 was obtained as a white solid (yield: 
5.77mmol, 97%). TLC (EtOAc/PE 1/1 (v/v)): Rf 0.49. 1H NMR (MeOD): δ 3.90 (t, 2H, H1, J1,2 = 5.1Hz), 3.60-
3.33 (m, 2H, H3, J3,4 = 8.0Hz), 3.25 (t, 2H, H2), 2.84-2.48 (m, 2H, H4). 13C NMR (MeOD): δ 56.8 (C1), 47.5 (C2, 
C3), 25.9, 25.4, 25.0 (C4). 19F NMR (MeOD): δ -1.17 (CF3), -33.5, -41.6, -42.5, -43.0, -46.1 (CF2). ESI-MS: 579.1 
[M+Na]+.
([1H,1H,2H,2H]-perfluorodecyl)sulfonylethoxycarbonyl chloride (5). 
Compound 4 (5.77mmol) was dissolved in freshly distilled THF (50mL). To 
this solution, phosgene (20% in toluene, 24mL, 9eq.) was added. After 16h, 
TLC indicated total conversion of the starting material. Phosgene and solvents were carefully removed in
vacuo in a fumehood. The residue was coevaporated with toluene (2x), yielding 3.56g (5.75mmol, quant.) as 
a pinkish white solid. TLC (EtOAc/PE 1/1 (v/v)): Rf 0.85. 1H NMR (CDCl3): δ 4.82-4.71 (m, 2H, H1), 3.51-
3.41 (m, 2H, H2), 3.41-3.26 (m, 2H, H3), 2.86-2.53 (m, 2H, H4). 13C NMR (acetone-d6): δ 120.3-110.6 (CF), 65.4 
(C1), 51.8 (C2), 45.9 (C3), 24.8, 24.4, 24.0 (C4). 19F NMR (CDCl3): ǅ -3.5 (CF3), -36.3, -44.6, -45.2, -45.8, -48.8 
(CF2). A sample of 5 was solvolyzed in MeOH to give the methyl carbonate, ESI-MS: 637.1 [M+Na]+.
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Loading of Wang Resin 
A flask was silylated using 20% TMSCl in CHCl3. Therein, the Wang resin was coevaporated with DCE, 
suspended in CH2Cl2 and treated with the first amino acid (3eq.), DIC (3eq.) and DMAP (0.1eq.) for 2h. The 
resin was filtered off, rinsed with CH2Cl2, MeOH and Et2O and air-dried. Loading of the resin was 
determined by measuring the UV absorbance at 300nm of released Fmoc-chromophore upon treatment of a 
resin sample with 20% piperidine/DMF for 10min. 
6.7.3 | FMsc Tagging Procedure
After SPPS, the free N-terminus of the full-length peptide was tagged by suspending the resin in DMF or 
NMP (1.5mL per 50Ǎmol on-resin peptide), and adding FMscCl  (5, 5eq.) and DiPEA (10eq.) and shaking at 
RT for 1h. The resin was filtered off and washed with DMF or NMP, MeOH and CH2Cl2. If TNBS or Kaiser 
test was positive, procedure was repeated. 
6.7.4 | FSPE Procedure
Crude peptide mixture was dissolved in the smallest amount of H2O possible, and AcOH was added to aid 
dissolution if necessary. This mixture was loaded onto a 5mL syringe that contained 0.7-2.0mL fluorous 
silica material (FTI, Pittsburg, USA) with a filter on top of the silica layer. The cartridge was subsequently 
eluted with volumes of 0.1% aq. TFA, 0.1% aq. TFA/MeOH 1/1 (v/v) and 0.1% TFA/MeOH and fractions 
(1-5mL) were collected. If LCMS analysis required the use of TFE, TFE instead of MeOH was used in the 
FSPE purification of these particular peptides. 
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7.1 | Summary & Future Prospects 
Given the alarming rate of evolving bacterial resistance against commonly used antibiotics, the 
demand for new classes of antimicrobials to stay ahead of bacteria is increasing. Cationic 
antimicrobial peptides (CAPs) are ubiquitous in nature and play key roles in the innate immune 
systems of virtually all living species. CAPs come in large variations regarding length, primary 
and secondary structures, but all share amphiphilicity. In fact, this amphiphilicity is the factor 
that appears to determine the preference of the majority of CAPs for Gram-negative bacteria by 
allowing initial electrostatic interactions with their anionic outer membranes. The General 
Introduction gives an overview on the current status of common antibacterial drugs and research 
towards new entities for combating especially Gram-negative bacterial infections, with special 
attention for the relatively new antibiotic class of CAPs and compounds inspired by CAPs. 
 Optimization of CAPs regarding secondary structure, amphiphilicity, toxicity, selectivity 
and stability for the discovery of lead structures is an on-going process driven by the demand for 
new antibiotics. The research area of CAPs, further expanded by research into CAP-inspired 
amphiphilic structures, inspires a large global scientific community and has led to a number of 
projects in which CAP-based compounds have arrived in different stages of clinical trials. 
Chapter 1 deals with the stability issue of drosocin (DRC), a CAP isolated from Drosophila 
melanogaster (fruit fly). This CAP is a potential candidate for further drug development: it 
possesses desired characteristics in that it kills Gram-negative bacteria in the low micromolar 
concentration range, does not bind the human equivalent of its target bacterial protein (i.e. it is 
selective) and is non-toxic to human erythrocytes. Unfortunately, it is broken down by proteases 
in serum before it can exert its activity. Substitution of amino acid residues 1, 6 and/or 7 led to a 
series of analogues of which the best compound (1, Table 1) showed a ~30-fold increased serum 
stability. This compound might be further optimized regarding stability and activity to become a 
new CAP-based drug lead. 
Substitutions are by no means limited to the Tyr6/Ser7 dipeptide nor limited to closely 
related amino acids as is illustrated by compounds 2-4 in the text below (see also Table 1). 
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TABLE 1 | The most stable DRC analogue (1), analogues containing a sugar amino acid (SAA) (2) or a MeArg 
residue (3). Derivative 4 enables identification of the binding location in its target protein 
DnaK. Structure of the amino acid (Tmd)Phe (Z) is depicted on the right.
SequenceC % leftA MICB (M)
DRC     GKPRP Y   SPRP TSHPR PI RV 3 6.3 
1 ȕAla-KPRP Y TPRP TSHPR PI RV 87 3.1 
2     GKPRP SAA-SPRP TSHPR PI RV <1 12.5 
3     GKPRP Y   SPRP TSHPR PIMeRV n/d 50 
4     GKPRP Z SPRP TSHPR PI RV n/d n/d 
            A After 8h in 25% human serum; B against E. coli ATCC 11775; C SAA= 
sugar amino acid, MeR=Nş-methylargininyl, Z=(Tmd)Phe. 
For example, in structure 2, a sugar amino acid (SAA) residue was designed in an attempt to 
combine two desired characteristics of such a substitute. First, the unnatural SAA acts as a 
dipeptide isostere, replacing the labile Tyr6/Ser7 amide bond. Second, these types of SAA 
structures are known to be capable of inducing a flexible ǃ-turn.1 The presence of a turn element 
was observed in proximity of this dipeptide in NMR studies of glycosylated DRC, and this turn 
element is suspected be involved in interactions with drosocin’s target.2 The Bn protecting group 
was retained to add hydrophobicity which is present in the original dipeptide. The intermediate 
Boc-protected building block 6 was synthesized in parallel with a recently published procedure3
from cyanide 5 (Scheme 1).4 Selective opening of the benzylidene moiety towards the 4-O-benzyl 
protected compound 7 was realized with DiBAl-H at -400C.
SCHEME 1 | Key steps in synthesis of Fmoc-SAA-OH (9). Reagents & conditions: i. DiBAl-H, toluene, -400C
(70%) ii. 25% TFA/CH2Cl2; iii. FmocOSu, dioxane/H2O (62% over 2 steps); iv. (1) IBX, CH2Cl2 (2) 
NaClO2, tBuOH, H2O, 2-methyl-2-butene (60% over 2 steps). 
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Amine protecting group manipulations (Æ8) and two-step oxidation of the primary alcohol 
function yielded the Fmoc-derivative 9 which was used in standard automated SPPS protocols to 
give DRC derivative 2 (HRMS: [M+H]+ 2194.258, calcd. 2194.260). Peptide 2 had a MIC value of 
12.5ǍM, but was completely degraded after 8h in 25% human serum. 
After stabilization of the major Tyr6/Ser7 cleavage site, attention should be directed 
towards modification of one of the other two minor cleavage sites. To stabilize the Ile17/Arg18 
minor cleavage site, substitution with natural and unnatural amino acids can be performed 
similar to the Ty6/Ser7 dipeptide modifications. To this end, N-Me-Arg18 was incorporated (3,
Table 1); this substitution however impairs antibacterial activity (MIC: 50ǍM). 
DRC finds its target, the bacterial heat shock protein DnaK, inside the Gram-negative 
bacterial cell. Determination of the exact location of binding to this protein is a step forward in 
the design of new DRC-based antibiotics. To this end, the Tyr6 residue in DRC could be 
substituted with a light-activatable alkylating L-4'-[3-(trifluoromethyl)-3H-diazirin-3-yl]-
phenylalanine ((Tmd)Phe, Z) residue5 to yield compound 4 (Table 1). After binding to 
commercially available Escherichia coli DnaK, light-activation of the (Tmd)Phe residue in 4 would 
result in a stable, covalent crosslink between the two compounds; subsequent digestion of the 
complex with a protease (e.g. trypsin) gives small peptide fragments that can be identified by MS 
to locate the position of the crosslink.6
The polymyxin family of CAPs, produced by Bacillus polymyxa, are among the most potent anti-
Gram-negative bacterial peptides known. As reported strategies towards the synthesis of 
polymyxin B1 (PMB1), based on cyclization in solution, resulted in inseparable mixtures of linear 
and cyclized products, a new synthetic approach towards PMB1 was devised. Through the use of 
the safety-catch approach described in Chapter 2, PMB1 was obtained conveniently as this 
strategy prevents any uncyclized products to be released from the resin after SPPS.  A number of 
PMB1 analogues containing substitutions in the hydrophobic regions were synthesized via this 
route. These compounds, containing analogues with different acyl chains or amino acid 
substitutions of hydrophobic amino acids in the ring, showed distinct MIC values. Unfortunately, 
none of the  analogues proved to be more potent than the parent compound. 
Although cyclized polymyxins can be conveniently obtained using this procedure, the 
yield of the cyclization step might be optimized (yield for polymyxins B ~10%). An alternative 
cleavage/cyclization strategy is the approach depicted in Scheme 2, which might lead to higher 
yields of cyclized material. In this approach, the 4-butyrylsulfonamide safety-catch linker (SCL) is 
first coupled to 2-chlorotrityl (Clt) resin (Æ10), rather than AM resin. After automated SPPS of 
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the linear polymyxin (11), the SCL is activated by alkylation. Subsequently, the activated resin is 
treated with treated with 3% TFA to liberate the Mtt group of Dab4 and cleave the peptide, still 
C-terminally connected to the SCL, off the resin (Æ12). Cyclization (DiPEA/THF) in a highly 
diluted solution then gives the protected polymyxin. As this cyclization occurs fully in solution, 
cyclization yields can be expected to be higher than the on-resin cyclization/cleavage strategy in 
Chapter 2. At this stage, the protected polymyxin should be purified by chromatography if 
necessary to remove unwanted linear 12 which is still connected to the SCL; these two can be 
expected, in contrast to the linear and cyclized PMB1 after cyclization in solutions, to differ in 
chromatographic behaviour. Care should be taken when searching for the optimal purification 
conditions, as the activated butyryl sulfonamide in 12 might react with the solvents used to give 
products with near-identical retention times. In any case, cyclization yields are expected to 
increase. Final acid treatment of the purified cyclized peptide removes all protecting groups 
(Æ13).  
SCHEME 2 | Alternative pathway for synthesis of polymyxins starting from Clt resin. The nature of the 
Dab1 acyl group determines the polymyxin B subtype. HPLC purification of 12 might be 
established by gel filtration due to the hydrophobic nature of the compound. 
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In Chapter 3, the identity of a by-product found in the last step of the synthesis of synthetic 
polymyxin B3 (PMB3) from Chapter 2 was elucidated. This by-product, which was also detected 
after acid treatment of polymyxin B1 isolated from a commercial sample in a different assay, 
displayed a different HPLC retention time than did the parent compound; however, its mass 
spectrum was identical. This isomeric molecule was hypothesized to be the polymyxin with the 
acyl chain migrated from the Nǂ to the NǄ position of the Dab1 residue. Following a synthetic 
route slightly adapted from the one described in Chapter 2, synthetic NǄ-PMB3 (14) was obtained 
(Figure 1). NǄ-PMB3 coeluted with the by-product formed from PMB3, and showed identical 
MS/MS spectra. 
FIGURE 1 | Structure of NŠ-PMB3, the by-product formed from PMB3 by acyl migration.  
Chapter 4 describes an approach to create conjugates of linear CAPs with the polymyxin B 
nonapeptide (PMBN). The two parts are incorporated for specific purposes. Whereas the CAP 
part was expected to exert the antibacterial activity, the PMBN moiety was incorporated for a 
three-fold task. First, it imposes selectivity upon the conjugate towards Gram-negative bacteria 
due to its selectivity for anionic membranes. Second, it sensitizes the outer membrane for 
enhanced uptake of the conjugate, and third, after antibacterial action had taken place, it is able to 
bind and neutralize LPS that is released from the killed bacteria. Compared to the untruncated 
polymyxin B (PMB) itself, PMBN has lost antibacterial activity but also its toxicity. Four 
conjugates were prepared that were linked by disulfide bonds (e.g. 15, Figure 2) to enable 
separation of the two moieties once inside the bacteria. To this end, the polymyxin synthesis of 
Chapter 2 was adjusted to incorporate a Cys residue to create CPMBN (16, Scheme 3).  
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The conjugates with membrane-active CAPs (tritrpticin and KFF) were found to possess 
antibacterial and hemolytic activity; one of them (KFF/PMBN 15, Figure 2) showed higher 
affinity for LPS than did the control polymyxin. Conjugates with peptides targeting internal 
structures (buforin II, drosocin) were devoid of antibacterial and hemolytic activity. 
FIGURE 2 | CAP/PMBN conjugate that showed higher affinity for LPS than the control polymyxin. 
Future prospects of this project include the conjugation of PMBN to the N-terminus of the linear 
CAP rather than its C-terminus. Derivatization of the N-terminus of drosocin (Chapter 1) appears 
to be allowed with respect to antibiotic activity; as for BF2, the reported N-terminal biotinyl-BF2 
conjugate was not subjected to antimicrobial tests,7 whereas inhomogeneous (i.a. N-terminal) 
FITC-labeling of BF2 did not interfere with antimicrobial action.8 Thus, the N-terminal conjugates 
CPMBN-SS-Cys-Ava-BF2 and CPMBN-SS-Cys-Ava-DRC were prepared via similar chemistry as 
the C-terminal conjugates, and will be evaluated for their biological properties. Furthermore, 
PMBN/CAP conjugates can be constructed through different methods. For instance, conjugation 
by native chemical ligation (NCL, Scheme 3) employs the earlier synthesized compound CPMBN. 
In a preliminary experiment, compound 15 was constructed through NCL from 16 and 17.
HN
HN
HN
HN
HNNH
O
O
O
NH2
NH2
O
HO
NH
O
NH
HN
O
HO
H2N
H2N
O
NH
O
O
O
H2N
S
15  KFF/CPMBN conjugate
H
N
H
N
N
H
H
N
N
H
H
N
N
H
H
N
N
H
OHO
S
OO
O
O
O
O
O
O
O
H
N
NH2
NH2
NH2
N
H
H2N
O
O
NH2
Chapter 7  
138 
SCHEME 3 | Preparation of a KFF/CPMBN conjugate through NCL. 
Instead of conjugating PMBN to CAPs, the LPS-affinity moiety could well be coupled to other 
antibiotics such as ǃ-lactam or macrolide derivatives to generate ‘dual-action’ antibiotics of which 
the antibiotic activity might be enhanced due to the sensitizing effect of the present PMBN. The 
approach of conjugating LPS-affinity moieties to CAPs can also be extended to other LPS-affinity 
moieties. Pentamidine,9 a drug mainly used to treat African trypanosomiasis (sleeping sickness) 
was elaborated to give a compound that could be used in thiol/maleimide conjugation to CAPs 
(Scheme 4). Pentamidine derivatives (PNT) are structurally and synthetically less complicated 
than CPMBN; moreover, LPS affinity of pentamidine and congeners was found to be higher than 
that of polymyxin B.10 The unoptimized synthetic route commenced with diethanolamine which 
was N-protected11 with Boc and converted into compound 18 by double Mitsunobu reaction with 
4-cyanophenol. After removal of the Boc protecting group, a linker containing an MMT-protected 
thiol moiety was introduced by coupling of S-(4-methoxytrityl)-ǃ-mercaptopropionic acid with 
the aid of EDC (Æ19). Of the many conditions12 tested for conversion of test-compound 
benzonitrile to their amidines (e.g. LiHMDS or KHMDS followed by aq. HCl, CuCl followed by 
NH3/NaOH/H2O, MeAl(Cl)NH2 followed by H2O, or Ac-Cys-OH followed by NH3/H+),13 the 
classical Pinner conversion (HCl/EtOH followed by NH3/EtOH) gave best results. Removal of 
the MMT group (Æ20) proved necessary prior to the Pinner conversion of the nitriles into the 
intermediate imidate salts, which are subsequently ammonolyzed with saturated NH3/EtOH, 
yielding the diamidine 21 (MS: 429.4 [M+H]+, 857.4 [2M+H]+). Following HPLC purification, 21
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was conjugated in aqueous solution to CAPs which were equipped with a 3-maleimidopropionyl 
(Mpa) group.14 After HPLC purification of these mixtures, conjugates 22 of PNT with TTC, DRC 
and BF2 were obtained. These compounds are to be assayed for bioactivity and LPS affinity. 
SCHEME 4 | Synthesis of CAP/PNT conjugates. Reagents & conditions: i. Boc2O, THF, 00C (94%); ii. PPh3,
DIAD, 4-cyanophenol, THF, 00C (31%); iii. TFA/TES/CH2Cl2 (8/1/11 v/v/v) (95%); iv. S-(4-
methoxytrityl)-ş-mercaptopropionic acid, EDC, sat. aq. NaHCO3, DMF (99%); v. 
TFA/TIS/CH2Cl2 (8/5/87 v/v/v) (98%); vi. (1) dry HCl (g), EtOH/CH2Cl2 (4/1 v/v), 0
0C to RT 
(2) sat. NH3/EtOH, microwave, 85
0C (3) HPLC purification (28% over these 3 steps); vii. (1) 
CAP with N-terminal Mpa group, H2O/MeCN, phosphate buffer, pH 7 (2) HPLC purification.
Hydrophobicity and cationicity, governing the antibacterial activity of CAPs, are also present in 
smaller structures, among which are the quaternary ammonium compounds (QACs). In Chapter 
5, a number of QACs were synthesized, based on either N-alkyl-N’-methyl imidazolium (MIM) or 
N-alkyl-N-methyl pyrrolidinium (MPD) cations. Gel formulations of a selection of these 
compounds were prepared using either water, ethylene glycol or glycerol as additive. All gels 
tested showed effective eradication (>99.9%) of the bacteria (Gram-negative E. coli or Gram-
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positive S. aureus) used. Compound 23 (Figure 3) in a gel containing 35% ethylene glycol as 
additive showed to be a candidate for further development of an antibacterial gel formulation for 
decontamination purposes. This particular gel of 23 showed increased stability characteristics, 
being largely stable against a one-minute, 20mL/min dropwise continuous flow of water when 
applied to a vertical surface, unlike the vast majority of the gels tested. The favorability of QACs 
as antibacterial compounds has also been proven by Klibanov et al. who prepared i.a. quaternized 
poly(vinylpyridine)15 that showed antibacterial effects similar to the gels reported here. 
FIGURE 3 | Structure of 23, which, in a gel of 35% (wt) ethylene glycol, showed highest water stability.
As crude mixtures of synthetic peptides generated through SPPS generally contain impurities, 
HPLC purification is necessary to obtain these peptides in pure form. In some cases, HPLC 
purification can be a tedious and time-consuming procedure if truncated sequences display 
rather similar chromatographic behaviour as the desired product. In Chapter 6,  two approaches 
to the use of fluorous techniques in the purification of synthetic peptides are presented. The first 
one is based on purification by tagging the desired full-length product during SPPS and 
subsequent chromatographic purification of the crude peptide mixture using fluorous HPLC or 
fluorous SPE. Non-tagged incomplete sequences elute before the (fluorous) desired product does. 
To this end, a novel, base-labile amine protecting group based on the Msc group (FMsc 24, Figure 
4) was synthesized.
FIGURE 4 | Structure of Msc-derived fluorous protecting group for use in fluorous chromatography of 
synthetic peptides (FMsc 24).
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The second method describes a ‘two-step fluorous capping’ approach, in which all non-desired 
impurities are equipped with a fluorous handle as the last step in SPPS sequence. The 
preliminary results of this approach still need optimization but omit a final detagging step (as in 
the tagging strategy) and allow more convenient fluorous purification as the desired product 
elutes first.
The fluorous purification techniques described in this Chapter were successfully applied 
to a number of synthetic peptides; optimization of the two-step fluorous capping approach might 
lead to a simple, cost and time-effective procedure able to compete with conventional HPLC 
purification. 
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General Materials & Methods 
Chemicals
Chemicals used in the reactions described in this thesis were obtained from the following commercial 
sources and used as received, unless otherwise stated (see last section of this paragraph). Chemicals were 
stored at temperatures indicated by the supplier and under inert atmospheres and dry conditions where 
necessary. 
Acros: 30% AcOOH/AcOH, 1-adamantaneacetic acid, 29% ammonium hydroxide, Boc2O, 1-bromodecane, 
1-bromododecane, 1-bromoheptane, 1-bromohexadecane, 1-bromooctadecane, 1-bromooctane, 1-
bromoundecane, butyric acid, chloranil, DAST, DIAD, 1,10-dibromodecane, 1,9-dibromononane, DIC, 2,2’-
dithiobispyridine, DMAP, ethylene glycol, glycerol, heptanoic acid, hexanoic acid, HFIP, hydrazine hydrate, 
ICH2CN, LiAlH4, 2-mercaptoethanol, 1-methylimidazole, MMTCl, NaBH4, nonanoic acid, octanoic acid, 
sodium thiophenolate, TFE, TMSCl, valeric acid. Aldrich: Ag2SO4, Ag3PO4, 1-bromononane, 1-
bromotridecane, EDC.HCl, ethyl-3-mercaptopropionate, 20% phosgene/toluene. Applied Biosystems:
HATU. Bachem: Fmoc-N-Me-Arg(Mtr)-OH, Fmoc-N-Me-Ser(tBu)-OH, 3-maleimidopropionic acid. Baker:
Na2PO4.12H2O (z.A.). BDH: cetyltrimethylammonium bromide. Biosolve: MeCN (HPLC-S gradient grade), 
DiPEA, DMF, NMP, piperidine, TFA (peptide synthesis grade), Ac2O, CHCl3, CH2Cl2, 1,4-dioxane, DMSO, 
Et2O, pyridine, tBuOH, THF (AR), MeOH (absolute HPLC), DCE (DNA synthesis grade). Boom: NaOH.       
Bruker Daltonik: ǂ-cyanohydroxycinnamic acid (recrystalized). Bufa: NaHCO3,, MgSO4. Cambridge 
Isotopes: acetone-d6, CDCl3, aq. DCl in D2O, DMSO-d6, D2O, MeOD, TFE-d3. Fluka: Boc-Cys(StBu)-OH, (R)-
citronellyl bromide, DTT, Fmoc-βHSer(tBu)-OH, Fmoc-βHTyr(tBu)-OH), Fmoc-Cys(StBu)-OH, Fmoc-
Mamb-OH, Fmoc-Pamb-OH, MS 3Å, MS 4Å, 1M PMe3/toluene, PyBroP, TCEP.HCl, TentaGel PHB 
(0.24mmol/g), TentaGel S NH2 (0.26mmol/g), TIS, 1% TNBS/DMF. FTI: fluorous silica gel, [1H,1H,2H,2H]-
perfluorodecyl iodide, [1H,1H,2H,2H]-perfluoroundecanoic acid. ICN: basic alumina. Iris Biotech: HCTU. 
Merck: AcOH (glacial), NH4Oac, silica gel. Molecular Probes: DPX. NeoSystem: Boc-Dab(Fmoc)-OH, Fmoc 
-Abu-OH, Fmoc-Ava-OH, Fmoc-Capro-OH, Fmoc-Cmpi-OH, Fmoc-Dab(Boc)-OH, Fmoc-DPhe-OH, Fmoc-
Sar-OH, Fmoc-Tran-OH, HBTU. Nova Biochem: Boc-Cys(Tr)-OH, 3-carboxypropanesulfonamide, Fmoc-
βAla-OH, Fmoc-Dab(ivDde)-OH, Fmoc-Dab(Mtt)-OH, Fmoc-DSer(tBu)-OH, Fmoc-DTyr(tBu)-OH, Rink 
amide resin (0.64mmol/g), Wang resin (0.96mmol/g). Perseptive Biosystems: HOAt. Riedel-de Haën:
EtOAc, PE 40/60 (puriss.), toluene (purum). Senn Chemicals: AM resin (0.36mmol/g), BOP, Fmoc-Abu-
OH, Fmoc-Ala-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Arg(Pmc)-OH, Fmoc-Asn(Tr)-OH, Fmoc-Asp(OtBu)-OH, 
Fmoc-Gln(Tr)-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Ava-OH, Fmoc-Cys(Tr)-OH, Fmoc-Gly-OH, Fmoc-His(Tr)-
OH, Fmoc-Ile-OH, Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-Phe-OH, Fmoc-Pro-OH, Fmoc-Sar-OH, Fmoc-
Ser(tBu)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Trp(Boc)-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Val-OH, FmocOSu, HOBt, 
PyBOP 
H2O was purified using a Millpore MilliQ purification instrument. MeOH was stored on MS 3Å, CH2Cl2 and 
DMF on MS 4Å. THF was distilled prior to use from LiAlH4 (5g/L). Toluene, PE and EtOAc used in sgcc 
and work-up procedures were distilled before use. 
Analytical Techniques
TLC – Reactions were followed by TLC on silica gel (Schleider & Schull F 1500 LS 254) or HPTLC 
sheets (Merck, silica gel 60, F 254), with detection by UV absorption (254nm) where applicable followed by 
charring at 1500C after spraying with ninhydrin (3g/L) in EtOH/AcOH (100/3 v/v), 20% H2SO4 in EtOH 
(25g/L), NH4Mo7O24.4H2O (25g/L) and NH4Ce(SO4)4.2H2O (10g/L) in 10% aq. H2SO4, or 2% KMnO4 in 1% 
aq. K2CO3.
NMR – 1H NMR, 13C NMR, 19F NMR and 31P NMR were recorded on Bruker AC200 (200MHz), 
Bruker DPX-400 (400MHz) and/or Bruker DMX-600 (600MHz). H-H COSY, C-H COSY, TOCSY, ROESY 
and NOESY spectra were recorded on a Bruker DMX-600 (600MHz). Chemical shifts are in ppm relative to 
tetramethylsilane as internal standard at 0.0ppm (1H NMR) or relative to shifts of deuterated solvents (13C
NMR) according to literature values (CDCl3 middle resonance at 77.0ppm) 
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HPLC – RP-HPLC analyses and purifications were performed on a ÄKTA Explorer HPLC system. 
Alltech Alltima C18 analytical (250x4.6mm) and semi-preparative (250x10.0mm) columns were used. 
Applied buffer systems:  maximal gradient of 5Æ80% MeCN in 0.1% aq. TFA. Eluents were degassed before 
use with helium. 
(LC)MS – Analyses were performed using a Jasco 900 LC system with simultaneous detection at 
214 and 254nm connected to a Perkin Elmer SCIEX API 165 Q-TOF monoquad ESI mass spectrometer in 
positive ion mode. The applied LC buffer system runs with a maximal gradient of 10Æ90% MeCN in 0.1% 
aq. TFA (eluents were degassed with helium) over an Alltima Alltech analytical C18 column (150x4.6mm) at 
1mL/min. LCMS samples were dissolved in mixtures containing any of AcOH, H2O, MeCN, tBuOH, TFA, 
TFE, MeOH and HFIP, and for MS any of MeCN, MeOH, DMSO, DMF or H2O, where applicable. 
HRMS – HRMS spectra were recorded on an API QSTAR Pulsar (Applied Biosystems) or TSQ 
Quantum (Thermo Finnigan) fitted with an acurate mass option, interpolating between PEG peaks. 
MALDI-MS – MALDI-MS analyses were performed on a Bruker Biflex III reflectron TOF mass 
spectrometer, equipped with delayed extraction and with a UV ionization laser (N2, 337nm). For the 
analyses in Chapter 1, 5ǍL amounts of peptide samples were mixed with 5ǍL matrix solution (sat. ǂ-
cyanohydroxycinnamic acid  with 0.1% TFA in MeCN/H2O 1/1 (v/v)). Of this matrix mixture, 0.5ǍL was 
brought on the target plate. 
Determination of loading of resin with first amino acid – The loading of resin with the first 
amino acid was determined by photospectrometric detection. To this end, a sample of resin 2-5mg was 
treated for 10min 20% piperidine/DMF (1mL), then the total volume was adjusted to 10mL by addition of 
MeOH, and UV-absorption was measured at 300nm in a 1cm cuvet (Perkin Elmer DMS 200 
spectrophotometer). The loading was caluclated using the expression below derived from Lambert-Beer’s 
Law where L is the loading in mmol/g, A300 the absorbance at 300nm, vol the initial volume of the sample 
(10mL) and wt is the weight of the resin sample in mg.  
L=(A300 x vol)/(7.8 x wt) 
Kaiser test1 – For identification of free primary amines, the Kaiser test was performed: to 2-3mg of 
resin, 20ǍL of the three solutions were added (5g ninhydrin in 100mL EtOH; 80g PhOH in 20mL EtOH; 2mL 
0.001M KCN in 98mL pyridine) and the mixture heated to 1200C for 5min. A blue/purple resin colour 
indicates a positive test. 
TNBS analysis2 – As alternative to the Kaiser test, the TNBS test for identification of primary 
amines was applied. To this end, 20ǍL of 1% DiPEA/DMF and 20ǍL of 1% TNBS/DMF were added to 
samples of 2-3mg of resin. A red/orange resin colour after standing for 5min at RT indicates a positive test.
Chloranil analysis3 – For identification of secondary amines, the chloranil test was applied: to a 2-
3mg sample of resin, 20ǍL of 1% chloranil/DMF and 20ǍL of 1% DiPEA/DMF were added and the sample 
allowed to react for 5min at RT. Coloured resin indicates a positive test.
Solid-Phase Peptide Synthesis 
Peptides were prepared by using automated Fmoc-based SPPS custom protocols using any of the following 
synthesizers; ABI433A (Applied Biosystems), Syro 2000 (MultiSyntech) or 336 System 3 Peptide Synthesizer 
(CS Bio). Standard cycles (of which the duration differed for the three synthesizers, but followed customized 
programs) for acylating preloaded Wang or Rink amide resins commenced with washing of the resin with 
NMP (and swelling with CH2Cl2 in the first cycle), followed by a Fmoc deprotection step applying 20% 
piperidine/NMP. In general. acylation  was effected by using 3-6eq. of Fmoc-amino acid/DiPEA (6-12eq.), 
with PyBOP (Syro 2000, in NMP with LiCl) or HCTU (ABI433A and CS Bio) in NMP or NMP/DMF 1/1 
(v/v). Less often used activators include BOP, HBTU and HATU. After coupling, the resin was washed with 
NMP and a capping step comprising either Ac2O/NMP, Ac2O/DiPEA/NMP or Ac2O/DiPEA/HOBt/NMP 
was applied. SPPS were performed with N2 as pressurizing gas and resulted in on-resin peptides with either 
the last Fmoc removed (ABI433A, Syro 2000) or maintained (CS Bio). Synthesis scales ranged from 10-
100Ǎmol.
                                                          
1. Kaiser, E.; Colescott, R.L.; Bossinger, C.D.; Cook, P.I.; Anal. Biochem. 1970, 34, 595 
2.  Hancock, W.S.; Battersby, J.E. Anal. Biochem. 1976, 71, 261 
3.  Vojkovsky, J. Peptide Res. 1995, 8, 236 
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New Cationic Amphiphilic Compounds 
as Potential Antibacterial Agents
Bacteriële resistentie tegen antibiotica is een wereldwijd, steeds groter wordend probleem. Door 
foutief en overgebruik van bestaande antibiotica is het aantal typen bacteriën dat niet meer te 
bestrijden valt met deze middelen sterk gestegen. In het bijzonder voor Gram-negatieve bacteriën 
is resistentie een niet te verwaarlozen bedreiging; naast het feit dat dit soort bacteriën moeilijk te 
bestrijden is door het vrij impermeabele extra celmembraan, zijn patiënten die te maken hebben 
met een verergerde Gram-negatieve bacteriële infectie (bloedvergiftiging of sepsis) niet atijd 
gebaat bij de huidige antibiotica. Immers, nadat de bacterie gedood is door het antibioticum, 
komen membraanfragmenten vrij in de bloedbaan, die elders (weer) immunologische reacties 
kunnen veroorzaken waardoor de toestand van de patiënt verslechtert. De kans op overleven bij 
een dergelijke septische shock (de verergerde toestand van sepsis) is slechts 50-70%. 
Het onderwerp van het in dit proefschrift beschreven onderzoek is de ontwikkeling van nieuwe 
verbindingen met antibacteriële activiteit, specifiek gericht tegen Gram-negatieve bacteriën. Deze 
verbindingen zijn afgeleid van kationische antimicrobiële peptides (CAPs), een klasse van 
antibiotica die volgens een alternatief mechanisme werkt. Hoewel in het midden van de vorige 
eeuw ontdekt, kreeg deze klasse van antibiotica pas de laatste paar decennia meer aandacht 
vanwege de unieke eigenschappen. De meeste CAPs zijn selectief voor Gram-negatieve bacteriën 
vanwege hun kationisch karakter, waardoor elektrostatische interacties kunnen optreden met 
anionische bacteriële membraancomponenten. Bovendien zijn de meeste CAPs door hun 
natuurlijke samenstelling niet toxisch voor het menselijk lichaam; het menselijk lichaam maakt 
zelf ook gebruik van CAPs (bijvoorbeeld ǂ- en ǃ-defensines) in het aangeboren immuunsysteem.  
De Algemene Introductie van dit proefschrift geeft een overzicht van de huidige status 
van antibiotica en lopend onderzoek naar nieuwe antibiotica gericht tegen Gram-negatieve 
bacteriën. De pathogenese van Gram-negatieve sepsis en septische shock worden verklaard aan 
de hand van de samenstelling van het buitenmembraan van Gram-negatieve bacteriën. In deze 
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Introductie wordt ook de CAP klasse van antibiotica besproken en een kort overzicht gegeven 
van onderzoek naar CAPs en door CAPs geïnspireerde verbindingen. 
Hoofdstuk 1 beschrijft de synthese van een aantal analoga van het CAP drosocine. Dit 
CAP, geïsoleerd uit de fruitvlieg, mag op grond van een aantal gewenste eigenschappen als lead
compound voor de ontwikkeling van nieuwe antibiotica worden beschouwd; het is volledig 
selectief voor Gram-negatieve bacteriën waarin het een heat shock protein inactiveert. Het bindt 
niet aan de menselijke variant van dit eiwit, is niet hemolytisch en niet toxisch. Het wordt echter 
afgebroken in menselijk serum voordat het zijn werk heeft kunnen doen. Door substituties van 
aminozuren aan weerszijden van de amide binding die in serum verbroken wordt, alsmede van 
het N-terminale aminozuur, werd een drosocine derivaat verkregen dat ~30x stabieler is dan 
drosocine zelf, maar met eenzelfde antibiotische activiteit. 
 De CAP subfamilie van polymyxines is onderwerp van Hoofdstuk 2. In dit hoofdstuk 
wordt een nieuwe syntheseroute voor deze cyclische lipopeptides gepresenteerd, die gebaseerd is 
op het gelijktijdig vormen van het cyclische peptide en afsplitsing van de hars waarop het 
peptide opgebouwd is. Deze synthese procedure vergemakkelijkt de zuivering van het 
eindprodukt aanzienlijk omdat niet-gecycliseerde peptides achterblijven op de vaste drager. Via 
deze syntheseroute werden een aantal polymyxine B1 analoga bereid met substituties in een van 
beide hydrofobe regionen, omdat de toxiciteit van polymyxines aan deze regionen wordt 
toegedicht. De verkregen analoga vertoonden echter lagere tot geen antibacteriële activiteit en 
verminderde affiniteit voor lipopolysaccharide (LPS), de anionische membraancomponent van 
Gram-negatieve bacteriën. 
Hoofdstuk 3 laat zien hoe de structuur van een bijprodukt opgehelderd is dat gevormd 
werd tijdens de laatste zuiveringsstap van de polymyxines beschreven in Hoofdstuk 2. Dit 
bijprodukt bleek hetzelfde molekuulgewicht te hebben als de betreffende polymyxine, maar een 
andere LC retentietijd en MS/MS fragmentatiepatroon. De hypothese dat het hier gaat om een 
isomeer waarin de acyl groep van de Nǂ van Dab1 verhuisd is naar de NǄ positie van hetzelfde 
aminozuur werd bevestigd door deze isomeer te synthetiseren en te karakteriseren. 
Hoofdstuk 4 behandelt het ontwerp en de synthese van antibiotica conjugaten gebaseerd 
op CAPs. In deze conjugaten zijn twee aparte verbindingen geconjugeerd door middel van een 
disulfide brug. Het betreft conjugaten van de CAPs tritrpticine, buforine II, het synthetische KFF 
peptide en een drosocine derivaat uit Hoofdstuk 1, met het polymyxine B nonapeptide (PMBN). 
Dit nonapeptide is een kleinere variant van polymyxine B dat niet alleen de antibiotische werking 
verloren heeft, maar tegelijkertijd ook de toxiciteit. Het nonapeptide heeft echter nog wel 
affiniteit voor LPS, en kan in deze conjugaten optreden als sensitizer; plaatselijke verstoring van 
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het buitenmembraan (sensitizing) zorgt ervoor dat het gehele conjugaat gemakkelijker het 
buitenmembraan kan passeren. Slechts de conjugaten met membraanactieve CAPs zijn 
antibacterieel actief; het KFF/PMBN conjugaat bleek in de tests zelfs een hogere affiniteit voor 
LPS te hebben dan de controle polymyxines. 
 Quaternaire ammonium verbindingen (QACs) behoren tot de eenvoudigste structuren 
die, net als CAPs, hydrofoob en kationisch zijn. In Hoofdstuk 5 wordt de synthese en de 
antibacteriële activiteit besproken van een aantal op imidazool- en pyrrolidine-gebaseerde QACs. 
De meeste van deze verbindingen konden in gelfase gebracht worden door toevoeging van 
water, ethyleen glycol of glycerol. Deze gels bleken alle zeer effectief in antibiotische tests tegen 
Escherichia coli. Van de gel bestaande uit N-hexadecyl-N’-methylimidazolium bromide met 35% 
(gew.) ethyleen glycol bleek, in tegenstelling tot bijna alle andere gels, slechts een klein gedeelte 
weg te spoelen in een waterstroom. Deze positieve eigenschappen kunnen leiden tot de 
ontwikkeling van antibacteriële gels voor (preventieve) ontsmettingstoepassingen. 
 Het onderwerp van Hoofdstuk 6 is peptide-gerelateerd en betreft de toepassing van 
polygefluoreerde groepen in de chemische synthese van peptiden. Door een polygefluoreerde 
(fluorous) groep te koppelen selectief aan een synthetisch peptide op de vaste drager, bleek dit 
gewenste peptide eenvoudig te zuiveren uit een mengsel met ongewenste incomplete 
verbindingen door middel van fluorous vloeistofchromatografie of fluorous vastestofextractie. 
Deze groep, FMsc genaamd, werd speciaal ontwikkeld voor dit doel. Voorts beschrijft dit 
Hoofdstuk ook een fluorous strategie waarin juist alle ongewenste verbindingen van een 
polygefluoreerde groep werden voorzien, zodat het gewenste peptide meteen verkregen kan 
worden zonder dat eerst de FMsc groep verwijderd hoeft te worden. 
 Tot slot wordt in Hoofdstuk 7 een samenvatting gegeven van de voorgaande 
Hoofdstukken en worden een aantal toekomstperspectieven behandeld, waaronder de synthese 
van pentamidine/CAP conjugaten, als uitbreiding op Hoofdstuk 4. Pentamidine, een 
geneesmiddel voor de behandeling van de Afrikaanse slaapziekte, blijkt een grotere affiniteit 
voor LPS te hebben dan het polymyxine B nonapeptide, en kan de laatstgenoemde vervangen in 
de constructie van verbindingen die zowel een antibacterieel als een LPS-affiniteitsgedeelte 
hebben.
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Nawoord
Het onderzoek beschreven in dit proefschrift is het resultaat van samenwerking met velerlei 
mensen –in en buiten de laboratoria- die ik hier dan ook graag wil bedanken. Allereerst mijn 
ouders; zij stonden aan de basis van dit proefschrift door mij de mogelijkheid te bieden een 
academische opleiding te volgen.  
In het bijzonder verdienen Marcel van Helden, Ruben Musson, Marthe Walvoort en 
Laurens Reiber een vermelding voor hun bijdragen aan het onderzoek in het kader van een 
(hoofdvak)stage. De chemie viel niet altijd mee, maar de sfeer en muzikaliteit waren altijd 
goed. Begoña Aguilera, Richard van den Berg, Leendert van den Bos, Silvia Cavalli, Jeroen 
Codée, Clara Comuzzi, Farid El Oualid, Dima Filippov, Gijs Grotenbreg, Amar Ghisaidoobe, 
Martijn de Koning, Nicole Kriek, Bas Lastdrager, Michiel Leeuwenburgh, Remy Litjens, Rian 
van den Nieuwendijk, Lene Petersen, Michael Raunkjær, Jim Rickard, Charles Simons, Karen 
Sliedregt, Paul van Swieten, Mattie Timmer, Erwin Tuin, John Turner, Steven Verhelst, 
Brigitte Wanner, Renate van Well en Tom Wennekes droegen allen een persoonlijk steentje bij 
aan de goede sfeer op het lab. Hans van der Elst en Nico Meeuwenoord stonden altijd klaar 
voor hulp bij LCMS analyses en peptide syntheses; bij het opnemen van NMR spectra waren 
Cees Erkelens en Fons Lefeber altijd behulpzaam en de ama’s Henny, Arnold en Marco bij 
allerhande problemen van technische aard. De menige uren die ik gesleten heb bij TNO 
Rijswijk voor het zuiveren van mijn verbindingen werden veraangenaamd door Peter van 
Hooft, Alex Fidder, Duurt Alkema, Maarten Tromp en Annemiek van Zuylen. Voor het 
uitvoeren van biologische assays bedank ik Bob Hartog (TNO Zeist) en Anne-Marij de Vries 
(TNO Rijswijk); Albert Hulst en Ad de Jong bedank ik voor MALDI en HRMS analyses. 
Cindy Govaerts en Ann Van Schepdael van de Katholieke Universiteit Leuven (België) wil ik 
hier vermelden voor hun bijdragen aan hoofdstuk 3. Op het medeleven van mijn huidige 
collega’s bij ProSensa aangaande het schrijven van mijn proefschrift kon ik altijd rekenen. 
 De afgelopen jaren heeft onder andere het Delta RA-team gezorgd voor sportieve 
activiteiten buiten de chemie. Voor buiten-chemische activiteiten moet ik ook zeker de (ex-) 
bandleden van ieverge  ten!    niet vergeten! De energieke repetities en optredens waren 
meestal precies wat ik nodig had. Rest mij nog Linda, goede vrienden en familie te bedanken 
voor hun steun en interesse (‘hoe staat het met je fruitvliegen?’) en natuurlijk Ilse: in 
tegenstelling tot de vaak voorkomende onvoorspelbaarheid van de chemie kon en kan ik 
blindelings uit gaan van jouw steun, interesse, begrip en liefde – eenvoudig onmisbaar.
